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Abstract 
 
 Type 1 diabetes mellitus (T1DM) is associated with compromised glycemic control 
and a heightened risk for cardiovascular disease. The common treatment of T1DM with 
strict glycemic control through intensive insulin therapy can be problematic (weight gain, 
insulin resistance, hypoglycemia). Regular exercise is known to improve cardiovascular 
health, yet most individuals with T1DM remain sedentary, and identify the risk of exercise-
induced hypoglycemia as a significant barrier. The investigation into the use of different 
forms of exercise (higher intensity, resistance) for preventing exercise-induced 
hypoglycemia in populations with T1DM has been promising, however, little work has 
investigated their cardiovascular benefit or whether the risk of exercise-induced 
hypoglycemia changes over the course of exercise training. As such, using a novel insulin-
treated rat model of T1DM the objectives of this dissertation were: (1) to determine whether 
the risk of hypoglycemia in response to different exercise modalities changes over the 
course of training in T1DM, (2) to characterize which exercise modality provides the 
largest amount of cardiovascular protection (as determined by recovery from an ischemia-
reperfusion injury and fine-wire vascular myography), while assessing risk for exercise-
induced hypoglycemia, and (3) to explore whether exercise training, when paired with 
modest glycemic control, results in larger cardiovascular protection than stringent glycemic 
control alone. The main findings of these collective studies were as follows; (1) the 
magnitude of the abrupt decline in blood glucose in response to different exercise 
modalities remains consistent after exercise training and infrequently reaches 
hypoglycemic concentrations if blood glucose concentrations are elevated prior to exercise 
in T1DM rats, (2) both exercise-induced fluctuations in blood glucose and the amount of 
cardiovascular protection obtained from regular exercise training appears to be modality-
specific; however, results suggest that high intensity aerobic exercise provides the largest 
amount of cardiovascular protection (increased recovery from ischemia-reperfusion injury, 
vascular insulin sensitivity, and glycemic control), and (3) maintaining more modest 
glycemic control may provide similar cardiovascular benefits as stricter glycemic control 
when combined with regular exercise. Overall, less of a reliance on strict glycemic could 
allow for exercise to be performed safely (and providing cardiovascular benefits), while 
preventing complications associated with intensive insulin therapy. 
 
 
 
 
 
 
 
 
 
Keywords: diabetes, exercise training, hypoglycemia, insulin sensitivity, cardiovascular 
disease 
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CHAPTER 1 
 
1 « Introduction » 
!
1.1!Type 1 Diabetes Mellitus 
Diabetes is identified by the inability of the body to produce insulin, or the failure 
of the body to utilize insulin properly. The disease is categorized into two types; Type 1 
diabetes (previously insulin-dependent or juvenile diabetes) and Type 2 diabetes mellitus 
(previously insulin-independent diabetes). Type 2 diabetes mellitus (T2DM) is the most 
common form of diabetes and is characterized by the development of insulin insensitivity 
(insulin resistance), a condition in which the body does not respond efficiently to normal 
levels of insulin and occurs as a result of a number of factors including aging, obesity or 
physical inactivity (115). As such, the body is unable to effectively utilize glucose in the 
blood, resulting in chronically elevated levels of blood glucose (hyperglycemia) (115). 
Type 1 diabetes mellitus (T1DM) is characterized by the autoimmune destruction of the 
insulin producing !-cells of the pancreas, which develops into an overall insulin 
deficiency. The onset of T1DM typically occurs during childhood or adolescence, 
although it is now recognized that the disease can develop during adulthood (4). Genetic 
factors are related to the development of T1DM and a number of genes have been 
identified (HLA region on chromosome 6P21, PTPN22; which encodes the lymphoid 
protein tyrosine phosphatase, IL2RA; Allelic variation in the interleukin (IL)-2 receptor-" 
gene (IL2RA), CTLA-4; cytotoxic T lymphocyte-associated protein 4, and the insulin 
gene) that make individuals more susceptible to the disease (8). Investigation into the 
triggers of T1DM has primarily implicated viral infections, although evidence exists for 
environmental (cow’s milk, wheat proteins, vitamin D) and bacterial factors (8). 
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Nonetheless, the development of T1DM appears to be a complex interplay between a 
number of factors (8). The overall incidence of individuals with T1DM are increasing, 
with areas of Canada representing the highest reported worldwide (92). 
1.2!Treatment of T1DM 
In the late 1800’s and early 1900’s the primary cause of mortality for patients with 
diabetes was ketoacidosis (diabetic coma)(59). By the 1920’s cardiovascular-renal disease 
had become the primary cause of death for patients with diabetes (59), which currently 
remains the leading cause of diabetes-related death to date (67, 85). Identified as a disease 
of high blood glucose concentrations (hyperglycemia), the original treatment option for 
diabetes was intermittent fasting (58). The largest breakthrough in the treatment of 
diabetes came in 1921 when Fredrick Banting and Charles Best discovered and 
successfully isolated insulin from the pancreata of dogs (5). Subsequently, insulin was 
genetically engineered from E. coli bacteria and the first biosynthetic insulin became 
commercially available in 1982 (46). 
Although hyperglycemia had been implicated in the pathogenesis of diabetic 
complications it was not until the Diabetes Control and Complications Trial (DCCT) that 
this view became widely accepted. The DCCT investigated the importance of strict 
glycemic control through intensive insulin therapy (IIT) on the prevention of diabetes-
related complications, while comparing this strategy to the traditional and more moderate 
means of glycemic control known as conventional insulin therapy (CIT)(121). The two 
cohorts of patients in the DCCT utilized either one or two insulin injections per day 
(CIT), or three or more insulin injections daily designed to achieve normoglycemia (IIT). 
As a result, blood glucose concentrations ranged from 9 to 15mmol/L in patients utilizing 
CIT, and significantly lower (<9mmol/L) in patients utilizing IIT. Results of the DCCT 
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demonstrated that significant reductions in retinopathy, nephropathy, and neuropathy 
were evident in patients following IIT in comparison to those utilizing CIT (121). These 
results were so convincing that due to ethical considerations the study was terminated 
early and all patients were switched to IIT. An observational study was completed 
following the DCCT termed the Epidemiology of Diabetes Interventions and 
Complications (EDIC), whereby patients originally using CIT in the DCCT (now 
reassigned to IIT) were continually monitored for overall cardiovascular health. Results 
from the EDIC provided further evidence that prescribing to IIT significantly reduces the 
risk of cardiovascular disease onset with diabetes (91). Further, the EDIC also revealed a 
phenomenon termed “metabolic memory”, in that those patients who were initially 
prescribed IIT during the DCCT had a reduced incidence of cardiovascular disease that 
persisted for up to 30 years. This level of protection was not evident in patients originally 
placed in the CIT cohort, suggesting that IIT should be initiated as early as possible into 
the progression of T1DM in order to obtain maximal cardiovascular benefits (34). Both 
the DCCT and EDIC have demonstrated a causal relationship between hyperglycemia and 
the progression of microvascular complications (retinopathy, neuropathy, etc.) associated 
with T1DM (34, 91, 123). However, the utilization of IIT requires constant attention to 
blood glucose concentrations and insulin dosing, as well as the close monitoring of daily 
eating habits and activity levels. Patients in the DCCT and EDIC undergoing IIT 
experienced a threefold increase in severe hypoglycemic episodes, highlighting the 
difficulty in intensively managing glycemia (121, 122). Despite these difficulties, the 
encouraging results of the DCCT and EDIC have formed the basis for the treatment of 
T1DM and its complications for the past 30 years.  
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1.3!Cardiovascular Disease in T1DM 
In populations with T1DM, there remains a tenfold increase in cardiovascular 
disease-related mortality that is not entirely accounted for by traditional risk factors such 
as hypertension, dyslipidemia, obesity, or smoking (67, 85, 113). The EDIC found a 42 
percent reduction in the risk of experiencing cardiovascular disease and a 57 percent 
reduced risk of nonfatal myocardial infarction, stroke, or death from cardiovascular 
disease when patients were prescribed IIT (123). However, the suitability of IIT for all 
patients with T1DM has recently been challenged (22).  Many patients prescribing to IIT 
often experience difficulty maintaining strict glycemic control whereby insulin 
overcorrection and hypoglycemia is common (28, 122). In addition to the increased risk 
of hypoglycemia, the amount of weight gain that can be associated with IIT has raised 
significant concerns (106), since it is often accompanied by insulin resistance, higher 
waist:hip ratios, and a more atherogenic lipid profile (22). Some researchers and 
clinicians have challenged the findings of the DCCT and EDIC, suggesting that the 
subjects in these trials were not representable of the patient population with T1DM. 
Indeed, the risk of cardiovascular disease for patients included in the DCCT was minimal, 
as individuals with established vascular disease, or exhibiting obesity, hypertension, or 
hypercholesterolemia were excluded from participation in the study (121). Two more 
recently completed clinical trials, the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) and the Action diabetes and Vascular disease: Preterax and Diamicron MR 
controlled evaluation (ADVANCE), found no benefit of strict glycemic control for 
preventing cardiovascular events in patients already at a heightened risk of cardiovascular 
disease (119, 120). In fact, the intensive glycemic control group in the ACCORD trial 
experienced an increase in cardiovascular disease associated death, which was attributed 
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to weight gain and the increased frequency of hypoglycemia (119). The equivocal 
findings of the DCCT, EDIC, ADVANCE and ACCORD studies has led many 
practitioners, researchers, and patients to question which insulin treatment strategy is 
ideal in order to limit the susceptibility of patients with T1DM to cardiovascular disease. 
1.3.1 Ischemic Heart Disease 
 Ischemic heart disease (coronary artery disease) is one of the more widely cited 
complications of cardiovascular disease in patients with T1DM (85, 96, 113). The 
diabetic heart is more susceptible to ischemic heart disease due to the development of 
micro- and macrovasculature dysfunction, as well as diabetic cardiomyopathy (130). The 
heart relies on sufficient blood flow from the coronary arteries to provide the necessary 
oxygen for oxidative phosphorylation, since glycolysis alone is unable to produce enough 
ATP for its continuous contraction and relaxation. A disruption in blood flow during 
myocardial ischemia is debilitating to the heart tissue, as a lack of oxygen leads to the 
accumulation of ADP, AMP and Pi, and a decrease in pH (due to the accumulation of 
lactic acid)(69). The degree of damage to the myocardium is related to the total length of 
ischemia, where prolonged ischemia can cause irreversible damage and cell death. 
Cardiac reperfusion following ischemia can further exacerbate damage to the 
myocardium, largely due to increases in intracellular calcium, reactive oxygen species 
(ROS), and inflammatory processes (69). Ischemic reperfusion also causes an attenuation 
of endothelium-dependent vasodilation, resulting from the inactivation of nitric oxide 
(NO) by superoxide and reduced NO bioavailability (100). In addition, production of 
endothelin by the endothelium is increased during reperfusion leading to greater 
vasoconstriction (100).  
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The term “diabetic cardiomyopathy” characterizes diabetic-related changes in the 
structure and function of the myocardium that occur in the absence of coronary artery 
disease or hypertension. The prominent feature of diabetic cardiomyopathy is cardiac 
hypertrophy; specifically, increased left ventricular mass and wall thickness, which 
occurs concomitant with impaired systolic and diastolic function (33). Diastolic 
dysfunction usually occurs earlier in the course of diabetes, while systolic dysfunction 
generally develops as the disease progresses (14). Dysfunction in Ca2+ handling and 
homeostasis in cardiomyocytes is recognized to be a contributing factor for diastolic 
dysfunction in diabetic cardiomyopathy (108, 141); although numerous other mechanisms 
have been proposed (for review (14)). Hyperglycemia has been shown to directly 
contribute to many of the pathologies associated with diabetic cardiomyopathy, such as 
cardiac hypertrophy, fibrosis, cardiac autonomic neuropathy, and changes in structure and 
function of the myocardium (141). 
Evidence examining the causal factors of diabetic cardiomyopathy in T1DM has 
been generated primarily from experimental studies using streptozotocin (STZ)-induced 
T1DM rats. The hearts of these insulin-deficient STZ rats typically experience diminished 
ventricular compliance, cardiomyocyte contractility, and strength of contraction (108, 
128). Interestingly, in untreated STZ-induced diabetic rats the myocardium can 
experience atrophy, as opposed to the hypertrophy typically observed in clinical diabetes 
(118). It appears that the lack of insulin in the STZ-treated animals is responsible for 
these differential changes to the heart, as the supplementation of insulin to STZ diabetic 
rats results in pathological hypertrophy (79). This suggests that while untreated STZ-
diabetic rats provide insight into how hyperglycemia influences the function of the 
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myocardium these studies may not be translational to clinical populations with T1DM, as 
patients with T1DM are seldom absent of some form of insulin treatment. 
1.3.2 The Vasculature  
The prevalence of cardiovascular disease in populations with T1DM can largely 
be attributed to dysfunction of the micro- and macrovasculature (24, 70). 
Microvasculature (small resistance arteries, arterioles and capillaries) disease generally 
results in retinopathy, nephropathy and neuropathy, while macrovasculature disease 
affects the peripheral arteries, coronary arteries, and cerebrovasculature. Historically, 
vascular dysfunction in T1DM has been primarily attributed to chronic hyperglycemia 
(70); however, there is emerging evidence that the development of insulin resistance is 
also associated with vascular dysfunction in T1DM (22, 35, 49, 98, 106). Several studies 
have demonstrated that T1DM-related alterations in insulin signalling can contribute to 
vascular dysfunction (6, 19, 95, 132).  
1.3.3 Endothelial Dysfunction 
The unicellular inner layer of blood vessels, the endothelium, is actively involved 
in the regulation of vascular permeability, inflammation, coagulation, and vascular tone 
(75). In order to regulate vascular tone, and subsequently blood flow, the endothelium can 
release vasodilators such as NO, prostacyclin and endothelium-derived hyperpolarizing 
factors (EDHF), as well as vasoconstrictors like endothelin-1 (ET-1) and angiotensin II 
(116). One of the most important molecules produced by the endothelium is NO, which is 
constitutively synthesized by endothelial nitric oxide synthase (eNOS) from L-arginine 
(24). Nitric oxide exerts its vasodilatory effects on vascular smooth muscle cells by 
reducing intracellular calcium, as a result of the activation of guanylate cyclase and the 
increased production of cyclic guanosine monophosphate (cGMP)(7). Aside from its 
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vasodilatory effects, NO also has numerous protective benefits such as preventing platelet 
and leukocyte interaction on the vascular wall, inhibiting smooth muscle cell proliferation 
and migration, and regulating inflammatory processes (7, 24). 
Endothelial dysfunction occurs when there is an imbalance in endothelium-
derived relaxing and contracting factors, which results from a reduction in the 
bioavailability of the vasodilator NO or the favouring of molecular pathways involved in 
vasoconstriction, inflammation, or thrombosis (24, 116). T1DM is typically associated 
with some level of endothelial dysfunction, as demonstrated by the reduced production 
and bioavailability of NO (32, 57, 64, 65, 102). Endothelial dysfunction often precedes 
other evidence of vascular disease and is a primary factor contributing to cardiovascular 
disease and its co-morbidities, such as atherosclerosis, arteriosclerosis, hypertension, 
peripheral neuropathy, and metabolic dysfunction (65, 88).  
Chronic hyperglycemia can have detrimental effects on most cells in the body, 
especially vascular endothelial cells, a type of cell that is not entirely reliant on insulin for 
glucose uptake (3, 60). It has been shown that the intracellular glucose concentrations of 
endothelial cells mirror that of their extracellular environment (60). When exposed to 
high blood glucose concentrations, comparable to levels experienced by patients with 
T1DM, endothelial cells experience a large influx of glucose, which ultimately results in 
an increase in ROS. Increased ROS, such as superoxide anion, can inactivate NO by 
forming peroxynitrite (93), which in turn, can cause the uncoupling of eNOS and 
decreased production of NO (84). The overproduction of ROS by the mitochondria in 
response to hyperglycemia potentiates endothelial dysfunction by increasing polyol 
pathway flux, intracellular advanced glycation end products (AGE) formation, protein 
kinase C (PKC) activation, and hexosamine pathway flux (see review (45)). Thus, a 
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significant driving force in the pathogenesis of vascular complications in T1DM is 
believed to be hyperglycemia-related endothelial dysfunction and oxidative stress (24, 
112, 116). Indeed, the degree of endothelial dysfunction in T1DM has been demonstrated 
to be closely related to HbA1c, a marker of long-term glycemic control (111). 
1.3.4 Vascular Insulin Resistance 
 Secondary to its metabolic effects, insulin can act as an important vasodilator (9, 
19, 88). Endothelium-dependent vasodilation occurs following the binding of the insulin 
molecule to its receptor and the activation of the phosphatidylinositol 3-kinase (PI3K)-
Akt signalling pathway. Subsequently, NO is produced by the phosphorylated form of 
eNOS. Insulin can also result in vasodilation by acting directly on vascular smooth 
muscle cells by modulating Ca2+ handling and sensitivity (9). It is believed that insulin-
induced vasodilation occurs in order to assist in the delivery of insulin and glucose to 
skeletal muscle (75, 88). Conversely, insulin can also result in endothelium-dependent 
vasoconstriction by activating the Ras/mitogen-activated protein kinase (MAPK) 
pathway, which subsequently releases ET-1. 
 The vascular actions of insulin can be diminished in populations with T1DM (6, 
19, 104, 132). Insulin resistance in the vasculature is characterized by diminished PI3K-
Akt signalling (vasodilation) and increased MAPK signalling (vasoconstriction)(97). 
Deficient actions of insulin on the vasculature often occurs early in the course of 
endothelial dysfunction, making it both an early biomarker, as well as a promising avenue 
for the early treatment of vascular disease development (39, 65, 88). The implications of 
vascular insulin resistance are abundant. A larger reliance on the MAPK insulin 
signalling pathway is detrimental for vascular health due to an increase in the binding of 
adhesion molecules, inflammation, and net vasoconstriction (56, 87, 97). Further, 
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impaired insulin-induced dilation in resistance arteries results in the reduced delivery of 
glucose and insulin to skeletal muscle, which in turn can compromise glycemic control 
(19, 66, 87). In the macrovasculature, vascular insulin resistance can cause a 
predisposition to atherosclerosis (107). Aortic cells lacking the insulin receptor gene 
experience accelerated progression of atherosclerosis in the absence of elevated plasma 
lipids or hypertension (107). Vascular insulin resistance is specific to the vessel, in that 
impaired insulin-induced vasodilation in T1DM can occur even without the presence of 
whole-body insulin resistance (132).   
1.4!Exercise and T1DM  
A sedentary lifestyle has been shown to contribute to a number of diseases that 
plague our society and physical activity has been demonstrated to prevent a number of 
chronic diseases, including many diabetic-related pathologies (12). Prior to the discovery 
of insulin in 1921, in the late 1800’s regular exercise was suggested as a treatment option 
by one of the first practitioners treating patients with diabetes, Apollinaire Bouchardat 
(58, 59). In a recent systematic review of the literature it was demonstrated that sufficient 
evidence exists for clinicians to advocate regular physical activity for the management of 
T1DM (20). The Canadian Diabetes Association recommends that individuals with 
T1DM participate in 150 minutes of moderate intensity aerobic exercise (50-70% of 
maximal heart rate) weekly (over at least 3 days)(2). It is also suggested that resistance 
exercise be incorporated at least twice per week (2). The benefits of regular exercise for 
populations with T1DM are widespread and include: improved physical fitness, reduced 
insulin requirement, improved lipid levels and endothelial function, increased insulin 
sensitivity, reduced cardiovascular disease, and decreased mortality (20, 137).  
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1.5 Cardiovascular Benefits of Exercise for T1DM 
 Difficulties have arisen when investigating the development of diabetic 
cardiomyopathy in exercising populations, since dynamic exercise stimulates cardiac 
hypertrophy via many of the same pathways involved in pathological remodelling of the 
heart (82). Typically, increased left ventricular diameter and wall thickness occurs 
following aerobic exercise training due to volume overload and increases in blood 
pressure, a process known as eccentric hypertrophy (82). These processes occur to 
increase maximal cardiac output and reduce maximal heart rate during exercise. In 
contrast, wall thickness is increased following resistance exercise due to increases in 
systolic and diastolic blood pressure, a process known as concentric hypertrophy, which 
results in a small increase in maximal cardiac output (82). In insulin treated STZ-diabetic 
rats our laboratory has shown that aerobic exercise training results in beneficial growth of 
the heart, while  sedentary T1DM rats develop pathological hypertrophy (79). Further, 
insulin-treated T1DM rats demonstrated increased constitutive levels of an important 
cardioprotective factor, Hsp70, which has been shown to protect the myocardium from an 
ischemic-reperfusion injury (79, 80, 99). In fact, myocardial Hsp70 has been shown to 
positively correlate (r=0.97) with a reduced infarct size following ischemia (53). Data 
showing the cardioprotective benefit of other modes of exercise in T1DM is limited. 
Although resistance exercise has been shown to provide protection from ischemic-
reperfusion injuries in non-T1DM rats (114), evidence is still needed to determine the 
cardioprotective role of this form of exercise in populations with T1DM. 
Slowed calcium clearance and abnormal cardiomyocyte excitation-contraction 
coupling is evident in T1DM (103, 108). Exercise training has been shown to increase the 
contractile force of the heart, largely through increased cardiac hypertrophy and 
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improvements in contractility of the cardiomyocyte. Further, exercise-induced 
enhancements in the contractility of the cardiomyocyte can occur due to the increased 
ability to transport calcium, as well as the improved response of myofilaments to calcium 
(61). Both aerobic or resistance exercise have been shown to increase sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) expression, an essential Ca2+ transporter (81, 125). Due 
to the substantial role insulin resistance can have on cardiomyocyte dysfunction, it is 
believed that the insulin sensitizing effect of regular exercise can have a beneficial impact 
on Ca2+ handling in T1DM (133).  
 The vascular benefits of aerobic exercise are believed to occur as a result of an 
increase in shear stress (or stretch) on the vessel, resulting in changes in endothelial cell 
gene expression and phenotype. However, questions still remain regarding the 
mechanosensory mechanisms governing these benefits (131). Instead of improving 
endothelial cell gene expression and phenotype, some argue that the changes to the 
endothelium that occurs with long-term exercise training are necessary to maintain a 
‘normal’ endothelial cell phenotype (12). Nonetheless, regular exercise training results in 
positive arterial remodeling and increased endothelium-dependent vasodilation in the 
vascular beds of active skeletal muscles, as well as larger conduit arteries (131, 134). 
Regular exercise has been shown to improve vascular and endothelial function in 
different vascular beds of human populations with T1DM (41, 74). These findings have 
been supported in animals models of T1DM where increased endothelium-dependent 
vasodilation was evident following both aerobic and resistance exercise training (18, 32, 
86, 90, 95). Increased endothelium-dependent vasodilation in response to exercise 
training occurs largely as a result of the increased bioavailability of nitric oxide, through 
the upregulation of eNOS (32, 90, 95, 134). Vascular function is also increased indirectly 
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by improving lipid levels (increased HDL, decreasing LDL and triglycerides)(20). 
Although oxidative stress (e.g. ROS accumulation) due to chronic hyperglycemia is a 
significant factor contributing to endothelial dysfunction (84, 93, 111), it is not entirely 
clear whether improved glycemic control following exercise training is driving enhanced 
vascular function. There are a lack of studies providing evidence for improved HbA1c 
following regular exercise in patients with T1DM (20, 137). 
Clinically, HbA1c, a marker of long-term glycemic control, is one of the more 
widely used predictors for the development of cardiovascular disease. In populations with 
T2DM, exercise is well established to reduce HbA1c  levels (126); however, similar 
results in subjects with T1DM have been conflicting (20, 137). For example, Yardley et 
al. (137) conducted a systematic review and meta-analysis of the literature and 
determined that although results are promising there is currently a scarcity of well-
designed studies to ascertain whether regular exercise training can reduce HbA1c. 
Reported improvements in glycemia following regular exercise have generally occurred 
following higher intensities of aerobic and resistance exercise (17, 38). However, the 
influence of exercise on HbA1c may be difficult to distinguish in clinical studies since 
physically active individuals with T1DM typically display higher HbA1c. In comparison 
to less active patients with T1DM, exercising patients with T1DM often intentionally 
elevate blood glucose levels prior to, and following exercise, in order to mitigate the risk 
of hypoglycemia (31).  
 Individuals with T1DM have also demonstrated impairments in the vascular 
actions of insulin (6, 19, 104, 132). While exercise training has been shown to have a 
positive role in enhancing vascular insulin sensitivity in a variety of populations (50, 83, 
94, 97), few have studied how exercise can modulate the vascular actions of insulin in 
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T1DM. Work from our laboratory has shown an improvement in insulin-stimulated nerve 
arterial vasodilation in insulin treated STZ-diabetic rats following long-term aerobic 
exercise training (95). Similar results were demonstrated in untreated STZ-diabetic rats, 
where aerobic exercise increased insulin signalling in the cutaneous microvasculature 
(50). However, research in the area of T1DM-related vascular insulin resistance has 
focused on the microvasculature and aerobic treadmill training only, ignoring other 
exercise modalities (i.e. resistance exercise). Limited research conducted in humans has 
suggested that exercise training appears to only improve insulin sensitivity in the 
vasculature supplying active skeletal muscles. For example, following one-legged aerobic 
or resistance training in humans with T2DM the increase in leg blood flow during an 
euglycemic-hyperinsulinemic clamp is larger in the trained leg (30, 51). It is believed that 
shear stress may be modulating the insulin sensitizing effects of exercise on the 
vasculature (97). Further, the insulin sensitizing effects of aerobic exercise results in an 
increase in NO-induced vasodilation, as well as a reduction in insulin-stimulated ET-1 
constriction (25, 97). Concurrent with increased insulin-stimulated nerve arterial 
vasodilation our laboratory has reported elevations in eNOS protein content following 
exercise training in T1DM rats (95). In models of T2DM, others have also shown a 
downregulation of molecular pathways involved in ET-1 production following exercise 
training (25, 83). Consequently, improvements in the vascular actions of insulin with 
regular exercise training could have positive implications on glycemic control by 
increasing insulin and glucose delivery to skeletal muscle and reducing the risk of 
atherosclerosis (19, 66, 87, 107). However, improvements in the vascular actions of 
insulin following exercise training are likely not a result of improved glycemia itself, 
since no improvements in insulin-stimulated vasodilation are evident following 
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metformin treatment in T2DM rats that exhibit lowered glycemia and body mass (26). 
This would suggest exercise training is essential to increase vascular insulin sensitivity in 
populations with diabetes and improving glycemic control alone is insufficient. 
Despite all the aforementioned evidence supporting exercise prescription for 
patients with T1DM, some research suggests that exercise does not promote the same 
cardiovascular benefit as seen in non-diabetic populations. For example, a cross-sectional 
study conducted by Mason et al. (74) found that while regular exercise can protect against 
cardiovascular disease progression, the improvement in vascular function in T1DM may 
not occur to the same extent as individuals without diabetes. Indeed, a retrospective 
analysis of the DCCT found no evidence that physical activity improves microvascular 
outcomes in patients with T1DM (71). 
1.6 Risks Associated with Exercise  
One of the important revelations from the DCCT is that accompanying IIT is an 
increase in the risk of hypoglycemia (121, 122). While individuals with T1DM should 
partake in regular exercise in order to prevent the progression of cardiovascular 
complications, one of the most frequently identified causes of severe hypoglycemia is 
exercise (10). In fact, fear of hypoglycemia is reported as the largest barrier to regular 
physical activity for individuals with T1DM (13). 
Maintaining blood glucose homeostasis is critical in order for the body to sustain 
metabolism. The brain, arguably the body’s most important organ relies almost entirely 
on circulating blood glucose. A person weighing 70kg relies on the continuous supply of 
approximately 4 grams of glucose in the blood for the optimal function of all cells in the 
body (129). Maintaining this concentration of blood glucose is accomplished at the 
expense of hepatic and muscle glycogen stores. Hepatic glycogen, through the process of 
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glycogenolysis, is responsible for increasing blood glucose concentrations by releasing 
glucose from glucose-6-phosphate (G6P) via the enzyme glucose-6-phosphotase 
(G6Pase). Since skeletal muscle lacks the enzyme G6Pase, muscle glycogen contributes 
to blood glucose homeostasis by sparing blood glucose and supplying working skeletal 
muscle with enough G6P to maintain glycolysis. Once glycogen stores are depleted, 
blood glucose concentrations are maintained by gluconeogenesis, the process of 
producing glucose from other sources besides glycogen, like the by-products lactate, 
glycerol or amino acids. The release of pancreatic hormones, insulin and glucagon, play 
an important role in the regulation of these processes, whereby insulin stimulates 
glycogen synthesis and glucagon initiates glycogen breakdown and the production of 
blood glucose.  
1.6.1 Exercise-induced Hypoglycemia 
The increased occurrence of hypoglycemia in patients with T1DM can be 
attributed to many factors. Intensive exogenous insulin regimes frequently cause 
hypoglycemia due to insulin overcorrection (insulin-induced hypoglycemia) (27, 76). 
Exercise can further increase the risk of hypoglycemia due to its insulin sensitizing 
effects (49) or through the increased mobilization of insulin from subcutaneous stores 
(40). The glucoregulatory defenses against hypoglycemia are also disturbed in T1DM. 
Shortly after the diagnosis of diabetes, the inability of the pancreas to secrete glucagon in 
response to hypoglycemia is evident (44). Although glucagon levels are still evident in 
the blood during exercise, the release of the hormone can be impaired during exercise and 
into recovery from exercise (76). Further, glucoregulatory defenses are altered following 
multiple bouts of exercise or prior hypoglycemia, as it has been reported that antecedent 
exercise or hypoglycemia reduces the release of glucagon during a subsequent exercise 
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session (29, 42, 43). Epinephrine, secreted from the adrenal gland, can also result in blood 
glucose production and is considered the last defense against hypoglycemia (27). 
Unfortunately, the epinephrine response to hypoglycemia is also diminished following a 
prior bout of hypoglycemia or exercise in populations with T1DM (29, 42, 43). 
Potentiating the risk of hypoglycemia, and secondary to impaired hormonal 
glucoregulation, is that patients with T1DM exhibit a deficiency in hepatic glycogen 
stores (11, 54, 76). Our laboratory has shown that in insulin-treated T1DM rats, several 
key enzymes involved in hepatic glycogen synthesis (glycogen synthase, glucokinase, 
phosphoenolpyruvate carboxykinase, etc.) are still present, and in some cases are even 
elevated compared to non-T1DM (76). These data suggest that other factors, such as the 
mechanisms governing hepatic glycogen storage and breakdown, may be altered in 
T1DM (76). Glycogen deficiencies can be detrimental when attempting to prevent 
hypoglycemia during exercise, since blood glucose production in response to both 
hypoglycemia and exercise originates predominantly from hepatic glycogen stores (62, 
101, 127). The risk of hypoglycemia with regular exercise is not limited to during or 
immediately after the exercise; individuals with T1DM experience a heightened risk of 
hypoglycemia eight to ten hours after an exercise bout (78, 124). Indeed, the risk of 
nocturnal hypoglycemia is increased in those with T1DM and is amplified following 
exercise (55, 72, 117). 
1.6.2 Exercise Prescription for T1DM 
 Due to the increased frequency of exercise-induced hypoglycemia, many research 
groups have attempted to determine the ideal exercise regime that could mitigate 
hypoglycemic risk. In populations with T1DM, moderate aerobic exercise leads to 
significant acute reductions in blood glucose, especially if the exercise is prolonged (16, 
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55, 135, 138). Due to its unique effects on glucose regulation, increasing the intensity at 
which exercise is performed has garnered the most attention in the literature (73). High-
intensity exercise in patients with T1DM results in elevations in blood glucose 
concentrations due to a significant rise in catecholamines, which could be advantageous 
to exercising patients with T1DM to mitigate the development of hypoglycemia (73). 
Indeed, performing as little as a ten second sprint prior to moderate intensity exercise can 
diminish the magnitude of the immediate drop in blood glucose evident with moderate 
intensity aerobic exercise alone (15, 16). Brief bouts of high-intensity exercise over short 
durations has also provided benefits for attenuating the drop in blood glucose 
concentrations (1, 47, 48, 55). While these types of high intensity exercises are beneficial 
for preventing hypoglycemia acutely, there is evidence that they may increase the risk of 
nocturnal hyperglycemia (72). Further, when partaking in higher intensities of exercise 
individuals are at a heightened risk for the development of ketoacidosis (109). More 
recently, the benefits of resistance exercise for attenuating hypoglycemia have been 
highlighted (139). Resistance exercise results in similar acute glycemic benefits as high-
intensity exercise and relies on similar anaerobic fuel sources. In contrast to higher 
intensities of aerobic exercise, resistance exercise does result in acute reductions in blood 
glucose, however, the drop in blood glucose is more gradual and does not appear to reach 
hypoglycemic blood glucose concentrations (135). Lastly, the integration of resistance 
and aerobic exercise has also showed promise. Indeed, prior resistance exercise attenuates 
hypoglycemia risk during subsequent aerobic exercise, believed to be due to the increased 
secretion of glucoregulatory hormones during resistance exercise  (138, 140).  
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1.6.3 Exercise Training and Glucoregulation 
 While the use of different forms of exercise (higher intensity, resistance) for 
preventing exercise-induced hypoglycemia in populations with T1DM has been 
promising (15, 16, 135, 140), little work has investigated their cardiovascular benefit. In 
this regard, studies have generally focused on the blood glucose response to a single bout 
of exercise, whereas the manifestation of hypoglycemia following exercise training, the 
form of exercise that would be effective for cardioprotection, is unknown. Many factors 
responsible for governing blood glucose control change over the course of exercise 
training. In T1DM, exercise training is known to result in alterations to insulin sensitivity 
and insulin dosing (35, 49), increased glucagon sensitivity and secretion during recovery 
from exercise (37, 68, 76), increased epinephrine secretion during exercise (76), and 
positive alterations to insulin-producing pancreatic !-cells (21, 23, 52). Further, the 
response of most glucoregulatory hormones have been shown to be blunted following a 
previous bout of exercise or hypoglycemia (29, 42, 43). Specifically, high intensity 
aerobic exercise has been shown to impact the glucose counterregulatory responses to 
subsequent hypoglycemia (77). While glycogen metabolism is also known to change over 
the course of exercise training, it appears that in T1DM aerobic exercise training is unable 
to increase hepatic glycogen stores, despite increases in hepatic glycogen synthase (76). 
On the other hand, resistance exercise has been shown to increase hepatic glycogen 
content in non-T1DM animals (105). While it is not clear whether resistance exercise can 
improve hepatic glycogen stores in patients with T1DM, resistance exercise has been 
shown to alleviate exercise-induced hypoglycemia in population with T1DM (136). 
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1.7!Rationale 
While strict glycemic control has been shown to provide cardiovascular benefits, 
mounting evidence has identified complications associated with this treatment strategy 
(risk of hypoglycemia, insulin resistance, weight gain). Regular physical activity is well-
established to have numerous health benefits, particularly relating to cardiovascular 
health, yet hypoglycemia remains a significant barrier to its prescription (12). Utilizing 
different modalities of exercise (higher intensity exercise or resistance exercise) has 
provided optimism for limiting the risk of exercise-induced hypoglycemia in patients with 
T1DM; however, the optimal intensity, duration or modality of exercise which provides 
the largest degree of cardiovascular protection has yet to be determined (20). In order for 
physical activity to become a common practice for individuals with T1DM, the overall 
cardiovascular benefit and risk of hypoglycemia development within each modality of 
exercise must be established.   
1.8!Thesis Objectives 
1)! To assess the risk of hypoglycemia development following different modes of 
acute exercise in T1DM and to establish whether this risk changes over the course 
of training.  
2)! To determine which modality of exercise training provides the largest degree of 
cardiovascular protection in T1DM. 
3)! To explore whether certain modalities of exercise training, when paired with 
modest glycemic control, results in larger cardiovascular protection than intensive 
insulin therapy alone. 
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1.9 Overview and Thesis Development 
It is clear from the current literature that chronic hyperglycemia often experienced 
by individuals with T1DM contributes to a heightened risk of cardiovascular disease 
(123). While this is supported in studies using the T1DM model induced by STZ, it is not 
entirely clear if the pathology of the disease evident with this experimental model is the 
same as that occurring in patients with T1DM. Further, STZ-induced T1DM animals 
exhibit blood glucose concentrations that are at least two-fold higher than patients with 
T1DM (110, 121), challenging our understanding of how glycemia may impact the 
development of cardiovascular disease. Indeed, due to the countless actions of insulin in 
the human body, it is important that insulin treatment be accounted for in experimental 
models of T1DM (63, 87). Individuals with T1DM that have the greatest risk for 
developing cardiovascular disease have difficulty achieving rigorous glycemic control 
through intensive insulin therapy (IIT), and thus, are often referred to as poorly controlled 
patients with T1DM (123). As such, the focus of this dissertation was to examine the 
impact of regular exercise on this particular population of T1DM, using a novel insulin-
treated, yet poorly controlled rat model of T1DM, believed to be more representative of 
human populations with T1DM (79, 110, 121). This model has been shown to display 
moderate hyperglycemia, comparable blood glucose fluctuations during exercise (76), 
and similar cardiovascular pathologies to human populations with T1DM (79, 89). 
The objectives of this thesis were to determine the ideal exercise regime which 
produces the greatest cardiovascular protection for populations with T1DM, while 
assessing the risk of exercise-induced hypoglycemia following exercise training. Initially, 
due to the paucity of data investigating whether the risk of exercise-induced 
hypoglycemia changes over the course of exercise training, it was determined whether the 
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magnitude of the acute reduction in blood glucose in response to exercise was changed 
over the course of exercise training in T1DM rats (Chapter 2). A moderate aerobic 
exercise was chosen in the first study since our laboratory had shown that this exercise 
regime provided a cardiovascular benefit to T1DM rats (79). In this first study, the results 
demonstrated that the abrupt reduction in blood glucose concentrations in response to 
moderate aerobic exercise remained similar throughout the duration of training. In a 
follow up study (Chapter 3), it was determined whether fluctuations in blood glucose in 
response to different exercise modalities (high intensity aerobic, low intensity aerobic, 
and resistance) were variable and whether a particular form of exercise provided a larger 
amount of cardioprotection. In this study, exercise training lasted for six weeks, a time 
period that was chosen because we had previously established that this duration of 
aerobic and resistance exercise training was sufficient to improve insulin sensitivity (49). 
It was concluded that high intensity aerobic exercise provided the largest amount of 
cardioprotection and that this exercise regime appears to be manageable provided that it is 
accompanied by less stringent glycemic control (CIT). While short-term resistance 
exercise did not result in improved cardioprotection, it was determined that a prolonged 
training period may be needed for this type of training modality to improve 
cardioprotection (36, 114). Accordingly, in the third study of this dissertation (Chapter 4) 
it was investigated whether prolonging resistance exercise training, or the integration of 
aerobic exercise with resistance exercise, would lead to similar cardioprotection as high 
intensity aerobic exercise alone. Secondly, and perhaps more importantly, it was also 
determined whether the degree of cardioprotection provided by these different exercise 
regimes (when paired with less stringent glycemic control) was larger than simply 
improving glycemia through intensive insulin therapy. Lastly, concurrent with the third 
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study (Chapter 4), vasomotor function was also assessed in the femoral artery following 
both aerobic and resistance exercise training, which in turn, was compared exclusively to 
intensive insulin therapy alone (Chapter 5). This final chapter was completed in order to 
determine if the magnitude of cardioprotection following different modalities of exercise 
training was similar in the peripheral vasculature and not specific to the heart itself.   
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CHAPTER 2 
 
2 «Morphological assessment of pancreatic islet 
hormone content following aerobic exercise training 
in rats with poorly controlled Type 1 diabetes 
mellitus» 
 
2.1 Introduction 
Type 1 diabetes mellitus (T1DM) is characterized by the autoimmune destruction 
of insulin producing β-cells within pancreatic islets, resulting in the requirement of 
exogenous insulin in order to limit chronic hyperglycemia and prevent long-term 
complications (43). Accompanying insulin supplementation is the risk of overcorrection, 
leading to an increased incidence of severe hypoglycemia (43, 44). Further, the lack of 
insulin management in T1DM often leads to the development of insulin insensitivity and 
increased cardiovascular risk (18, 24). Regular exercise has been shown to improve many 
diabetes-related complications including enhanced glucose tolerance and improved 
cardiac function in T1DM (18, 33). However, due to a lack of insulin control and 
heightened incidence of hypoglycemia during and following exercise, many patients with 
T1DM refrain from exercise (3, 32).  
Insulin and glucagon are the two most important hormonal regulators of blood 
glucose concentrations in response to hypoglycemia, as well as glucose production during 
moderate intensity aerobic exercise (8, 11, 29, 47). While a reduction in islet insulin 
content and its release from pancreatic islets is well characterized in T1DM, impaired 
glucagon release from islet α-cells is poorly understood. Shortly after the onset of the 
disease, secretion of glucagon is absent upon exposure to hypoglycemia, concomitant 
with an overall decrease in the hepatic response to glucagon (17, 36). Interestingly, 
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impaired glucagon function occurs despite postprandial hyperglucagonemia becoming 
more apparent as the disease progresses (6). Experimentally, α-cell expansion is evident 
in streptozotocin (STZ)-induced rats with T1DM in comparison to non-diabetic rats (27).  
It is well recognized that following aerobic training both insulin and glucagon 
sensitivity are improved (13, 18, 25). It is unknown if exercise training can improve 
pancreatic islet hormone content in populations with T1DM. Findings have supported a 
role of aerobic training in improving insulin content within pancreatic islets of STZ-
induced T1DM animals; however, research to date has been completed in severely 
hyperglycemic animals not treated with exogenous insulin (10, 20). This model is not 
reflective of the exercising population with T1DM, as patients are not likely to partake in 
exercise without accompanying exogenous insulin treatment. Further, most patients with 
T1DM display moderate levels of blood glucose even in the presence of insulin 
supplementation, due to the difficulty of maintaining tightly regulated blood glucose 
concentrations (42). Exercise training has been shown to limit the progression of type 2 
diabetes onset by inducing β-cell hyperplasia, by stimulating proliferation and 
suppressing apoptosis through the activation of the insulin/IGF-1 signaling cascade (9). 
Further, exercise training can stimulate islet growth and survival pathways in non-diabetic 
rats (7). It has yet to be established if glucagon content in T1DM pancreatic islets is 
normalized following aerobic training; although differences in glucagon sensitivity have 
been reported following training. Drouin et al.(13) reported that exercise trained subjects 
demonstrate an increased hepatic sensitivity to glucagon, while Légaré et al.(25) reported 
an increased density of glucagon receptors in the liver of swim trained rats. Further work 
is needed to better understand the impact of aerobic training in the restoration of 
pancreatic islet morphology, particularly in insulin-treated rats with T1DM. 
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Given the risks associated with exercise-induced hypoglycemia, studies 
examining blood glucose concentrations in response to exercise are acute in duration (a 
single bout of daily exercise)(1, 22, 49). Our group recently demonstrated that exercise 
training of various modalities is beneficial for improving insulin sensitivity measures and 
insulin dosage requirements in rats with T1DM (18). It is unknown if the increase in 
insulin sensitivity as a result of exercise may result in an increased risk of exercise-
induced hypoglycemia, as exogenous insulin is a contributing factor in hypoglycemia 
development in response to exercise (5, 12). It is unknown if acute reductions in blood 
glucose as a result of exercise may change following exercise training in populations with 
T1DM.  
 Using a model in which rats are moderately hyperglycemic and insulin-treated, 
the purpose of the present investigation was to: 1) determine the impact of a 10-week 
aerobic training program on its ability to normalize pancreatic islet composition; 2) 
examine if the acute exercise-mediated reduction in blood glucose is altered over the 
course of exercise training. It was hypothesized that 10 weeks of exercise training would 
lead to restoration of pancreatic insulin and glucagon content; however, exercise training 
will cause exercise-induced reductions in blood glucose to increase in magnitude.  
2.2 Methods 
Ethics Approval and Animals. This study was approved by the Research Ethics 
Board of The University of Western Ontario in accordance with the guidelines of the 
Canadian Council on Animal Care. Eight-week old, male Sprague-Dawley rats were 
obtained from Charles River Laboratories (St. Constant, QC, Canada), housed in standard 
rat cages, and maintained on a 12-hour light/dark cycle at a constant temperature and 
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humidity. Rats were allowed access to standard rat chow and water ad libitum. Twenty-
two rats were randomly assigned to either non-T1DM sedentary control (C; n=5), non-
T1DM moderate aerobic exercise (C-ATmod; n=5), T1DM sedentary (D-CIT; n=6), T1DM 
moderate aerobic exercise (D-ATmod; n=6).  
Diabetes Induction. A multiple low-dose STZ-induced T1DM model was 
employed. T1DM was induced by intraperitoneal injection of STZ (20mg/kg; Sigma-
Aldrich, Oakville, ON, Canada) dissolved in citrate buffer (0.1 M, pH 4.5) on five 
consecutive days. This multiple low-dose model of T1DM has been established to elicit 
immune-mediated destruction of pancreatic β-cells similar to the normal pathogenesis of 
a patient with T1DM (33, 35). All injections were sterile, filtered (0.2µm), and occurred 
within 5 minutes of STZ being dissolved in the citrate buffer. Diabetes was confirmed 
following two consecutive blood glucose concentrations of >18mM. Following T1DM 
confirmation, an insulin pellet (1 pellet; 2U insulin/day; Linplant, Linshin Canada 
Canada, Inc., Toronto, ON, Canada) was implanted subcutaneously in the abdomen. 
Blood glucose concentrations were closely monitored throughout the study (see below) 
and insulin pellets were adjusted to maintain blood glucose within a moderate glycemic 
range (9-15mM). This blood glucose range is typically observed in patients with T1DM 
prior to the initiation of exercise and undergoing conventional insulin therapy (CIT)(39, 
43). 
Exercise Protocol. Animals were gradually introduced to the exercise training 
program with familiarization to the treadmill on two separate occasions (15m/min, 2% 
grade for 15 minutes). Subsequently, training consisted of treadmill running for one hour 
each day at a 2% grade, 5 days a week for a total of 10 weeks. The 10 weeks of treadmill 
training consisted of 17m/min (week 1), 24m/min (week 2), and subsequently 27m/min 
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for the completion of the study (week 3-10). Treadmill running at 27m/min represents 
approximately 70-80% of a STZ-induced diabetic rat’s VO2 max (40). Continuous 
running was encouraged by compressed air or tactile stimulus when rats reached the back 
of the treadmill and broke a photoelectric beam. 
Blood Glucose Concentrations. Non-fasted blood glucose concentrations were 
obtained from the saphenous vein at the beginning of and following exercise training 
using a Freestyle Lite Blood Glucose Monitoring System (Abbott Diabetes Inc., 
Mississauga, ON, Canada). Blood glucose concentrations were also recorded prior to, and 
immediately following an acute bout of treadmill training, during weeks 1, 4, 7 and 10 of 
the aerobic training period. 
Tissue collection and immunohistochemistry. Pancreatic tissue was extracted from 
animals four days following the last exercise bout. Pancreata were fixed in 10% normal 
buffered formalin for 72 hours at 4°C and placed in ethanol prior to tissue processing and 
paraffinization. Paraffin embedded tissue was sectioned at 5µm and mounted on 
positively charged slides (Fischer Scientific Superfrost Plus #12-550-15). 
Immunohistochemical staining was conducted using the avidin-biotin complex technique. 
Paraffin embedded pancreata were deparaffinized and hydrated in xylene and graded 
ethanol solutions. Following deparaffinization, pancreata were subjected to heat-induced 
epitope retrieval (antigen retrieval buffer: 10mM sodium citrate buffer, pH 6, 0.05% 
Tween-20). Slides were then quenched in 3% hydrogen peroxide solution for 20 minutes, 
washed in phosphate buffered saline (PBS) for 5 minutes and blocked in 10% goat serum 
overnight at 4°C. All antibodies were diluted with 1% goat serum and incubated for one 
hour at room temperature: insulin (1:100; Dako: A0564), glucagon (1:4000; abcam: 
k79bB10) and Ki67 (1:100; abcam: ab16667). Corresponding biotinylated secondary 
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antibodies were diluted in 1% goat serum (1:200, Vector Laboratories Inc.) and incubated 
for 1 hour at room temperature. Sections were then treated with Vectastain solution 
(Vectastain ABC Elite Kit, PK-6100 Vector Laboratories Inc.) for 1 hour at room 
temperate prior to being exposed to diaminobenzidine (DAB; Vector Laboratories, SK-
4100) for 7 minutes. Tissues were then counterstained with hematoxylin (Sigma-Alderich 
hematoxylin solution: GHS-3). 
Immunohistochemistry Quantification. Insulin and glucagon within pancreatic 
islets were examined by measuring the cumulative signal strength of images, a 
quantitative immunochemistry technique established by Matkowskyj and colleagues (30, 
31). Approximately 30 islets from each animal were visualized using a Zeiss Axiovert 
S100 inverted microscope in combination with a Sony PowerHAD (DXC950-3CCD 
color) camera. For each islet analyzed, two serial secretions of pancreata within 5µm 
were used, with only one section being exposed to primary antibody. In order to account 
for possible visual differences in exocrine tissue between stained and unstained images, 
and to make backgrounds more homogenous, each islet was placed on a black 
background. A black pixel is represented by a zero in each of the three (red, blue, green) 
colour channels. All islets were cropped using Photoshop (Adobe Photoshop CS6) and 
placed on a black background. Consistent with Matkowskyj and colleagues (30, 31) the 
amount of ‘energy units (eu)’ from the image of a non-stained islet was subtracted from 
the eu of the same stained islet using Matlab (Mathworks, Version R2009a). Differences 
in islet size were accounted for by dividing eu by the number of pixels making up each 
individual islet. Ki67 positive cells within pancreatic islets were counted by two 
observers blind to experimental conditions. Pancreatic islet area and diameter were 
determined for each individual cropped islet with the mean islet diameter in the current 
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study being ~50µm. Small islets were classified as having a diameter of 50µm or less 
while large islets had a diameter of greater than 50µm. 
 Western Blotting. Red vastus muscle (100 mg) was homogenized in a 1:10 ratio of 
homogenizing buffer (100 mmol/L NaCl, 50 mmol/L Tris base, 0.1 mmol/L EDTA, 0.1 
mmol/L EGTA and 1% Triton × 100, adjusted to pH ~7.5%, 1% phosphatase inhibitor 
and 1% protease inhibitor) and protein concentrations were determined using the 
Bradford method (4). Homogenates were mixed with equal volumes of sample buffer (0.5 
M Tris base, 13% glycerol, 0.5% SDS, 13% β-mercaptoethanol and bromophenol blue) 
and separated according to their molecular weight on 10% acrylamide separating gel and 
4% acrylamide stacking gel. Each gel contained a molecular weight marker (Bio-Rad: 
catalog no. 161-0373) to determine the molecular weight of the proteins as well as a 
soleus muscle, which served as a positive control to permit the standardization of each 
band across the various gels. After electrophoresis, proteins were transferred to 
nitrocellulose membranes and blocked in 5% milk blotto (BioRad 170-6404) in Tris-
buffered saline (TBS; 10 mmol/L Tris, 100 mmol/L NaCl, 0.1% Tween-20, pH 7.5) for 2 
hours. Membranes were incubated with primary antibodies specific to GLUT4 (rabbit 
mAb anti-GLUT4, Cell Signaling 2213, 1:1000) and insulin receptor (rabbit mAb anti-
insulin receptor beta, Cell Signaling 3025, 1:1000) in TTBS (0.01% Tween 20 and TBS) 
with 2% milk blotto. Membranes were then washed and incubated for 1 hour with 
horseradish peroxidase-conjugated secondary antibody specific for rabbit IgG (goat anti-
rabbit IgG-HRP conjugate, BioRad, 1:5000) diluted in TTBS with 2% non-fat dry milk. 
Following 3 washes in TTBS for 10 minutes membranes were developed using 
chemiluminescent substrate (BioRad Western C Enhanced Chemiluminescent Kit, 170-
5070). Protein bands were captured using a BioRad Chemidoc XRS imager and optical 
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densities were quantified using BioRad Quantity One software Software (#170-9600 Bio-
Rad, Hercules, CA, USA). Optical densities were normalized to the soleus muscle 
positive control on each blot. 
 Statistical Analysis. Body weight, blood glucose concentrations, GLUT4 and 
insulin receptor protein content, islet hormone content (insulin and glucagon) and islet 
area were compared using a two-way ANOVA. Blood glucose concentrations in response 
to aerobic exercise were analyzed using a two-way repeated measure ANOVA. Insulin 
and glucagon content, as well as Ki67 positive cells based on islet size, were compared 
using a three-way ANOVA. A Tukey’s post hoc test was performed with a significance 
level set at P<0.05. All data are expressed as mean ± SE and statistical analysis was 
performed using SigmaPlot 11 statistical software.   
2.3 Results 
Animal weights and blood glucose. All rats gained weight following the 
completion of the 10-week aerobic exercise training program (p<0.05). C weighed 
significantly more than both D-CIT and D-ATmod (p<0.05), while D-ATmod weighed 
significantly less than C-ATmod (p<0.05; Table 2.1). All rats began the experiment at 
similar blood glucose concentration, while at the completion of the aerobic training 
program blood glucose concentrations of D-CIT and D-ATmod were significantly higher 
than both C and C-ATmod (p<0.05). This was not influenced by aerobic training (p>0.05). 
The acute reduction in blood glucose concentrations in response to a single bout of 
aerobic exercise were significantly different between C-ATmod and D-ATmod (Figure 2.1; 
p<0.05). D-ATmod demonstrated a significant reduction in blood glucose concentrations 
after each exercise bout, while C-ATmod demonstrated significant increases in blood 
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glucose concentrations compared to pre-exercise (p<0.05). These acute changes in post-
exercise blood glucose concentrations were not altered over the course of 10 weeks of 
exercise training in C-ATmod or D-ATmod rats (P>0.05). 
Pancreatic islet insulin and glucagon content. Pancreatic islet insulin content was 
significantly reduced in rats with T1DM compared to rats without (p<0.05; Figure 2.2), 
while islet glucagon content was significantly increased in rats with T1DM compared to 
rats without (p<0.05; Figure 2.3). The aerobic exercise program did not significantly alter 
insulin or glucagon content in rats with or without T1DM (p>0.05). 
Comparisons of pancreatic islets by size. T1DM led to a significant reduction in 
pancreatic islet size (p<0.05), independent of aerobic training (p>0.05; Figure 2.4). There 
was no significant three-way interaction for islet insulin or glucagon content between 
T1DM, aerobic training and islet size (p>0.05). There was a main effect of islet size on 
hormone content, as smaller islets had significantly more insulin and glucagon than large 
islets (p<0.05; Figure 2.5). Large islets had significantly more Ki67 positive cells than 
small islets based on the three-way ANOVA (p<0.05; Figure 2.6). Further, there were 
also main effects of diabetes and exercise (p<0.05). However, there was no significant 
interactions for Ki67 positive cells and islet size, diabetes or exercise (p>0.05). 
GLUT4 and insulin receptor protein content. Exercise training led to a significant 
increase in GLUT4 protein content in rats with T1DM (p<0.05; Figure 2.7). There were 
no significant differences in insulin receptor protein content across experimental groups 
(p>0.05). 
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 Weight (g) Blood Glucose Conc. (mM) 
 Pre Training Post Training Pre Training Post Training 
C (n=5) 338.9 ± 5.3 631.2 ± 26* 5 ± 0.1 4.6 ± 0.2 
C-ATmod (n=5) 350.6 ± 6.1 596.5 ± 16.8* 5.6 ± 0.3 4.1 ± 0.6 
D-CIT (n=6) 345.4 ± 3.1 561.8 ± 11.5*† 6.4 ± 0.5 12.2 ± 1*†# 
D-ATmod (n=6) 341.7 ± 3.2 526.6 ± 14.7*†# 6 ± 0.3 11.6 ± 1.6*†# 
Table 2.1: Animal characteristics. (*) indicates a significant difference from pre-training 
(p<0.05). (†) indicates a significant difference from non-T1DM sedentary rats (C) 
following training (p<0.05). (#) indicates a significant difference from non-T1DM 
exercised rats (C-ATmod) following training period (p<0.05). Data are expressed as a 
mean ± SE for each group. 
 
 
 
 
Figure 2.1. The change in blood glucose concentrations from pre to post exercise. The 
change in blood glucose concentrations in response to exercise was significantly different 
between non-T1DM exercised rats (C-ATmod) and T1DM exercised rats (D-ATmod; P<0.05). A 
significant increase in blood glucose was evident in response to exercise in C-ATmod rats 
while a significant decrease was evident in D-ATmod rats (P<0.05). The change in blood 
glucose concentration following exercise was not significantly changed at any point during 
training in C-ATmod or D-ATmod rats (P>0.05). Data are expressed as a mean ± SE for each 
group. 
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Figure 2.2. Representative images of pancreatic islet insulin (A) and insulin 
quantification (B). Pancreatic islets from both sedentary and exercised rats with T1DM 
had significantly less insulin staining than sedentary and exercised non-T1DM rats 
(P<0.05). (*) indicates a significant difference from C. (#) indicates a significant 
difference from C-ATmod (P<0.05). Data are expressed as a mean ± SE for each group 
(40x magnification; Bar=50µm). 
 
 
 
Figure 2.3. Representative images of pancreatic islet glucagon (A) and glucagon 
quantification (B). Pancreatic islets from both sedentary and exercised rats with T1DM had 
significantly more glucagon staining than sedentary and exercised non-T1DM rats (P<0.05). 
(*) indicates a significant difference from C. (#) indicates a significant difference from C-
ATmod (P<0.05). Data are expressed as a mean ± SE for each group (40x magnification; 
Bar=50µm). 
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Figure 2.4. Pancreatic islet area. Pancreatic islets from both sedentary and exercised rats with 
T1DM were significantly smaller than sedentary and exercised non-T1DM rats (P<0.05). (*) 
indicates a significant difference from C. (#) indicates a significant difference from C-ATmod 
(P<0.05). Data are expressed as a mean ± SE for each group.  
 
 
 
 
 
Figure 2.5. Pancreatic islet insulin (A) and glucagon (B) staining by diameter (small islets < 
50 µm). Small islets had significantly more insulin and glucagon staining than larger islets. 
(*) indicates a significant difference (P<0.05). Data are expressed as a mean ± SE for each 
group.  
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Figure 2.6. Representative Ki67 stain (A) and number of Ki67 positive cells per islet (B) 
based on islet diameter (small islets < 50 µm). Large islets had significantly more Ki67 
positive cells. (*) indicates a significant main effect of islet size (P<0.05). Both diabetes and 
exercise training had a significant main effect on Ki67 positive cells (P<0.05). Data are 
expressed as a mean ± SE for each group (40x magnification; Bar=50µm). 
 
 
 
 
Figure 2.7. GLUT4 (A) and insulin receptor (B) protein content in the red vastus muscle. 
Exercise training resulted in a significant increase in GLUT4 protein content in rats with 
T1DM (P<0.05). No change in insulin receptor protein content was evident across 
experimental groups (P>0.05). (*) indicates a significant difference compared to D-CIT 
(P<0.05). Data are expressed as a mean ± SE for each group.  
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2.4 Discussion 
 While exercise training has been shown to increase insulin sensitivity in patients 
with T1DM, it is unknown if this is accompanied by increased islet insulin content. 
Coskun et al.(10) determined via immunohistochemistry that aerobic training has positive 
effects on pancreatic β-cells during the induction phase of T1DM through STZ injections. 
Further, it has been reported that following 6 weeks of free-wheel training, STZ-induced 
T1DM mice demonstrated elevated levels of islet insulin staining, as a well as basal 
insulin release from isolated islets (20). Contrary to these findings, the present 
investigation found that 10 weeks of aerobic training failed to significantly alter insulin 
content in pancreatic islets. A possible explanation for these discrepancies might be the 
time at which the exercise regime was initiated. In the study by Coskun et al.(10), 
treadmill exercise was initiated prior to, and during STZ administration, while free-wheel 
exercise in the Huang et al.(20) study took place just three days following STZ 
administration. Indeed, similar to the current study, Howarth et al.(19) found that 
treadmill exercise initiated one week after the last STZ injection had no effect on the 
distribution of insulin within islets. These findings may suggest that aerobic exercise can 
have a positive influence on islet insulin content if exercise is initiated early in the course 
of T1DM development. Further, the role of exercise may be better suited to alleviate β-
cell degradation, rather than reversal of insulin loss after T1DM onset (10).  
 The current study also significantly differs from others with regard to the blood 
glucose level at which TIDM rats were maintained. In the present study both exercise 
trained and sedentary rats with T1DM were treated with subcutaneous insulin pellets in 
order to maintain blood glucose in a moderately hyperglycemic range (9-15 mM). This 
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range is within that typically observed for patients with T1DM treated with conventional 
insulin therapy (43). Further, individuals with T1DM are typically educated to refrain 
from exercise when blood glucose concentrations are greater than 14mM, as elevated 
blood glucose likely implies elevated ketones which can become detrimental and 
exacerbated by exercise (39). It is suggested that T1DM populations begin an exercise 
bout when blood glucose concentrations are between 5-13.9mM (39), however, most 
studies utilize animal models of T1DM in the absence of insulin supplementation and are 
severely hyperglycemic. In contrary to Coskun et al.(10), in the current investigation rats 
with T1DM were insulin treated and had similar blood glucose levels in both sedentary 
and trained groups. In this respect, exercise training may not have increased islet insulin 
content in the Coskun et al.(10) study but rather sedentary diabetic rats experienced larger 
insulin degradation as a result of their higher glycemic level (10). Indeed, prolonged 
exposure of isolated islets to high glucose concentrations greatly reduces islet insulin 
content (15). 
 It is well-recognized that T1DM is associated with an insulin deficiency within 
pancreatic islets; however, there is still uncertainty whether islet glucagon content may 
change over the course of diabetes. Some evidence has suggested there is little change in 
islet α-cells and glucagon content in both genetically-induced Biobreeder (BB) rats and 
chemically-induced STZ rats with T1DM (37), while others have shown significant 
increases in islet glucagon (19, 20, 27, 38). Consistent with the latter studies, we 
demonstrate that rats with T1DM had significantly more glucagon content per islet than 
rats without T1DM. The potential role that increased glucagon content in the pancreatic 
islet may have in exacerbating hyperglycemia has historical context. In 1975, Unger and 
Orci (46) proposed the bihormonal-hypothesis which suggests that chronic hyperglycemia 
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in T1DM is due to an insulin deficiency combined with an excess in circulating glucagon. 
T1DM is typically associated with postprandial hyperglucagonemia as the disease 
progresses, which may be reflected by the increased pancreatic glucagon content 
demonstrated in the present study (6). Elevated levels of glucagon as T1DM progresses 
has been suggested as a potential therapeutic target in the early course of T1DM (6). As 
such, the potential impact that aerobic training may have in reducing pancreatic islet 
glucagon content and subsequently hyperglucagonemia may prove useful as a therapeutic 
strategy.   
Exercise training has been shown to increase glucagon sensitivity through changes 
in glucagon receptor density and increased hepatic glucose production in response to a 
glucagon bolus (13, 25). Despite these changes it is unknown how glucagon content 
within pancreatic islets may change following exercise training. In the current study, the 
aerobic training program did not alter glucagon content in pancreatic islets of rats with 
T1DM. While these results were surprising, they may suggest that islet hormone content 
may not be the primary determinant governing its release and sensitivity; rather, neural or 
hormonal factors regulating islet hormone release may be of greater importance. This is 
supported by the fact that extremely low amounts of glucagon producing α-cells are still 
capable of maintaining glycemic control (45). Further, in comparison to rats without 
diabetes, STZ-induced T1DM animals exhibit a two-fold greater glucagon response to 
epinephrine, which is returned to normal levels following 10 weeks of aerobic training 
(34). Interestingly, this training-mediated alteration in glucagon release was also not 
explained by islet glucagon or insulin content, and similarly to the current findings, islet 
hormone content remained unchanged as a result of the training program (34). 
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Exercise-induced reductions in blood glucose occurs frequently in individuals 
with T1DM (3). Similarly, in the present study rats with T1DM frequently experienced 
significant exercise-induced reductions in blood glucose, while rats without T1DM 
experienced a rise in blood glucose concentrations. The different blood glucose responses 
to exercise between rats with and without T1DM likely occurred due to an inability to 
inhibit blood insulin concentrations in rats with T1DM, concomitant with increased 
insulin sensitivity as a result of the exercise (41, 50). The normal physiological response 
to exercise is to decrease the insulin to glucagon ratio, therefore promoting glucose 
production (47). However, similarly to the exercising T1DM population, rats with T1DM 
are unable to reduce exogenous insulin in circulation and thus blood glucose levels fall. 
 A significant portion of individuals with T1DM have difficulty regulating insulin 
dosing and suffer from insulin insensitivity and insulin resistance. While it is unclear as to 
the mechanisms by which T1DM individuals develop insulin resistance, they are 
disassociated from mechanisms-related to T2DM (2). As a consequence, insulin 
overcorrection is an unavoidable contributing factor to most hypoglycemic episodes (44). 
Further, insulin therapy is also problematic during glucose demanding states whereby 
circulating insulin levels must be intensely regulated (i.e. exercise)(5, 12). Exogenous 
insulin can potentiate the glucose demand of exercise and increase blood glucose 
clearance. Our laboratory has shown that exercise, regardless of modality, results in an 
increase in insulin sensitivity, shown by reduced exogenous insulin requirements, 
increased glucose clearance to a glucose tolerance test, as well as alterations in GLUT4 in 
skeletal muscle (18, 33). Exercise has also been shown to increase subcutaneous insulin 
absorption, which can ultimately lead to more significant insulin-induced reductions in 
blood glucose (12). As such, it was hypothesized that concomitant with the expected 
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increase in insulin sensitivity from exercise training, the reduction in blood glucose in 
response to an exercise bout would become larger in depth, ultimately increasing the 
frequency of exercise-induced hypoglycemia. Contrary to our hypothesis, the reduction in 
blood glucose which occurred following an exercise bout remained the same throughout 
10 weeks of training. This exercise-induced reduction in blood glucose occurred despite 
elevations in GLUT4 being evident following exercise training in rats with T1DM. The 
increase in GLUT4 protein content is likely even larger than shown in the current study, 
as translocation of GLUT4 to the cell membrane is transient and is typically greatly 
reduced by 48 hours post-exercise (16). A possible explanation for this finding is that 
increases in glucagon sensitivity likely occurred concurrently with insulin sensitivity. 
Indeed, it has been shown that aerobic training can increase the response of 
gluconeogenesis and glycogenolysis to glucagon (13, 14). This expected increase likely 
attenuated significant reductions in blood glucose, as glucagon itself accounts for more 
than 60% of glucose production during exercise (47, 48). In summary, these results and 
the findings of others suggest that regulation of blood glucose post-exercise is multi-
faceted and that several factors must be considered when attempting to improve the 
metabolic response to exercise in patients with T1DM.  
 While aerobic training was unable to alter pancreatic islet hormone content in rats 
with T1DM, evidence exists which suggests that pancreatic islets respond differently 
based on their size (21, 26, 28). Early reports suggested that the bulk of islet endocrine 
function comes from larger islets and small islets had little functional importance (23). 
However, to date this view has been challenged by evidence suggesting that small islets 
contain more insulin, are superior in insulin secretion, and have better transplantation 
outcomes compared to large islets (21, 26, 28). The majority of this work cites larger 
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increases in C-peptide and insulin secretion from small islets in isolated islet preparations; 
therefore, it was important to explore different islet subpopulations in an in vivo setting 
(21, 26, 28). Results from the present study support the view that small islets (<50µm in 
diameter) in rats with and without T1DM have significantly more insulin content per islet 
than larger islets. Huang et al.(21) also observed in vivo through immunochemistry that 
small islets had more insulin content than larger islets in rats without T1DM; however, 
until now this observation had not been demonstrated in T1DM pancreatic islets. Less 
information is available as to the distribution of glucagon with respect to islet size.  
MacGregor et al.(28) observed that glucagon content within small and large islets was 
distributed similarly between both subpopulations. However, to our knowledge, this is the 
first experiment to demonstrate that glucagon content was higher in smaller islets in rats 
with and without T1DM. Ultimately, the differences in the amount of insulin and 
glucagon content in different sizes of pancreatic islets supports the view that different 
subpopulations of pancreatic islets exist. Further, this suggests that the significant 
increase in glucagon content within the pancreatic islets of rats with T1DM may exist due 
the presence of more small islets than large. In order to determine if the increase in islet 
hormone content in small islets occurred as a result of increased cell proliferation the 
number of Ki67 positive cells were examined. While Ki67 positive cells were 
significantly higher in large islets, cell proliferation was likely occurring at the same rate 
between small and large islets, as proliferating cells within islets were minimal. Despite 
cell proliferation not occurring at a high rate, islets may be undergoing dedifferentiation 
or hypertrophy. Indeed, others have shown that small islets consistently had a higher cell 
density when compared to larger islets (21). Further work is required to determine the 
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implications of islet size on both insulin and glucagon release, although it does not appear 
that aerobic training is able to alter changes in islet size in rats with T1DM. 
 To date, studies examining alterations in islet hormone content following aerobic 
training were conducted in T1DM animals without insulin supplementation, an 
environment not representative of human population with T1DM. Using a conventional 
insulin therapy model, the present investigation determined whether 10 weeks of aerobic 
training could restore T1DM pancreatic islet hormone composition to similar levels as 
age matched rats without T1DM. It was concluded that 10 weeks of exercise training was 
unable to improve insulin and glucagon content in pancreatic islets. Further, the current 
study supports the view that different islet subpopulations, based on size, may exist. 
Although no islet composition changes were evident following exercise training, the 
magnitude of exercise-induced blood glucose reductions remained constant across the 10 
weeks of training.   
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CHAPTER 3 
 
3 «Ischemia-reperfusion injury and hypoglycemia risk 
in insulin-treated T1DM rats following different 
modalities of regular exercise» 
 
3.1 Introduction 
Ischemic heart disease is a major complication that is associated with significant 
morbidity and mortality, particularly for patients with Type 1 Diabetes Mellitus (T1DM) 
(36). Experimental evidence supports the view that populations with T1DM are more 
susceptible to ischemia, as hearts from streptozotocin (STZ)-induced diabetic models are 
more sensitive to damage following ischemic-reperfusion injury (I/R-injury), as 
demonstrated by increased infarct size (15). Regular exercise can improve cardiovascular 
function, as well as other diabetes-related complications including bone health, body 
composition, kidney function, insulin sensitivity, and overall quality of life (8, 10, 21, 25, 
31). Despite these benefits, many patients with T1DM refrain from participating in regular 
exercise, largely due to the increased risk of experiencing hypoglycemia. Exercise is the 
most frequently identified cause of known hypoglycemia, while fear of experiencing a 
hypoglycemic event is the number one barrier for exercise participation for patients with 
diabetes (5, 6). 
The Canadian Diabetes Association guidelines advise patients with diabetes to 
participate in regular exercise of moderate intensity (50-70% maximal heart rate (MHR)) 
to vigorous intensity (>70% MHR), at least 3 times a week for a total of 150 minutes (1, 
51). However, there is a lack of evidence that regular exercise is capable of improving the 
primary clinical treatment outcome measure, HbA1c, which has led many to question 
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whether exercise is as advantageous to patients with T1DM as it is for those with Type 2 
diabetes mellitus (8, 28). In fact, patients with T1DM regularly compensate their glucose 
management by elevating pre-exercise blood glucose concentrations through a reduction in 
insulin dosage to offset the risk of hypoglycemia (47). In a recent study, we examined the 
role of a ten-week moderate intensity aerobic exercise training program on cardiac function 
in poorly controlled STZ-induced T1DM rats. (31). Maintaining T1DM rats in a moderately 
hyperglycemic range through insulin supplementation was conducted to measure the 
cardiovascular benefit of regular aerobic exercise in a T1DM model that more accurately 
reflects those individuals with T1DM who exercise (31, 47, 50). Regular moderate intensity 
aerobic exercise led to significant improvements in cardiovascular function, as evidenced 
by an improved ratio of the early (E) and late (A) ventricular filling velocities (E/A ratio: a 
marker of left ventricle diastolic function), as well as improvements in other diabetic 
complications including bone density, insulin sensitivity measures and body composition 
(31). In rats with T1DM, regular aerobic exercise also led to a significant increase in Hsp70 
protein content in the heart to the same degree as non-diabetic exercised rats (31). Elevated 
Hsp70 is believed to combat diabetes-related damage in many organ systems through 
enhanced antioxidant defenses, which provides a potential mechanism by which exercise 
may offset hyperglycemic-related oxidative stress (37, 38).  
Promising clinical data have shown that higher levels of exercise intensity, either 
aerobic or resistance exercise, may alleviate the onset of hypoglycemia in T1DM subjects 
through increased secretion of glucose counter-regulatory defenses  (1, 48, 49). However, 
few studies have examined the cardiovascular benefits of these forms of exercise. In fact, 
many practitioners encourage patients with diabetes to avoid intense exercise, as vigorous 
physical activity can acutely and transiently increase the risk of a cardiovascular event (46). 
  
However,  a recent study in patients with coronary heart disease reported that although a 
low risk of experiencing a cardiovascular event is present, given the tremendous advantages 
over lower intensity exercise, high intensity exercise should be considered in a coronary 
heart disease rehabilitation setting (41). Indeed, our laboratory has shown that higher 
intensities of regular aerobic exercise in rats with T1DM leads to improvements in 
vasorelaxation responsiveness, insulin dose requirements and insulin sensitivity measures 
in comparison to lower intensities of exercise (18, 34). Experimental work is needed to 
further understand the cardiovascular benefits associated with different modalities of 
exercise, while taking into consideration which of these exercise modalities provide the 
lowest risk of exercise-mediated hypoglycemia.  
The present study employed an insulin-treated STZ model of T1DM in which rats 
were maintained at moderately elevated blood glucose concentrations, which more 
accurately reflects the exercising patient population of T1DM. Using this model, we 
examined which mode of exercise training elicited the greatest cardiovascular benefit, as 
determined by the recovery from ischemia-reperfusion (I/R) injury. Secondly, we measured 
the blood glucose concentration of rats with T1DM prior to, and following exercise, in 
order to examine which mode of regular exercise delivers the lowest risk of hypoglycemia 
development. It was hypothesized that higher intensities of regular exercise such as 
resistance and high intensity aerobic exercise would lead to the greatest cardiovascular 
benefit while limiting the onset of exercise-mediated hypoglycemia during the course of 
the exercise program.  
3.2 Methods 
 
Eight-week old male Sprague-Dawley rats were obtained from Charles River 
Laboratories, housed two per cage and maintained on a 12-hour dark/light cycle at a 
constant temperature (20 ±1°C) and relative humidity (50%). Rats were allowed access to 
standard rat chow (Prolab-RMH-3000; PMI Nutrition International: 22% crude protein, 5% 
crude fat, 5% fiber, 6% ash) and water ad libitum. Ethics approval for the participation of 
rats in this study was acquired through the Research Ethics Board of the University of 
Western Ontario, which is in accordance with the guidelines of the Canadian Council on 
Animal Care. 
Experimental groups. Fifty rats were randomly assigned to one of five groups: 1) 
Non-diabetic sedentary control (C; n=10), 2) diabetic sedentary control (D-CIT; n=10), 3) 
diabetic resistance exercise (D-RT; n=10), 4) diabetic low intensity aerobic exercise (D-
ATlow; n=10) and 5) diabetic high intensity aerobic exercise (D-AThigh; n=10).  
Diabetes Induction. Upon arrival rats were housed for a minimum of five days to 
allow them to become familiar with their new surroundings. T1DM was induced by 
administering 20 mg/kg of filtered (0.2µm) streptozotocin (STZ; Sigma Alderich, Oakville, 
Ontario) dissolved in a citrate buffer (0.1M, pH 4.5) via intraperitoneal (IP) injection on 
five consecutive days. Diabetes was confirmed by measuring two consecutive blood 
glucose concentrations of greater than 18mM. If diabetes confirmation was not obtained 
following five injections, the animals were given subsequent 20mg/kg STZ-IP injections 
until two readings of 18mM were obtained. Following the confirmation of diabetes, insulin 
pellets (LinShin, Toronto, Ontario) were implanted subcutaneously above the abdomen.  
According to manufactures instruction, each insulin pellet slowly releases insulin at an 
approximate rate of two International Units (IU) per day. Insulin pellet dosages were then 
monitored for 1 week and adjusted in order to obtain daily non-fasting blood glucose 
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concentrations in the range of 9-15mM, representative of conventional insulin therapy 
(CIT). 
Exercise Protocols. The exercise protocols consisted of six weeks of regular 
exercise (5 days per week, starting at 9am). D-RT rats were required to climb a ladder with 
a weighted bag secured to the proximal portion of their tail. The ladder was 1.1 m tall on 
an 80-degree incline with 2 cm spacing between rungs. This protocol describes an animal 
model of resistance exercise that closely resembles the exercise parameters and 
physiological adaptations observed in humans who participate in resistance training (19). 
During the first week of the exercise intervention, D-RT rats were familiarized to the 
weighted ladder climb. To do so, rats performed 10 climbs per day with varying weights 
attached to their tails (5%, 15%, 20%, and 35% of each rat’s body mass). Between each 
climb, rats were allowed to rest for 120 seconds in a 20 cm3 darkened box placed at the top 
of the ladder. The rest of the resistance training intervention (week two to six) consisted of 
rats carrying 50%, 75%, 90% and 100% of their maximal lifting capacity for the first four 
climbs. Subsequent climbs were performed at 100% of their maximal lifting capacity until 
rats reached exhaustion (unable to finish a climb despite tactile stimulation to haunches). 
To determine maximal lifting capacity, rats were initially required to climb carrying 75% 
of their body weight. Thirty grams of weight was then added to each subsequent climb until 
rats reached exhaustion. The weight carried prior to exhaustion was marked as the new 
maximal lifting capacity. Maximal lifting capacity was determined and checked every four 
exercise sessions. During the first week of exercise, D-ATlow were familiarized on the 
motor-driven treadmill (6 percent grade) at progressive running speeds of 7 m/min for 10 
minutes, 11 m/min for 10 minutes, 13 m/min for 30 minutes and 15 m/min for 10 minutes. 
Following familiarization (Weeks 2-6), D-ATlow rats exercised for 1 hour per day at a speed 
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of 15 m/min (6 percent grade). Week one of D-AThigh familiarization consisted of 
progressive running on the motor-driven treadmill (6 percent grade) at 7 m/min for 10 
minutes, 15 m/min for 10 minutes, 21 m/min for 30 minutes and 24 m/min for 10 minutes. 
Following familiarization (Weeks 2-6), D-AThigh rats ran for 1 hour per day at a speed of 
27 m/min (6 percent grade). The exercise intensity chosen for D-ATlow and D-AThigh was 
approximately 50-60% and 70-80% of VO2max, respectively (3). Continuous running during 
the aerobic exercise sessions was encouraged by small blasts of compressed air when rats 
broke a photoelectric beam close to the rear of the treadmill belt. 
Body Weights and Blood Glucose Concentrations. Body weights and blood glucose 
concentrations for C, D-CIT, D-RT, D-ATlow and D-AThigh were measured prior to the STZ 
administration and exercise intervention, as well as prior to the last exercise session. Post-
exercise blood glucose measures were collected every 15 minutes for 2 hours following an 
exercise bout and occurred during week three and week six of the exercise intervention.  
Weeks three and week six of the exercise interventions were selected as the early and late 
phases, respectively. To remove any stress-related changes in blood glucose responses to 
exercise, week three was selected as the early time phase, as animals have become familiar 
with the mechanics of the exercise by this stage and require little encouragement to 
complete the one hour exercise session. Blood was obtained from the saphenous vein (50 
ul drop) and blood glucose concentrations were detected using a One Touch Ultra 2 Blood 
Glucose Monitoring System (Lifescan Canada Ltd, Burnaby, BC) and One Touch test strips 
(Lifescan Canada Ltd, Burnaby, BC). Following blood collection at sacrifice, samples were 
clotted at room temperature for at least 30 minutes and then centrifuged at 10,000 rpm for 
15 minutes at 4°C. Aliquots of serum were collected and analyzed for HDL cholesterol, 
total cholesterol, and triglycerides using a Hitachi 911 analyzer. Exogenous insulin 
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concentrations were measured by ELISA (Alpco, Salem, NH: Catalog #80-INSRT-E01) 
following the exercise intervention.  
Heart collection and Langendorff preparation. Eighteen hours after their last 
exercise bout animals were anaesthetized via intraperitoneal injection of sodium 
pentobarbital (65mg/kg) and sacrificed. Hearts were extracted and immediately arrested by 
placing them in ice cold Krebs-Henseleit buffer (KHB). Hearts were cannulated for 
unpaced retrograde aortic constant flow perfusion (15 ml/minute) of coronary arteries with 
KHB (120mM NaCl, 4.63mM KCl, 1.17mM KH2PO4, 1.25mM CaCl2, 1.2mM MgCl2, 
20mM NaHCO3, and 8mM glucose gassed with 95% O2, and 5% CO2 ) maintained at 37°C 
(37). Hearts were equilibrated for 30 minutes to determine baseline function (pre-ischemic 
value) and then flow was terminated for 50 minutes to induce ischemia. Following 
ischemia, hearts were subsequently reperfused for 30 minutes at 15 mL/minute. Measures 
of left ventricular mechanical function were measured throughout the 30 minute 
reperfusion period. These measures of left mechanical function include left ventricular 
developed pressure (LVDP), left ventricular end-diastolic pressure (LVEDP), maximal rate 
of contraction (+dP/dt) and maximal rate of relaxation (-dP/dt). Each cardiac functional 
measure obtained during the reperfusion period was then converted to a percentage of pre-
ischemic values. Immediately following the ischemia-reperfusion protocol, hearts were 
removed from the cannula and the left ventricle was dissected, frozen in liquid nitrogen, 
and stored at -70°C until analyzed.  
Western blotting. Left ventricles were homogenized in a 1:10 (weight:volume) ratio 
of buffer (100mM NaCl, 50mM Tris base, 0.1mM EDTA, 0.1mM EGTA and 1% Triton-
X 100, adjusted to pH ~7.5, 1% phosphatase inhibitor and 1% protease inhibitor) using a 
polytron, and centrifuged at 14000 rpm for 20 minutes. The Bradford protein assay was 
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used to calculate total protein concentration in each homogenate sample. Polyacrylamide 
gels were composed of a 10% acrylamide separating gel and 4% acrylamide stacking gel. 
Homogenates were placed in a 1:1 ratio of sample buffer (0.5M Tris base, 13% glycerol, 
0.05% SDS, 13% 2-beta-mercaptoethanol, and bromophenol blue) to homogenates. Each 
gel contained a molecular weight marker to determine the molecular weight of the proteins. 
Electrophoresis was then performed and proteins were run at a constant voltage of 150V 
for 1.5 hours in running buffer (25mM Tris base, 200mM glycine, and 0.1% SDS, pH ~8.3). 
Gels were placed in transfer buffer (10% running buffer, 20% methanol, 70% ddH20) and 
proteins were electrophoretically transferred to nitrocellulose membranes at 70V for 1.5 
hours. The membranes were blocked in 5% non-fat dry milk (BioRad, Mississauga, ON 
170-6404) in Tris buffered saline (TTBS; 10mM Tris, 100mM NaCl, 0.1 % Tween-20, pH 
7.5) for 1 hour. Membranes were then incubated overnight at 4°C with primary antibodies 
specific to Hsp70 (Enzo Life Sciences Inc., Farmingdale, NY; 1:4000), MnSOD (Enzo Life 
Sciences Inc., Farmingdale, NY; 1:2000), and Cu/Zn SOD (Enzo Life Sciences Inc., 
Farmingdale, NY; 1:2000) in TTBS with 2% non-fat dry milk. After primary antibody 
incubation, nitrocellulose membranes were washed in TTBS 3 times for 10 minutes. 
Membranes were then incubated for 1 hour with horseradish peroxidase-conjugated 
secondary antibody specific for rabbit IgG (goat anti-rabbit IgG-HRP conjugate, BioRad, 
Mississauga, ON; 1:5000) diluted in TTBS with 2% non-fat dry milk.  Membranes were 
again washed in TTBS 3 times for 10 minutes and subsequently imaged using 
chemiluminescent detection. A luminol-based chemiluminescent substrate (BioRad, 
Mississauga, ON;Western C Enhanced Chemiluminescent Kit, 170-5070) was placed on 
the membranes, allowing protein bands to become visible. Protein bands were captured 
using a BioRad Chemidoc XRS imager and optical densities were quantified using BioRad 
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Quantity One software. Optical densities were normalized to a soleus positive control as 
well as β-actin. 
Data analysis. Body weight, blood lipids, exogenous insulin, glucose 
concentrations, Langendorff measures (AUC), Hsp70, MnSOD and Cu/Zn SOD protein 
content were compared via one-way ANOVA. Post-exercise blood glucose concentrations 
were compared using a two-way repeated measures analysis of variance (ANOVA). When 
a significant effect was found, a least squares difference post hoc test was performed. A 
significance level was set at p<0.05. All data are expressed as mean ± SE. All statistical 
analysis was performed using SigmaPlot and SigmaStat computer software.   
3.3 Results 
Animal Characteristics. In comparison to C, all diabetic animals (D-CIT, D-RT, D-
ATlow and D-AThigh) demonstrated significantly lower mean body weight, while 
demonstrating significantly higher blood glucose concentrations prior to both the onset of 
the exercise intervention and the last bout of exercise (p<0.05; Table 3.1). These measures 
did not differ across the diabetic groups (p>0.05). Regular exercise reduced exogenous 
insulin requirements independent of the exercise modality (p<0.05). Several components 
of the blood lipid panel were significantly altered as a result of diabetes in comparison to 
non-diabetic animals (p<0.05; Table 3.1). Triglyceride and LDL cholesterol were 
significantly lower than C animals (p<0.05), and were not altered as a result of exercise 
training (p>0.05). Total cholesterol was reduced in D-RT and D-ATlow, and the lowest in 
D-ATlow (p<0.05). Total cholesterol:HDL was significantly lower in the exercise trained 
(D-RT, D-ATlow, and D-AThigh) animals and lowest in the D-ATlow animals (p<0.05). 
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Left ventricle mechanical performance. Compared to C, diabetic groups (D-CIT, D-
ATlow, D-RT and D-AThigh) demonstrated greater cardiac functional performance in post-
ischemic left ventricular developed pressure (LVDP), maximal rate of contraction (+dP/dt) 
and maximal rate of relaxation (-dP/dt) (Figure 3.1; p<0.05). The demonstrated protective 
effects of exercise, as assessed by left ventricular performance, were not consistent across 
each of the modalities of exercise. D-AThigh animals showed the greatest positive benefit in 
cardiovascular recovery in comparison to D-CIT and D-RT in all four variables examined 
(LVDP, LVEDP, +dP/dt, -dP/dt) (p<0.05). Both the D-AThigh and D-CIT animals had 
significantly lower left ventricular end-diastolic pressure (LVEDP), which was not 
significantly different amongst the rest of the groups (p<0.05).  
SDS-PAGE and Western blot analysis. Compared to both C and D-CIT, D-AThigh 
rats exhibited higher cardiac Hsp70 expression (Figure 3.2; p<0.05). Hsp70 content of both 
D-RT and D-ATlow trained rats were not significantly different from either C or D-CIT 
(p>0.05). There were no differences in MnSOD across experimental groups (Figure 3.3A; 
p>0.05). Compared to C, both D-ATlow and D-AThigh had significantly higher expression 
of Cu/Zn SOD, while D-ATlow had significantly elevated levels of Cu/Zn SOD in 
comparison to D-CIT (Figure 3.3B; p<0.05). 
Exercise-mediated blood glucose reductions. At week three, blood glucose 
concentrations in D-RT animals declined slowly following the exercise, reaching 
significantly lower concentrations (vs. pre-exercise) at 45 minutes post-exercise, and 
remained significantly lower until 110 minutes post-exercise (Figure 3.4A; p<0.05). In D-
ATlow and D-AThigh animals, the decline in blood glucose concentrations in response to 
exercise during week three was evident immediately following the exercise session (Figure 
3.4B and 3.4C; p<0.05). The reduction in blood glucose concentrations of D-ATlow rats 
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remained significantly lower (vs. pre-exercise) at 120 minutes post-exercise, while D-
AThigh rats returned to pre-exercise blood glucose concentrations by 90 minutes post-
exercise (p<0.05). At week six of training, D-RT rats demonstrated a delayed blood glucose 
response to exercise in comparison to the week three exercise session, whereby a significant 
drop in blood glucose was not evident until 60 minutes post-exercise (p<0.05). Similarly, 
D-AThigh rats demonstrated an altered blood glucose response to exercise at week six, 
exhibiting a quicker return to pre-exercise blood glucose concentrations by 60 minutes 
(p<0.05). At week six, a drop in blood glucose was absent in D-ATlow rats, but rather an 
increase in blood glucose was evident at 30, 105 and 120 minutes post-exercise (p<0.05).  
 Despite a reduction in blood glucose concentration being apparent across the 
different modalities of exercise, the extent of the drop in blood glucose did not approach 
hypoglycemic concentrations (<3.0mM) in either week three or six of exercise training. 
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 C D-CIT D-RT D-ATlow D-AThigh 
Blood glucose (mM)      
 Pre-STZ 
administration 
5.6 ± 0.09 5.8 ± 0.2 5.8 ± 0.2 5.3 ± 0.2 5.4 ± 0.2 
 Pre-exercise 
intervention 
5.6 ± 0.1 11.8 ± 1.2* 14.5 ± 1.5* 12.0 ± 1.7* 15.2 ± 0.5* 
 Prior to the last 
bout of exercise 
5.13 ± 0.15 15.45 ± 0.84* 15.27 ± 0.75* 13.2 ± 1.24* 14.81 ± 0.76* 
Body weight (g)      
 Pre-STZ 
administration 
366 ± 7.88 371 ± 9.09 365 ± 6.94 345 ± 7.10 360 ± 8.10 
 Pre-exercise 
intervention 
408 ± 7.90 376 ± 5.81* 372 ± 5.34* 369 ± 7.33* 365 ± 8.48* 
 Prior to the last 
bout of exercise 
574 ± 9.05 471 ± 9.05* 452 ± 11.16* 448 ± 21.72* 438 ± 8.43* 
Exogenous insulin (IU)  25.41 ± 10.58 11.90 ± 3.62# 14.53 ± 7.46# 11.00 ± 3.77# 
Total cholesterol (mM) 1.81 ± 0.13 1.63 ± 0.11 1.42 ± 0.07 * 1.33 ±0.07 *# 1.59 ±0.03 
Triglycerides (mM) 1.72 ± 0.13 1.09 ± 0.14* 1.16 ± 0.20 * 0.857 ± 0.18* 1.09 ± 0.13* 
HDL cholesterol (mM) 0.78 ± 0.16 1.11 ± 0.15 1.10 ± 0.08 0.98 ± 0.06 1.03 ± 0.03 
Total cholesterol:HDL 1.90 ± 0.3 1.67 ± 0.09 1.59 ± 0.13* 1.38 ± 0.05*# 1.54 ± 0.04* 
LDL cholesterol (mM) 1.95 ± 0.30 0.84 ± 0.21* 0.84 ± 0.32* 0.45 ± 0.15* 0.77 ± 0.18* 
Data are means ± SE; n=10. (*) significantly different from C (p<0.05). (#) significantly different from                   
D-CIT (p<0.05). 
Table 3.1. General animal characteristics at the completion of the study. 
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Figure 3.1. Effect of T1DM and exercise training modality on left ventricle mechanical 
function. The data are presented in time course format (A) and area under the curve 
measurement (B). Compared with control, diabetic stress and exercise training lead to 
enhancement in post-ischemic LVDP, +dP/dt , –dP/dt but not LVEDP in rat hearts. (*) different 
than C (P<0.05), (†) different than D-CIT (P<0.05), (‡) different than D-RT (P<0.05), (ψ) 
different than D-AThigh (P<0.05). Data presented as a mean ± SE. 
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Figure 3.2. Effect of T1DM and exercise training modality on left ventricle Hsp70 protein 
content. High intensity aerobic exercise training led to an enhancement in Hsp70 expression in 
rat hearts compared to sedentary rats. (*) different than C (P<0.05), (†) different than D-CIT 
(P<0.05). Data presented as a mean ± SE. 
 
 
 
Figure 3.3. Effect of diabetic stress and training on left ventricle MnSOD (A) and Cu/Zn SOD 
(B) protein content. No change in MnSOD was evident across experimental groups while both 
low and high intensity exercise aerobic training led to elevations in Cu/Zn SOD when 
compared to sedentary control rats. Low intensity aerobic exercise also demonstrated 
significantly more Cu/Zn SOD compared to sedentary diabetic rats. (*) different than C 
(P<0.05), (†) different than D-CIT (P<0.05). Data presented as a mean ± SE. 
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Figure 3.4. Two-hour post-exercise blood glucose measures. Blood glucose was measured in (A) D-RT 
(B) D-ATlow and (C) D-AThigh every 15 minutes for 2 hours post-exercise. D-RT and D-AThigh 
demonstrated no significant difference in post-exercise blood glucose response between week 3 and 
week 6; D-ATlow demonstrated an attenuated blood glucose response at week 6 compared to week 3 
(p<0.05). (*) indicates a significant difference in blood glucose from pre-exercise (-15 minutes) at week 
3 (P<0.05), (†) indicates a significant difference in blood glucose from pre-exercise (-15 minutes) at 
week 6 (P<0.05). Data presented as a mean ± SE.  
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3.4 Discussion 
Using an insulin-treated model of T1DM, the purpose of the present study was to 
investigate the cardiovascular benefit of several different exercise regimes which have been 
previously shown clinically to minimize the onset of hypoglycemia by exercise (29, 48). 
Here, we demonstrate that the extent of exercise-related protection from ischemia-
reperfusion (I/R) damage appears to be dependent on the exercise modality, whereby high 
intensity aerobic exercise demonstrates the greatest recovery following an ischemic insult. 
Secondly, although insulin-treated rats with T1DM demonstrated a significant drop in 
blood glucose concentration regardless of exercise modality, blood glucose concentrations 
failed to reach hypoglycemic concentrations (<3.0mM) and aerobic exercise was associated 
with the fastest return to pre-exercise glucose concentrations, especially with longer periods 
of regular exercise. These findings would suggest that each exercise modality can be 
performed safely, at least under conditions in which blood glucose concentrations are 
elevated before exercise is initiated; however, the greatest cardiovascular benefit is evident 
following high intensity aerobic exercise.  
In partial agreement with our hypothesis, these results demonstrate an intensity-
related effect on the reduction of I/R-injury in aerobically trained rats. These findings 
would support previous literature in otherwise healthy individuals in which exercise 
performed at higher relative intensities elicited greater cardiovascular benefit than 
moderate intensity levels of exercise, independent of the volume of activity (26). Less 
information is available with regards to the impact of higher levels of exercise intensity in 
patients with T1DM, a population well characterized to be at greater risk for cardiovascular 
disease (36). In line with these findings, our laboratory has previously reported that high 
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intensity aerobic exercise training is able to restore the diabetes-related loss of nerve arterial 
vasodilation, decreased vascular responsiveness, and insulin sensitivity (18, 34, 35). In 
contrast to high intensity aerobic training, we found little evidence of cardiovascular 
protection from I/R-injury following six weeks of resistance exercise (D-RT) and low-
intensity aerobic exercise (D-ATlow) in comparison to sedentary diabetic (D-CIT) rats. To 
our knowledge, the present investigation is one of the first studies to have measured I/R-
injury in resistance exercised animals with T1DM. Doustar et al. (12) examined the impact 
of a 4-week resistance training program on I/R-injury in healthy rats and reported no 
exercise-related benefits. However, in a subsequent study it was demonstrated that 12 
weeks of resistance training led to significant improvements in coronary flow, developed 
pressure, diastolic pressure and infarct size, suggesting that this form of exercise can be 
effective for cardiac protection (42). Thus, the current findings may be reflective of the 
slower beneficial adaptations this form of exercise training may have in comparison to 
aerobic exercise. Indeed, endurance exercise has been shown to elicit rapid cardiovascular 
adaptations following as little as 6 days of training (16, 17). While it is difficult to 
extrapolate these reports to our model of T1DM, it is plausible that lengthening the 
resistance training program may lead to enhanced cardiac protection to a similar degree as 
high intensity exercise.  
Our laboratory, as well as others, have demonstrated that exercise-related increases 
in Hsp70 can protect the myocardium against I/R injury (4, 20, 32, 37). It has been 
established that Hsp70 protein is reduced in several tissues including the heart in severely 
hyperglycemic rats with STZ-induced T1DM (2). Further, the elevated expression of Hsp70 
in the heart, which normally occurs following moderate intensity aerobic exercise, is 
suppressed in untreated STZ-induced T1DM animals (2). Using the same insulin-treated 
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diabetic model used in the current study we recently reported that rats with T1DM are able 
to elicit elevations in constitutive Hsp70 content in the heart to similar levels as non-T1DM 
controls following moderate intensity exercise training (31). These discrepancies are likely 
due to the use of insulin supplementation in our rat model of T1DM. It has been established 
that insulin treatment alone can increase Hsp70 expression, as well as enhance myocardial 
recovery of contractile function post-ischemic injury (27). Here, we demonstrate that the 
elevations in heart Hsp70 expression were modality specific and positively associated with 
the level of cardiovascular protection. High intensity aerobic exercise (D-AThigh) 
demonstrated a significant elevation in Hsp70 and exhibited the largest recovery from I/R 
injury. In contrast, low intensity regular aerobic exercise (D-ATlow) did not exhibit evidence 
of improved cardioprotection, nor did this exercise regime display significant increases in 
heart Hsp70. Indeed, it has been reported that an intensity dependent threshold exists in the 
expression of Hsp70 following aerobic exercise in otherwise healthy animals (33).  
A notable finding of the current study is that in comparison to C animals, D-CIT 
animals demonstrated some level of protection from I/R injury. This ischemia resistance 
has been demonstrated in STZ models of T1DM elsewhere in the literature (24, 44) and 
may be due to the duration and severity of the diabetic state (for detailed review, see (39)). 
Enhanced antioxidant defenses may contribute to this heightened cardioprotection, as it has 
been reported that animals with STZ-induced T1DM demonstrate elevations in antioxidant 
defenses, such as catalase, Mn-SOD, and Glutathione S Transferase  (GST), which are 
evident as early as two weeks following STZ-administration (23, 45). Although rats with 
T1DM in the present study did not exhibit changes in cardiac MnSOD or Cu/Zn SOD 
protein, it is possible that their activity or other antioxidant defenses may be elevated and 
contribute to increased cardioprotection (40). It has been shown that hearts of rats with 
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T1DM demonstrate a decrease in the accumulation of glycolytic products during ischemia 
(lactate and protons), which has also been proposed to be beneficial during an ischemic 
event (14). Further, T1DM hearts have been shown to have alterations in intracellular 
calcium signaling, which has been shown to induce protection in the normal heart (40). It 
is important to note that enhanced protection from I/R injury has also been reported in 
patients with T1DM undergoing forearm ischemia (13). Increased nitric oxide production 
coupled with changes in vascular diameter may also contribute to improved cardiovascular 
function in the early stages of streptozotocin induced diabetes (9).  Lastly, rats with T1DM 
in the current study were supplemented with insulin, which may have put them in a 
heightened protective state in comparison to control sedentary animals (27). Nonetheless, 
the current data provide evidence that high intensity aerobic exercise can greatly improve 
cardiovascular function in insulin-treated rats with T1DM. Further work is still required to 
fully understand the susceptibility of patients with T1DM to damage during ischemic stress 
and the impact of insulin treatment on the severity of the stress.  
While benefits in cardiovascular function and protection from I/R damage are 
evident following high intensity aerobic exercise, a primary consideration when prescribing 
exercise to populations with T1DM is the elevated risk of experiencing hypoglycemia. 
Exercise-mediated reductions in blood glucose differed based on the exercise modality, an 
observation well documented in patient populations with T1DM (11, 22, 48). In the present 
investigation we observed that at week three of the exercise intervention both aerobic 
exercise modalities (low and high intensity) led to a significant drop in blood glucose 
immediately post-exercise. In contrast, resistance exercise resulted in a more gradual 
decline in blood glucose, which did not return to pre-exercise values until approximately 
four hours post-exercise (data from 2-4 hours not shown). This gradual decline in blood 
 	

glucose in response to resistance exercise may be more beneficial for patients with T1DM, 
as it provides ample time to combat the drop in blood glucose following exercise. 
Precautionary measures such as carbohydrate ingestion or a decrease in insulin dosage 
could mitigate the reduction in blood glucose altogether. Managing the immediate drop in 
blood glucose which occurs in response to aerobic exercise is more challenging, and as 
such, patients often compensate by elevating blood glucose concentrations prior to exercise 
through carbohydrate ingestion or insulin dosage adjustments (47, 50). However, it is 
important to note that despite the rapid drop in blood glucose, exercising rats with T1DM 
failed to reach hypoglycemic blood glucose concentrations (<3.0mM) when they started 
with moderately elevated blood glucose concentrations. As such, maintaining blood 
glucose concentrations at a higher target range prior to exercise, significantly reduces the 
risk of hypoglycemia associated with aerobic exercise.  
In a recent publication, our group demonstrated that the immediate exercise-induced 
reduction of blood glucose in response to moderate intensity aerobic exercise is unaltered 
after ten weeks of training (30). Here, it appears that the magnitude of blood glucose 
reduction in response to different exercise modalities, and the return to pre-exercise blood 
glucose concentrations, may adapt during the course of the six-week exercise intervention. 
For instance, an elevation in blood glucose was evident post-exercise following six weeks 
of low intensity aerobic exercise rather than a significant decline in blood glucose, which 
was apparent at week three. This is of particular interest given that insulin sensitivity is 
heightened following exercise training and it is unlikely that a robust sympathetic response 
would be present at this level of exercise intensity (18, 43). However, it is likely that a 
reduction in the reliance on blood glucose as an energy source occurred, as running speed 
was consistent across the treatment period. Thus, the relative exercise intensity likely 
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declined towards the later stages of the experiment, which in turn may have led to a shift 
in fuel source from primarily carbohydrate to fat (7). On the other hand, high intensity 
aerobic and resistance exercised rats displayed a smaller blood glucose adaption post-
exercise following the exercise intervention. It is plausible that the higher level of intensity 
in these exercise modalities led to a similar, or even increased (resistance exercise), glucose 
demand during the course of the exercise intervention period.  
In summary, we demonstrate that the extent of exercise-related protection from I/R 
damage appears to be dependent on exercise modality, whereby higher intensities of 
aerobic exercise demonstrate the greatest recovery following an ischemic insult.  Secondly, 
although the magnitude and time course is different, a significant decrease in blood glucose 
is apparent following each modality of exercise. Maintaining rats at a higher target blood 
glucose concentration prior to exercise may reduce the risk of post-exercise hypoglycemia. 
These findings would suggest that each exercise modality can be performed safely when 
combined with moderately elevated blood glucose; however, the greatest benefits are 
evident following high intensity aerobic exercise.  
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CHAPTER 4 
 
4 «!Exercise training induced cardioprotection with 
moderate hyperglycemia versus sedentary intensive 
glycemic control in Type 1 diabetic rats» 
 
4.1 Introduction 
Individuals with Type 1 diabetes mellitus (T1DM) exhibit a heightened risk for 
cardiovascular disease (CVD) not entirely accounted for by traditional risk factors 
(hyperglycemia, obesity, hypertension, dyslipidemia, and smoking)(39). Since the advent 
of the Diabetes Control and Complications Trial (DCCT) the predominant treatment to 
limit diabetic complications such as CVD, has been intensive insulin therapy (IIT)(26). 
Regular exercise is also well-recognized for its cardiovascular benefits for populations 
with T1DM (5, 20, 22). However, both IIT and exercise potentiate the risk of 
hypoglycemia, especially when attempted collectively (4, 26). Over 60% of individuals 
with T1DM are inactive (30), with fear of hypoglycemia identified as their largest barrier 
to exercise participation (4). Further, accumulating evidence suggests that while IIT 
decreases HbA1c it can also lead to weight gain and insulin resistance development, 
leading many to question HbA1c as a marker for  cardiovascular risk (7).  
Individuals with T1DM often intentionally elevate their blood glucose 
concentrations prior to exercise through changes in insulin dosing and/or carbohydrate 
ingestion in order to counteract the risk of hypoglycemia (48). Indeed, it has been shown 
that physically active individuals with T1DM exhibit higher HbA1c values compared to 
sedentary patients with T1DM (8). The reduced focus on glycemic control, characteristic 
of a more conventional style of insulin therapy (CIT)(41), may be counterproductive 
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since elevations in glycemia (HbA1c) are known to increase the risk of cardiovascular 
complications (26). Moreover, a retrospective analysis of the DCCT found no evidence 
that physical activity improves microvascular outcomes (19). Contrary to this work, our 
group has demonstrated that the combination of CIT and high-intensity aerobic exercise 
training (AThigh) in experimental T1DM rats, not only decreases the risk of exercise-
induced hypoglycemia (20), but numerous cardiovascular benefits are apparent such as 
increased recovery from an ischemic insult (20), reduction in cardiovascular autonomic 
dysfunction (15), improvement in systolic and diastolic heart function (22), and improved 
vascular reactivity (25, 27). Additional work is needed to better evaluate the 
cardiovascular benefits and risks associated with regular exercise in physically active 
individuals with T1DM that often prescribe to less stringent glycemic control (i.e. CIT). 
Specifically, these studies need to compare the importance of regular physical activity 
versus IIT alone, the predominant treatment option for individuals with T1DM (26, 41) 
which is typically accompanied by a more sedentary lifestyle (8).   
At both the experimental (21) and clinic level (3), it has been shown that poor 
glycemic control in patients with T1DM leads to hepatic glycogen deficiencies. Thus, the 
restoration of hepatic glycogen content could represent a mechanism for combatting 
hypoglycemia, as hepatic glycogen is the predominant source of blood glucose during 
exercise (44) and insulin overcorrection (18). Our laboratory has recently shown that ten 
weeks of AThigh fails to normalize hepatic glycogen in T1DM rats despite significantly 
elevated levels of hepatic glycogenic storage enzymes (21). In contrast, resistance 
training (RT) has been shown to increase hepatic glycogen content in rats (32), while  
also alleviating the risk of exercise-induced hypoglycemia in T1DM (20, 46). Recent 
work has also shown that compared to abrupt reductions in blood glucose with aerobic 
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exercise, RT results in less of an initial decline in blood glucose (46, 47). While still 
allowing for the cardiovascular benefits associated with regular aerobic exercise, the 
integration of RT with aerobic exercise may allow individuals with T1DM to exercise 
safely by reducing the risk of hypoglycemia development. In fact, the Canadian Diabetes 
Association recommends that RT be incorporated into aerobic exercise regimes at least 
twice a week (1). 
The objective of the present study was two-fold: 1) to determine if 12 weeks of 
CIT paired with AThigh results in larger cardioprotection from an ischemia-reperfusion (I-
R) injury than IIT alone; 2) to establish if the combination of RT with AThigh, results in 
similar cardioprotection as AThigh alone, while also limiting abrupt reductions in blood 
glucose in response to exercise. It was hypothesized that CIT paired with AThigh results in 
similar levels of cardioprotection as IIT alone and that comparable levels of 
cardioprotection would be evident between both combined exercise training (AThigh and 
RT) and AThigh alone. Further, the integration of RT with AThigh would augment hepatic 
glycogen storage and prevent abrupt reductions in blood glucose in response to aerobic 
exercise. 
4.2 Methods 
This study was approved by the Research Ethics Board of the University of 
Western Ontario which is in compliance with the guidelines of the Canadian Council on 
Animal Care. Eight-week old male Sprague-Dawley rats were obtained from Charles 
River Laboratories, provided standard rat chow ad libitum, and housed in pairs at a 
standard temperature and humidity (21.5°C and 50% humidity).  
 
	
Experimental Protocol. Sprague-Dawley rats were randomly divided into one of 
five diabetic groups: conventional insulin therapy (D-CIT; n=12), intensive insulin 
therapy (D-IIT; n=12), high-intensity aerobic exercise training (D-AThigh; n=8), resistance 
exercise training (D-RT; n=8) and combination aerobic/resistance exercise training (D-
ART; n=8). During week one, T1DM was induced after five consecutive daily injections 
of streptozotocin (Sigma-Aldrich; 20mg/kg; dissolved in 0.1M citrate buffer, pH 4.5) and 
T1DM was confirmed after two non-fasting blood glucose concentrations greater than 
18mM. After diabetes confirmation, subcutaneous insulin pellets (Linshin, Toronto, 
Canada) were implanted in the abdomen (week two of study). Through insulin pellet 
adjustments it was intended to maintain blood glucose concentrations in D-CIT, D-AThigh, 
D-RT and D-ART between 9-15mM and D-IIT between 4-9mM. Exercise training 
occurred five times a week over a twelve-week period. D-AThigh rats exercised on a 
motorized treadmill at 27m/min (six percent grade) for one hour. Continuous running was 
encouraged by small blasts of compressed air at the rear of the treadmill. In D-RT rats, 
resistance training consisted of climbing a vertical ladder with weights secured to the 
proximal portion of the tail, as previously described (20). Briefly, familiarization occurred 
the week prior to training and consisted of 10 climbs a day with varying weights attached 
(5%, 15%, 20% and 35% of each rat’s body mass). Regular resistance training sessions 
consisted of incremental increases in weight (50%, 75%, and 90% of maximal lifting 
capacity) followed by 100% of their maximal lifting capacity until exhaustion (unable to 
finish climb despite tactile stimulation to haunches). Maximum lifting capacity was 
calculated every fourth exercise session and was determined by sequentially adding 30 
grams of weight to the rat’s tail until exhaustion (starting at 75% of their body mass). In 
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D-ART rats, exercise training consisted of alternating daily between the aerobic and 
resistance exercises.  
Blood Analysis. Blood samples were taken over two consecutive days from the 
saphenous vein during the last week of exercise training (pre/post exercise) to determine 
if antecedent AThigh or RT altered the blood glucose response to a subsequent exercise 
bout (37). In D-ART, this measure was conducted at week 11 and week 12 of training to 
determine if performing AThigh (or RT) first had an effect on glucoregulation following a 
subsequent bout of RT (or AThigh). Blood glucose concentrations were detected using a 
One Touch Ultra 2 Blood Glucose Monitoring System (Lifescan Canada Ltd, Burnaby, 
BC, Canada) and One Touch test strips (Lifescan Canada Ltd). Epinephrine 
concentrations prior to, and after exercise were determined via ELISA (Cusabio, Catalog 
#CSB-E08678r). Fructosamine concentrations were determined using the procedure 
outlined by Oppel et al. (28). Briefly, serum samples taken at the completion of the study 
were added to a carbonate buffer (pH 10.8) containing 0.25mM nitroblue tetrazolium 
(NBT) at 37°C. Following a 20 minute incubation at 37°C the reaction was read at 530nm 
and compared to standards of 1-deoxy,1-morpholinofructose (DMF; Sigma-Aldrich) and 
albumin (40g/l). 
 Langendorf Heart Preparation. Three days following the last exercise bout all rats 
were anaesthetized with isoflurane and hearts were extracted and placed in cold Krebs-
Henseleit buffer (KHB; 120mM NaCl, 4.63mM KCl, 1.17mM KH2PO4, 1.25mM CaCl2, 
1.2mM MgCl2, 20mM NaHCO3, and 8mM glucose). Hearts were rapidly cannulated for 
unpaced retrograde perfusion of KHB (37°C; gassed with 95% O2 and 5% CO2) at 
15ml/min. A small water-filled latex balloon was inserted through the mitral valve and 
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into the left ventricle. Hearts were equilibrated to the preparation for 30 minutes (pre-
ischemia) followed by the termination of flow for 50 minutes. Subsequently, reperfusion 
occurred for a total of 30 minutes at 15m/min. Left ventricle pressures (LVDP, left 
ventricle developed pressure; LVEDP, left ventricle end-diastolic pressure) were 
measured with a pressure transducer (Statham Gould P23ID) and the rate of pressure 
development (+dp/dt) and relaxation (-dp/dt) were obtained using a Powerlab 8/30 Data 
Acquisition System and analyzed by Labchart 7.0 Pro Software (ADInstruments, 
Colorado Springs, Colorado, USA). Area under the curve (AUC) was determined for the 
pressure curves of each rat in the study in order to correlate measures to glycemic control 
and insulin resistance. 
Glucose Tolerance Test. Intravenous glucose tolerance tests (IVGTT) were 
conducted following training after an 8-12 hour fast and consisted of a sterile injection 
(1g/kg) of dextrose solution (50% dextrose, 50% ddH2O) into the lateral tail vein. Blood 
glucose concentrations were measured at 5, 10, 20, 30, and 40 minutes post-injection and 
area under the curves (AUC) were determined for each individual rat. Prior to the IVGTT, 
blood samples were taken from the saphenous vein and exogenous insulin concentrations 
were measured via ELISA (Alpco, Salem, NH: Catalog # 80-INSHU-E01.1). The 
measure of insulin resistance was considered the AUC of the IVGTT multiplied by 
exogenous insulin concentration. We have previously reported that when using this 
T1DM model, sedentary rats can become insulin resistant and require substantial more 
exogenous insulin in order to maintain the desired blood glucose concentrations (16, 21). 
Accordingly, when determining the insulin resistance measure the amount of circulating 
insulin present in the rat during the IVGTT was factored into the calculation.  
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Western Blotting. Liver and left ventricles were homogenized in buffer (100mM 
NaCl, 50mM, Tris base, 0.1mM EDTA, 0.1 EGTA, pH ~7.5) using a polytron and total 
protein concentrations were determined by the Bradford protein assay. Homogenates (40-
80µg of protein) were mixed with equal volumes of sample buffer (0.125M Tris, 20% 
Glycerol, 4% SDS, 10% !-mercaptoethanol, 0.015% Bromophenol blue, pH ~6.8), 
separated by SDS-PAGE (4% stacking, 10% separating) and transferred to nitrocellulose 
membranes. Membranes were blocked in 5% non-fat dairy milk in TTBS (10mM Tris, 
100mM NaCl, 0.1% Tween-20, pH 7.5) for 1 hour and incubated overnight at 4°C with 
primary antibodies (Cell Signaling: Hsp70 1:4000, glycogen synthase 1:1000; abcam: 
glycogen phosphorylase 1:2000, SERCA2 1:1000; Santa Cruz: glucose-6-phosphotase 
1:200) diluted in TTBS with 2% non-fat dairy milk. Following washes in TTBS, 
membranes were exposed to corresponding secondary antibodies (IgG-HRP conjugated, 
Bio-rad) in TTBS with 2% non-fat dairy milk for 1 hour at room temperature. After 
successive washes in TTBS, protein bands were visualized with a luminol-based 
chemiuminescent substrate (Western C Enhanced Chemiluminescent Kit; Bio-rad), 
imaged with the Chemidoc XRS System (Bio-rad), and analyzed with Quantity One 
Software (Bio-rad). Optical densities were normalized to a consistent non-T1DM control 
sample and subsequently !-actin.  
Statistical Analysis. Body mass, blood glucose, fructosamine, exogenous insulin, 
insulin resistance and Western blot data were compared using a one-way analysis of 
variance (ANOVA). Langendorf measures were compared using a two-way repeated 
measures ANOVA. Blood glucose concentrations and epinephrine concentrations in 
response to exercise, and over consecutive days, were compared using a two-way 
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repeated measures ANOVA. Relationships between left ventricular mechanical 
performance and fructosamine or insulin resistance were determined via Pearson 
correlation. When a significant effect was found, a least squares difference post hoc test 
was performed and significance was set at p<0.05. All data are presented as a mean ± 
standard error. All statistical analyses were completed using GraphPad Prism 6. 
4.3 Results 
Animal Characteristics. Blood glucose concentrations were lower in D-IIT 
compared to D-CIT, D-AThigh and D-ART, and lower in D-RT compared to D-ART 
(Table 4.1; p<0.05). Body mass was higher in D-IIT compared to D-AThigh, D-RT, and D-
ART (p<0.05). Fructosamine concentrations were lower in D-IIT and D-AThigh compared 
to D-CIT and D-ART (p<0.05). Exogenous insulin concentrations were lower in D-RT 
compared to D-IIT, and lower in D-ART compared to D-CIT and D-IIT (p<0.05). The 
insulin resistance measure was higher in D-IIT compared to D-AThigh, D-RT and D-ART 
(p<0.05), D-CIT compared to D-ART (p<0.05), and D-AThigh compared to D-RT and D-
ART (p<0.05). 
Left ventricular mechanical performance. For the first objective of the study we 
compared left ventricular mechanical performance following ischemia in D-CIT, D-
AThigh and D-IIT. There was a significant increase in LVDP in D-AThigh compared to D-
CIT (Figure 4.1A; p<0.05). No difference in LVDP was observed between D-AThigh and 
D-IIT (p>0.05), and LVDP between D-CIT and D-IIT did not reach significance 
(p=0.052). LVEDP was lower in D-IIT compared to D-CIT (Figure 4.1B; p<0.05), while 
D-AThigh was lower than D-CIT at 5 and 10 minutes during reperfusion (p<0.05). There 
was no difference in +dp/dt or –dp/dt across any of the groups (Figure 4.1C/D; p>0.05).  
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 For the second objective of the study we compared left ventricle mechanical 
performance following ischemia in D-AThigh, D-RT, and D-ART. There were no 
differences in LVDP or LVEDP between D-AThigh, D-RT, or D-ART (Figure 4.2A/B; 
p>0.05). D-ART had a higher +dp/dt at 25 and 30 minutes during reperfusion (Figure 
4.2C; p<0.05), while D-AThigh had a slower –dp/dt than both D-RT and D-ART (Figure 
4.2D; p<0.05).  
Molecular Analysis.  In comparison to both D-CIT and D-IIT, an elevation in left 
ventricle Hsp70 content was evident in D-AThigh (Figure 4.3A; p<0.05), while no 
differences were evident in SERCA2 between D-CIT, D-IIT or D-AThigh (Figure 4.3B; 
p>0.0.05) Differences existed between exercise regimes in that D-AThigh resulted in 
higher left ventricle Hsp70 compared to D-RT (p<0.05), but did not differ significantly 
from D-ART (Figure 4.3A; p>0.05). No differences in SERCA2 expression was evident 
among exercise regimes (Figure 4.3B; p>0.05). 
Correlations of left ventricular mechanical performance. There was a significant 
correlation between the AUC of LVDP and fructosamine concentration (Table 4.2; 
p=0.01; r=-0.4), while no correlation was evident between the AUC of LVEDP, +dp/dt, -
dp/dt and fructosamine concentration (p>0.05). There was a significant correlation 
between the AUC of +dp/dt and insulin resistance (p=0.03; r=-0.4), but no correlation 
between insulin resistance and the AUC of LVDP, LVEDP, or –dp/dt (p>0.05). 
Hepatic glycogen content and regulatory enzymes. Hepatic glycogen content was 
lower in D-AThigh, D-RT and D-ART compared to both D-CIT and D-IIT (Figure 4.4A; 
p<0.05). No differences in glycogen synthase, glycogen phosphorylase, and glycogen-6-
phosphotase were apparent between experimental groups (Figure 4B/C/D; p>0.05). 
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Exercise-mediated changes in blood glucose. Significant declines in blood glucose 
concentrations following exercise were apparent in D-AThigh at day 1 and day 2 of 
exercise (week 12 of training; Table 4.3; p<0.05). No change in blood glucose 
concentrations were apparent following RT at day 1 or day 2 (week 12 of training; 
p>0.05). In D-ART, significant declines in blood glucose concentrations were apparent 
only on AThigh days (both week 11 and 12 of training; p<0.05). In D-AThigh, no change in 
epinephrine concentrations were evident from pre to post exercise (week 12 of training; 
p>0.05; Table 4.4), and epinephrine concentrations were similar between day 1 or day 2 
(week 12 of training; p>0.05). In D-RT, no change in epinephrine concentrations were 
evident from pre to post exercise (week 12 of training; p>0.05); however, epinephrine 
concentrations were lower overall on day 2 compared to day 1 (week 12 of training; 
p<0.05). In D-ART, when RT occurred the day before AThigh (week 11 of training), 
epinephrine concentrations were reduced overall during AThigh (p<0.05). In D-ART, no 
change in epinephrine occurred from pre to post exercise (both week 11 and 12 of 
training; p>0.05). 
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! D#CIT! D#IIT! D-AThigh! D#RT! D#ART!
Body!Mass!(g)! 567±20! 598±213,4,5! 510±15! 520±21! 534±19!
Blood!glucose!conc.!
(mM)!
15.0±1.2! 10.9±1.21,3,5! 15.6±0.5! 12.4±1.95! 16.7±1.4!
Fructosamine!conc.!
(mM)!
3.0±0.5! 1.0±0.21,5! 1.3±0.31,5! 2.0±0.1! 2.6±0.7!
Exogenous!Insulin!(IU)! 27.3±5.4! 35.8±7.8! 19.0±7.7! 11.1±7.12! 4.1±2.01,2!
Insulin!Resistance!(AU)! 10665±20785! 16055±45583,4,5! 4722±1988! 1438±623! 1260±6013!
Data!are!means!±!SE!
1different!from!D#CIT;!2different!from!D#IIT;!3different!from!D-AThigh;!4different!from!D#RT;!
5different!from!D#ART!
!
Table 4.1. General animal characteristics at the completion of the study 
!
!
!
!
!
!
!
!
!
!
!
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Figure 4.1. Left ventricle mechanical performance during ischemia-reperfusion. The data are 
presented in time course format. LVDP(A), LVEDP (B), +dP/dt (C), -dP/dt (D). (*) significant 
main effect (P<0.05); (φ) different from D-CIT (P<0.05). Data are presented as a mean ± SE. 
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Figure 4.2. Left ventricle mechanical performance during ischemia-reperfusion and 
following different modalities of exercise training. The data are presented in time course 
format. LVDP(A), LVEDP (B), +dP/dt (C), -dP/dt (D). (ψ) different from D-AThigh (P<0.05); 
(α) different from D-RT (P<0.05); (β) different from D-ART (P<0.05). Data are presented as 
a mean ± SE. 
!
 
 vs. Fructosamine (mM) vs. Insulin resistance (AU) 
 p value r p value r 
LVDP (AUC) 0.01* -0.4 0.7 - 
LVEDP (AUC) 0.8 - 0.7 - 
+dp/dt (AUC) 0.7 - 0.03* -0.4 
-dp/dt (AUC) 0.8 - 0.5 - 
*significant (p<0.05) 
 
Table 4.2. Correlation of left ventricle mechanical performance on glycemia and insulin 
resistance.  
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Figure 4.3. Left ventricle Hsp70 (A) and SERCA2 (B) protein content. (φ) different from D-
CIT; (#) different from D-IIT; (α) different from D-RT. Significance p<0.05. Data are 
presented as a mean ± SE. 
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Figure 4.4. Hepatic glycogen content (A), glycogen-6-phosphotase (B), glycogen synthase 
(MGS, muscle glycogen synthase; LGS, liver glycogen synthase) (C), and glycogen 
phosphorylase (D). (φ) different from D-CIT (P<0.05); (#) different from D-IIT (P<0.05). 
Data are presented as a mean ± SE. 
 
 
 
 
D-CIT D-IIT D-AThigh D-RT D-ART
0
2
4
6
H
ep
at
ic
 g
ly
co
ge
n 
(g
/1
00
g 
of
 ti
ss
ue
)
φ #
φ # φ #
β-actin 42kDa
36kDaG6Pase
D-CIT D-IIT D-AThigh D-RT D-ART
0
4
8
12
G
lu
co
se
-6
-p
ho
sp
ho
ta
se
(A
U
)
D-CIT D-IIT D-AThigh D-RT D-ART
0
2
4
6
8
10
G
ly
co
ge
n 
Sy
nt
ha
se
 (A
U
)
β-actin 42kDa
85kDa
80kDa
MGS
LGS
β-actin 42kDa
PYGL
D-CIT D-IIT D-AThigh D-RT D-ART
0
2
4
6
8
G
ly
co
ge
n 
Ph
os
ph
or
yl
as
e 
(A
U
)
97kDa
A
D
C
B
 
 
 
 
 
 Day 1 Day 2 
 Pre-exercise 
(mM) 
Post-exercise 
(mM) 
Pre-exercise 
(mM) 
Post-exercise 
(mM) 
D-AThigh 15.0±0.4 8.0±1.1* 14.6±0.5 6.9±1.0* 
D-RT 12.2±1.6 12.0±0.9 13.6±2.2 15.1±1.6 
D-ART  
(week 11; RT then AThigh) 
14.9±1.6 15.6±1.2 15.4±1.7 8.0±1.8* 
D-ART  
(week 12; AThigh then RT) 
16.7±1.4 8.8±1.4* 15.2±2.0 15.6±1.2 
Data are means ± SE 
*significantly lower than pre-exercise (p<0.05) 
 
Table 4.3. Blood glucose concentrations in response to exercise at week 11 or 12 of 
training 
 
 
 Day 1 Day 2 
 Pre-exercise 
(pg/ml) 
Post-exercise 
(pg/ml) 
Pre-exercise 
(pg/ml) 
Post-exercise 
(pg/ml) 
D-AThigh 254.3±44.6 93.1±24.9 237.0±43.8 298.0±109.1 
D-RT 320.8±72.2 238.3±58.2 110.0±46.1* 136.3±66.3* 
D-ART  
(week 11; RT then AThigh) 
254.3±107.2 150.8±98.0 38.7±9.3* 57.8±15.1* 
D-ART 
(week 12; AThigh then RT) 
331.0±169.8 112.6±45.7 202.2±33.0 184.6±41.8 
Data are means ± SE 
*significantly lower than day 1 (p<0.05) 
 
Table 4.4. Epinephrine concentrations in response to exercise at week 11 or 12 of training 
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4.4 Discussion 
The present investigation established that the magnitude of cardioprotection 
following I-R injury was similar between D-AThigh (undergoing CIT) and D-IIT. This 
exercise-related cardioprotection does not appear to be exercise-specific; although each 
exercise modality may provide unique advantages. For example, the exercise-related 
protection from I-R injury experienced by D-ART was comparable to D-AThigh and D-RT 
in many of the measures during the I-R protocol, while D-ART provided the largest 
increase in the rate of developed pressure. Further, D-AThigh had the largest increase in 
cardioprotective Hsp70 expression and perhaps most importantly, the largest 
improvement in glycemia (fructosamine concentrations). Regardless of the exercise 
training modality, hepatic glycogen deficiency is still apparent in T1DM rats, which 
likely reflects the inability of RT to improve the rapid drop in blood glucose evident 
during aerobic exercise. However, it is important to note that T1DM rats in each of the 
different training modalities failed to reach hypoglycemic blood glucose concentrations 
(less than 3mM). 
Clinically, stringent management of blood glucose concentrations through 
intensive insulin therapy is the primary treatment strategy in order to limit the progression 
of CVD (26). Indeed, D-IIT resulted in greater recovery from an I-R injury than D-CIT, 
supporting the deleterious effects of chronic hyperglycemia on the micro- and 
macrovasculature in individuals with T1DM (10, 41). During recovery from I-R injury, 
D-AThigh showed improvements in cardiac functional recovery compared to D-CIT, while 
D-AThigh and D-IIT displayed similar recovery values. In a previous study, we reported 
that six weeks of high intensity aerobic exercise led to significant improvements in I-R 
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functional recovery (20). Here, we demonstrate that this modality of exercise when 
combined with CIT can lead to comparable recovery from I-R injury as IIT alone. It is 
likely that glycemic control played a significant role in contributing to the increased 
cardioprotection of IIT and AThigh, since both exhibited similar serum fructosamine 
concentrations. Indeed, the negative correlation between serum fructosamine, indicative 
of glycemic control, and LVDP would support this finding.  
While it is well-recognized that regular exercise can improve glycemic control 
(lowered HbA1C) in Type 2 diabetes, results in T1DM have generally failed to show this 
glycemic benefit (5). A number of factors may contribute to this lack of evidence in 
previous studies, including the predominant use of adolescent subjects, the use of 
questionnaires to estimate activity levels, or the increased food consumption that is 
typically associated with the initiation of an exercise program (5). The current study 
measured fructosamine concentrations and demonstrated that D-AThigh had similar levels 
of glycosylated protein in the blood as D-IIT. Although comparable to HbA1c, the 
measure of glycosylated hemoglobin, fructosamine is a measure of the amount of serum 
proteins that have undergone glycation and is thus, a better marker for shorter-term 
glycemic control (approximately two weeks). While there is a shortage of evidence 
supporting increased glycemic control in T1DM following aerobic exercise (5), exercise 
intensity appears to play a significant role as to whether glycemic benefits are obtained 
(5, 35). In the present study the aerobic exercise training program was intensive, 
representing approximately 70-80% of the rats VO2max (2). The potential ability of RT to 
improve glycemic control (determined by HbA1C) in populations with T1DM is 
inconclusive (47) and the present results would support work citing that it has no benefit 
on long-term glycemia (33). No improvement was evident in D-ART, despite 
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supplementing RT with AThigh, suggesting that the frequency of AThigh may be an 
important factor to experience glycemic benefits.  
In a previous report we demonstrated that six weeks of RT provided little 
protection against an I-R injury in T1DM rats (20). The current study demonstrated that 
longer term RT, conducted alone or paired with AThigh (D-ART), is necessary in order to 
provide similar levels of cardioprotection as performing strictly AThigh. Indeed, it has 
been demonstrated in non-T1DM rats that short-term RT provides little cardioprotection 
(11), however, if the RT is prolonged the cardioprotective effects of this form of exercise 
becomes evident, as demonstrated by reduced infarct size following I-R injury (40). In 
this regard, longer term RT did provide some exercise-specific improvements following I-
R injury in D-RT and D-ART. For example, the maximal rate of pressure development 
(+dp/dt) and relaxation (-dp/dt) in T1DM rats were significantly improved in 
experimental groups utilizing RT, that were not evident in D-AThigh. It has been reported 
that just a single bout of RT can improve the rate of left ventricular systolic pressure in 
hypertensive rats undergoing Langendorf-perfusion (13). Further, Melo et al. (23) 
reported faster cardiomyocyte contraction and relaxation in rats following eight weeks of 
RT, believed to be due to increased sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) 
expression. While neither +dp/dt or –dp/dt were altered in D-AThigh, these results may not 
be surprising as little change in Ca2+ regulatory mechanisms are reported elsewhere in rat 
hearts following 12 weeks of treadmill training (9). Thus, these findings may support the 
incorporation of RT into the treatment of T1DM, since slowed Ca2+ clearing and 
abnormal cardiomyocyte excitation-contraction coupling is prominent in T1DM (34).  
The finding that rates of pressure development and relaxation were increased in 
D-RT and D-ART despite no improvement in glycemia (fructosamine), indicates that 
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other factors may contribute to changes in rates of pressure development. For example, 
cardiomyocytes from insulin resistant rats have demonstrated mechanical defects and 
impaired Ca2+ handling (12, 38). In the present investigation we report a negative 
correlation between the degree of insulin resistance and the rate of developed pressure. 
Indeed, the experimental groups that demonstrated the greatest insulin sensitivity, D-RT 
and D-ART, also displayed the quickest rates of pressure development and relaxation. In 
the insulin resistant state, impaired SERCA activity is well documented to contribute to 
cardiomyocyte dysfunction (45), and RT itself has been shown to increase SERCA 
expression (23). In the present study, SERCA2 expression was not changed as a result of 
RT or ART. This lack of change may not reflect changes in the activity levels of this 
enzyme, as impaired SERCA activity has been reported in insulin resistant animals 
despite normal protein content (45). Nonetheless, the implications of insulin resistance in 
the recovery from an I-R injury are significant and require further investigation, given the 
emerging evidence of “double diabetes”, a separate classification of patients with T1DM 
that exhibit both insulin deficiency and resistance (6). 
In seeking to explain the mechanistic means by which a specific exercise training 
regime may prove to be more beneficial for the functional recovery of the heart during I-
R injury, we examined Hsp70 protein expression in each of the groups (17, 29). In the 
current study we observed an increase in left ventricular Hsp70 content in D-AThigh 
compared to both sedentary T1DM groups (D-CIT and D-IIT). Our laboratory, as well as 
others, have established the importance of exercise-induced Hsp70 expression in recovery 
from I-R injury (17, 29). This finding is in line with previous work from our laboratory 
that demonstrated both short and long-term aerobic exercise can result in increased Hsp70 
in the hearts of insulin-treated T1DM rats (20, 22). Further, we showed that D-AThigh had 
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higher Hsp70 expression than D-RT which supports an earlier finding by our laboratory 
(20). While it is not clear why differences in the expression of Hsp70 exists between 
exercise modalities, it may be reflective of exercise-specific modulation to Ca2+ handling 
or oxidative stress. While improvements in muscle contractility can be associated with the 
interaction of Hsp70 and SERCA (43), evidence suggests that Hsp70 may be more 
involved in oxidative stress following exercise (42). Indeed, Hsp70 only modestly binds 
to SERCA following exercise, in comparison to the Hsp70-SERCA binding in response 
to heat stress (14). We have previously shown that antioxidant enzymes are elevated in 
the myocardium following AThigh but not following RT (20). Further, increases in 
myocardial antioxidant defenses are likely associated with the duration and frequency of 
training (31) and exercise-induced elevations in Hsp70 are known to be intensity-
dependent (24). Since D-ART demonstrated similar Hsp70 expression as D-AThigh, it is 
plausible that neither the same quantity or intensity of exercise was achieved in D-RT. 
 The largest barrier to exercise prescription for individuals with T1DM is exercise-
induced hypoglycemia (4). Thus, independent of which exercise provides the largest 
cardiovascular benefit, the risk of exercise-induced hypoglycemia must also be 
considered. Similar to past findings (20), D-AThigh resulted in a significant drop in blood 
glucose immediately following exercise, while D-RT did not. Contrary to our hypothesis, 
the integration of RT and AThigh (D-ART) did not alter the abrupt drop in blood glucose 
in response to AThigh. It is conceivable that the lack of improvement in the blood glucose 
response to exercise in D-ART was a result of the inability of this form of exercise to 
improve hepatic glycogen levels. Recently, our group has demonstrated that both 
sedentary and exercised trained T1DM rats using CIT demonstrate hepatic glycogen 
deficiencies (21), similar to what has been reported using clinical populations (3). Despite 
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increased glycemic control in IIT there was no difference in hepatic glycogen content 
between D-IIT and D-CIT. Further, exercise trained T1DM rats, regardless of training 
modality, demonstrated significantly lower liver glycogen content. While these findings 
are contrary to previous work (21), it is likely that the amount of insulin in circulation in 
the exercise trained rats contributes to deficient hepatic glycogen. Both D-CIT and D-IIT 
had similar exogenous insulin concentrations, which would in turn regulate glycogen 
storage by increasing the activity of glycogen synthase (36). Moreover, independent of 
exercise modality, trained T1DM rats displayed the smallest amounts of hepatic 
glycogen, concurrent with the lowest exogenous insulin requirements. Despite the 
apparent cardiovascular benefits associated with regular exercise, the decreased hepatic 
glycogen content in trained T1DM rats could have implications for combatting 
hypoglycemia, since hepatic glycogen is a prominent source of blood glucose during 
glucose demanding states (18, 44).  
The first objective of the present investigation was to determine if AThigh coupled 
with CIT resulted in larger cardioprotective benefits than IIT alone. Findings presented 
here demonstrate that when CIT was paired with AThigh the increase in cardioprotection 
from I-R injury was similar to that of D-IIT. In fact, the current findings may suggest that 
CIT with AThigh may lead to a larger cardiac improvement in T1DM rats than IIT alone, 
given the increased expression of left ventricular Hsp70 with this form of exercise. While 
addressing our second objective, we determined that following long-term exercise 
training both D-ART and D-RT resulted in similar levels of overall cardioprotection as D-
AThigh; although each exercise training modality did appear to provide unique benefits.  
For example, improved glycemic control was only evident in D-AThigh, while the largest 
improvements in insulin sensitivity measures were evident in exercises that utilize 
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resistance exercise (D-ART, D-RT). To this point, this study underlines the need to 
consider other factors besides glycemic control (i.e. insulin resistance) when tailoring an 
exercise treatment program for the patient with T1DM to reduce the risk of developing 
CVD. 
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CHAPTER 5 
 
5 «High intensity aerobic exercise training improves 
insulin-induced vasorelaxation in a rat model of 
Type 1 diabetes mellitus» 
 
5.1 Introduction 
Type 1 diabetes mellitus (T1DM) is associated with an increased susceptibility to 
cardiovascular disease (CVD)(38). Both clinical and experimental T1DM are associated 
with impaired endothelial function, due to reduced production and bioavailability of nitric 
oxide (NO)(9, 18, 20, 34). Evidence suggests that vascular insulin resistance plays a 
central role in endothelial dysfunction, which is increasingly viewed as the primary factor 
contributing to CVD and its co-morbidities such as atherosclerosis, hypertension, 
peripheral neuropathy, and metabolic dysfunction (22, 29). Diminished vascular actions 
of insulin are evident in patients with T1DM (1, 35, 40) and the development of treatment 
strategies to improve vascular insulin sensitivity may provide an important means to 
mitigate the increased risk of cardiovascular disease in populations with T1DM. Indeed, 
impaired insulin-induced vasodilation is believed to play a pivotal role in the 
predisposition to atherosclerosis (36) and endothelial dysfunction (22, 29). 
Aside from its metabolic effects, insulin stimulates endothelium-dependent 
vasodilation, as well as vasoconstriction in order to regulate the delivery of insulin and 
glucose to skeletal muscle (2, 28). Briefly, endothelium-dependent insulin dilation occurs 
following the activation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, which 
phosphorylates eNOS and increases the production of NO. Insulin can also lead to 
endothelium-dependent vasoconstriction by activating the Ras/mitogen-activated protein 
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kinase (MAPK) pathway, which subsequently releases endothelin-1 (ET-1). During states 
of vascular insulin resistance, there is a downregulation of the PI3K-Akt pathway and a 
favoring of the MAPK insulin signalling pathway, resulting in reduced NO availability, 
larger ET-1 production, and a net vasoconstriction (17, 28, 33).  
It is well-established that poor glycemic control is a contributing factor to 
endothelial dysfunction in T1DM (20, 21, 37, 41). The findings of the Diabetes Control 
and Complications Trial (DCCT) clearly establishes that microvascular disease risk is 
significantly reduced in patients with T1DM following tight blood glucose management 
using an intensive insulin therapy (IIT) approach (39). Regular exercise has also been 
shown to improve the vascular actions of insulin (7, 25, 32, 33). However, patients with 
T1DM that adhere to a physically active lifestyle often maintain a higher level of  
glycemia, representative of a more conventional insulin therapy (CIT), in the attempt  to 
mitigate the risk of hypoglycemia that can accompany exercise (8). Although a 
relationship exists between glycemic control (HbA1c) and the degree of endothelial 
dysfunction in T1DM (37), physical activity may be a more effective means to improve 
the vasoreactivity to insulin (6, 24, 25). Indeed, it has been reported in Type 2 diabetes 
mellitus (T2DM) that aerobic exercise training improves the vascular actions of insulin 
(24, 25), while metformin treatment alone does not enhance insulin-stimulated 
vasodilation, despite lowered HBA1c, body weight and body mass (6). These findings 
stress the importance of regular exercise in the improvement of vascular insulin 
sensitivity and suggest that lowering glycemia through intensive insulin therapy alone 
may not be sufficient to improve the vasoreactivity to insulin. 
Due to the risk of hypoglycemia associated with aerobic exercise training in 
T1DM the use of other forms of exercise such as resistance exercise training (RT) has 
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gained attention (23, 42, 43). RT has been shown to have positive benefits on endothelial 
function (11, 14, 27) and vascular insulin sensitivity (16). For instance, it has been shown 
that insulin stimulated increases in leg blood flow are larger following both RT and 
aerobic exercise in subjects with T2DM (7, 16). It is not clear whether these same 
improvements are evident in patients with T1DM, as our group has reported that RT does 
not result in same level of improvements in vascular responsiveness as high intensity 
aerobic exercise (AThigh)(31). However, this may be reflective of the longer time it takes 
for beneficial vascular adaptations that RT may have in comparison to aerobic exercise. 
Nonetheless, the potential of RT to protect against exercise-induced hypoglycemia, while 
providing benefits to the vasculature in patients with T1DM is promising and should be 
further explored.  
The purpose of the present study was to determine which modality of exercise 
(AThigh or RT), when paired with CIT, results in superior femoral artery vasomotor 
function. Secondly, it was determined whether long-term AThigh or RT, when paired with 
CIT, results in superior vasomotor function compared to IIT, the standard treatment 
regime for T1DM. It was hypothesized that enhanced vasomotor function and insulin-
induced vasorelaxation would be evident in both AThigh and RT. Further, AThigh and RT 
(paired with CIT) would result in superior vasomotor function compared to IIT alone. 
5.2 Methods 
All procedures were in compliance with the Canadian Council on Animal Care 
and were approved by the Research Ethics Board of the University of Western Ontario. 
Male Sprague-Dawley rats (8-weeks old) were obtained from Charles River Laboratories 
(Saint-Constant, Quebec, Canada). Rats were housed in pairs, at a constant humidity and 
   
temperature (21.5°C and 50% humidity), and were provided water and standard rat chow 
ad libitum. 
Experimental Protocol. Diabetic rats were randomly divided into intensive insulin 
treatment (D-IIT; n=10), conventional insulin treatment (D-CIT; n=10), high intensity 
aerobic exercise training (D-AThigh; n=8), and resistance exercise training (D-RT; n=8). 
During week 1, T1DM was induced in all rats with multiple low doses of streptozotocin 
(Sigma-Aldrich; STZ; 20mg/kg; citrate buffer 0.1M, pH 4.5) over five consecutive days, 
and was confirmed after two consecutive non-fasting blood glucose concentrations 
greater than 18mM. A single rat in D-RT did not reach the desired blood glucose 
concentration and was excluded from the study. Starting during week 2, and for the 
duration of the study, exogenous insulin was provided to T1DM rats via subcutaneous 
insulin pellets (Linshin, Toronto, Canada). Through daily blood glucose monitoring and 
insulin pellet adjustment, blood glucose was maintained between 4-9mM in D-IIT and 
between 9-15mM in D-CIT, D-AThigh, and D-RT. From week 3 to week 14 of the 
experimental protocol D-IIT and D-CIT remained sedentary and D-AThigh and D-RT 
underwent their designated exercise training programs.  
Exercise Protocol. In D-AThigh, rats exercised on a motorized treadmill at 
27m/min and 6% grade (1hr, 5 days/week). In D-RT, rats climbed a vertical ladder as 
previously described (13, 23). Briefly, rats were familiarized to the ladder during week 2 
by climbing the ladder with increases in weight secured to the proximal portion of their 
tail (5%, 15%, 20%, and 35% of body mass). Regular RT sessions consisted of climbing 
the vertical ladder with incremental increases in weight attached to the tail (50%, 75%, 
90% of maximal carrying capacity), followed by climbing with their maximal carrying 
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capacity until exhaustion. Every fourth day, maximal carrying capacity was determined 
by adding 30 grams of weight to their tail (beginning with 75% of their body mass) until 
rats reached exhaustion. Exhaustion was defined as failure to climb despite tactile 
stimulation to the haunches of the rat. 
Tissue Collection. Three days after the last exercise bout rats were anaesthetized 
with isoflurane and euthanized via heart excision. Femoral arteries were carefully 
dissected and placed in cold Krebs-Henseleit buffer (118.1mM NaCl, 4.7mM KCl, 
1.5mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 11.1mM glucose, and 25mM NaHCO3, 
pH 7.4). Vessels were cleaned of any connective or adipose tissue and were partitioned 
into ~2mm rings for in vitro isometric tension analysis. Remaining femoral arteries were 
flash frozen in liquid nitrogen for protein quantification. 
Blood Analysis. Blood glucose concentrations were measured and recorded 
weekly using a One Touch Ultra 2 Blood Glucose Monitoring System (Lifescan Canada 
Ltd, Burnaby, BC, Canada) and One Touch test strips (Lifescan Canada Ltd). Serum 
endothelin-1 (Enzo Life Sciences, NY, USA; ADI-900-020A) and exogenous insulin 
concentrations (Alpco, Salem, NH: Catalog # 80-INSHU- E01.1) were determined via 
ELISA.  
Isometric Vascular Myography. Vessel rings were carefully mounted on wire 
brackets connected to an isometric force transducer (GlobalTown, Microtech, Sarasota, 
FL) and were submerged in 5ml of Krebs-Henseleit buffer at 37°C. Vessel rings were 
washed every 15 minutes and gradually equilibrated over 1 hour to a baseline tension of 
~1g, based on previous work (and pilot testing) from our laboratory (30, 31). Femoral 
arterial rings were pre-contracted with phenylephrine (PE; 3e-7M) and following a steady-
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state level of contraction, dose-response curves for acetylcholine (ACh; half-log doses; 
1e-8.5 – 1e-5 M), sodium nitroprusside (SNP; whole-log doses; 1e-11 – 1e-6 M), and insulin 
(whole-log doses; 1e0 – 1e5 uIU/ml) were conducted. Thereafter, beginning with basal 
resting tension (~1g), femoral rings underwent dose-response curves of PE (half-log 
doses; 1e-8 – 1e-5 M). To evaluate the contribution of the endothelium, arterial rings were 
treated with nitric oxide inhibitor (NOS) NG-Monomethyl-L-arginine (L-NMMA; 1e-5 
M) for 10 minutes, pre-contracted with PE (3e-7 M), and following a basal steady-state 
level of contraction, were treated with either ACh (1e-6.5 M) or insulin (1e3 uIU/ml). Data 
were excluded if the response of 3 consecutive doses were ± 3 standard deviations from 
the mean. 
Western Blotting. Triton X-100 tissue lysates were used to produce Western blot-
ready Laemmli samples. Protein samples (10 µg/lane) were separated by SDS-PAGE and 
transferred to polyvinylidene difluoride membranes. Membranes were probed with the 
following primary antibodies: eNOS (#610296; 1:500) and phospho-specific eNOS at 
Ser1177 (#61239; 1:250) from BD Biosciences, Akt (#4691; 1:500) phospho-specific Akt 
at Ser473 (#4061; 1:250), p44/42-MAPK (#4695; 1:500), phospho-specific p44/42-
MAPK at Thr202/Tyr/204 (#4370; 1:250) and GAPDH (#5174, 1:1000) from Cell 
Signaling, and endothelin-1 (#117757; 1:2000) from Abcam. Intensity of individual 
protein bands were quantified using FluoroChem HD2 (AlphaView, version 3.4.0.0), and 
expressed as ratio to control band of GAPDH. 
Statistical Analysis. Weekly body mass and blood glucose concentrations were 
compared using a two-way repeated measures analysis of variance (ANOVA). Dose-
responses were compared using a two-way repeated measures ANOVA. Differences in 
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vasorelaxation with L-NMMA, western blot data, systemic ET-1 concentrations, and 
insulin dose were determined using a one-way ANOVA. When a significance difference 
was evident, a least squares difference post-hoc test was performed with a significance 
level set at p<0.05. All data are presented as a mean ± standard error and all statistical 
analysis was completed using Graphpad Prism 6.  
5.3 Results 
Animal Descriptives. There was an interaction between experimental week and 
body mass in that D-IIT weighed more than D-AThigh after week 7, and more than D-RT 
after week 8 (Figure 5.1A; p<0.05). Further, D-CIT weighed more than D-AThigh at weeks 
11 and 12, and more than D-RT at week 12 (p<0.05). There was an interaction between 
experimental week and blood glucose concentration in that D-IIT had lower blood 
glucose concentrations than D-CIT at every week but 1, 3, and 8, while D-IIT was lower 
than D-AThigh at weeks 2 and 12 (Figure 5.1B; p<0.05). Further, D-CIT was higher than 
D-RT at weeks 2, 3, and 10, and higher than D-AThigh at weeks 3, 4, and 7 (p<0.05). 
Exogenous insulin concentrations were lower in D-AThigh and D-RT compared to D-IIT 
(Table 5.1; p<0.05) and no differences were evident in serum endothelin-1 (p>0.05). 
Isometric Vascular Myography. No differences were observed across all doses of 
acetylcholine (Figure 5.2A; p>0.05). Insulin-induced vasorelaxation was greater in D-
AThigh at every dose of insulin compared to D-IIT, D-CIT, or D-RT (Figure 5.2B; 
p<0.05). In regards to endothelium-independent vasorelaxation, no differences were 
evident at any dose of sodium nitroprusside (Figure 5.2C; p>0.05). No difference in 
phenylephrine-induced contraction was evident across all groups (Figure 5.2D; p>0.05). 
   
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When vessels were treated with L-NMMA there was no difference in percent 
vasorelaxation following ACh or insulin dose (Table 5.1: p>0.05). 
Western Blotting. In the femoral artery Phospho(Ser473) Akt/Total Akt was 
elevated in D-AThigh compared to all other groups (Figure 5.3A; p<0.05). No differences 
were evident between Phospho(Ser1177) eNOS/Total eNOS (Figure 5.3B; p<0.05). Both 
D-IIT and D-AThigh demonstrated elevated Phospho-p44/42 MAPK/Total p44/42 MAPK 
compared to D-CIT and D-RT (Figure 5.3C; p<0.05). No difference in ET-1 protein 
content was evident (Figure 5.3D; p>0.05). 
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Figure 5.1. Weekly body mass (A) and blood glucose concentrations (B) in T1DM rats. 
!; D-IIT different from D-AThigh, "; D-IIT different from D-RT, #; D-AThigh different 
from D-CIT, $; D-RT different from D-CIT; p<0.05. All data are means ± SE. 
 
 
 
 
 D-IIT D-CIT D-AThigh D-RT 
Insulin dose (IU/kg) 65.8±12.3 54.2±9.5 23.5±81 21.3±13.31 
Serum ET-1 (pg/ml) 21.6 ± 4.4 22.2 ± 3.8 15.8 ± 2.9 19.8 ± 2.4 
ACh + L-NMMA  
(%pre-contraction) 
7.1 ± 4.0 4.9 ± 3.0 3.1 ± 1.7 4.2 ± 2.9 
Insulin + L-NMMA 
(%pre-contraction) 
4.8 ± 5.9 3.0 ± 3.8 4.6 ± 4.4 -4.6 ± 1.7 
All data are means ± SE. 1different from D-IIT (p<0.05). 
 
Table 5.1. Blood analysis and L-NMMA data 
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Figure 5.2. Dose response curves for acetylcholine (A), insulin (B), sodium nitroprusside 
(C), and phenylephrine (D) in the femoral artery of T1DM rats. *different from all 
groups; p<0.05; All data are means ± SE. 
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Figure 5.3. phospho-specific Akt/Akt (A), phospho-specifc eNOS/eNOS (B), phospho-
specific MAPK/MAPK (C), and ET-1 (D) in the femoral artery of T1DM rats. *different 
from all groups, !; different from D-CIT, "; different from D-RT; p<0.05. All data are 
means ± SE. 
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5.4 Discussion 
Findings demonstrate that vasomotor function in the femoral artery was similar in 
sedentary T1DM rats undergoing either CIT or IIT, despite different ranges of blood 
glucose maintained in these two groups. Acetylcholine-induced vasorelaxation was 
similar across experimental groups, while only long-term AThigh resulted in increased 
insulin-induced vasorelaxation and was accompanied by an increase in the active 
phosphorylated form of Akt. This study emphasizes the importance of AThigh for the 
improvement of vascular insulin sensitivity in T1DM, which may be an important factor 
in mitigating T1DM-related endothelial dysfunction and overall cardiovascular risk in this 
population.  
 The T1DM model used in the current investigation has demonstrated endothelial 
dysfunction at varying levels (30, 32). In the current study we report no difference in 
vascular responsiveness between sedentary T1DM rats (D-CIT and D-IIT) that were 
different only with regards to blood glucose concentrations and insulin treatment 
strategies. This finding would challenge the belief that glycemia, as measured by HbA1c, 
is closely related to the degree of endothelial dysfunction (37). Indeed, studies examining 
endothelial function in experimental models of T1DM have been contradictory, whereby 
some studies demonstrate an enhancement in endothelium-dependent vasodilation (34), 
while others have shown impairments (for review see (4)). Differences in disease 
duration, artery examined, or the use of insulin supplementation may explain many of 
these discrepancies. Despite different blood glucose levels in D-IIT and D-CIT, similar 
amounts of insulin administration were used between these two sedentary groups, which 
may account for the comparable levels of acetylcholine-stimulated vasorelaxation 
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reported in the current study. Indeed, short-term insulin supplementation in T1DM rats 
has been shown to attenuate endothelial dysfunction by inducing the expression of eNOS 
(21), which may also explain why eNOS expression was similar between these two 
sedentary groups (D-IIT and D-CIT). Further, comparable levels of acetylcholine-induced 
vasorelaxation has been reported elsewhere in STZ-T1DM rats when animals are treated 
with either low or high doses of insulin, even when these same experimental groups 
differed dramatically in blood glucose concentrations (19).  
No difference in insulin-stimulated vasorelaxation was evident between D-CIT 
and D-IIT in the current study. This finding is supported by evidence in T2DM rats, 
whereby metformin failed to enhance insulin-stimulated vasodilation despite lowered 
HBA1c (6). Increased expression of the active phosphorylated form of MAPK was only 
evident in D-IIT (compared to D-CIT), suggesting that the femoral artery of D-IIT rats 
may be in the beginning stages of vascular insulin resistance. It is well established that 
hyperinsulinemia leads to the selective inhibition of PI3K and the inability of insulin to 
stimulate eNOS, which in turn, may cause a functional shift of insulin to a mitogenic role 
in the vessel (26). Indeed, despite comparable expression levels of eNOS in all of the 
experimental groups, the phosphorylated active form of MAPK was higher in D-IIT. It is 
unclear whether this is an indication of pathology to the vessels, as ET-1, the 
vasoconstrictive factor activated by MAPK, was not elevated. Additional work is 
warranted to discern whether the increases in the phosphorylated form of MAPK in D-IIT 
is detrimental to the vasculature of these animals (5). 
 Given that the benefits of aerobic exercise and RT on endothelium-dependent 
vasodilation in T1DM has been established both clinically (12) and experimentally (3, 9, 
12, 27), the inability of both exercise regimes to improve acetylcholine-induced 
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vasorelaxation in the current study is surprising. However, these discrepancies may be 
explained in part by the use of insulin supplementation in the current study. We have 
previously reported that both AThigh and RT increased whole-body insulin sensitivity in 
T1DM rats (13), which results in a reduction in the required insulin dose that is necessary 
to maintain a desired blood glucose concentration. Further, both insulin treatment (21) 
and exercise training (9, 31, 32) are well established to increase eNOS expression in 
T1DM. Thus, it is conceivable that the benefits of exercise training on acetylcholine-
induced vasorelaxation may have been masked by the increase in the insulin dosage 
necessary to maintain the desired blood glucose ranges in both sedentary T1DM groups 
(D-IIT and D-CIT). Insulin treatment alone can restore endothelial-dependent 
vasorelaxation in STZ rats (19–21). It is important to note that others have reported that 
AThigh fails to improve NO-dependent relaxation in the aorta of STZ rats (44). 
 The main finding of the current study was that AThigh resulted in significant 
increases in insulin-induced vasorelaxation that appears to be Akt-dependent. The ability 
of regular exercise to enhance the vascular actions of insulin within resistance and 
conduit arteries in different populations has recently been reviewed (33). However, few 
studies have determined the implications of exercise training on the vascular actions of 
insulin in T1DM (15, 32). Using this insulin-treated model of T1DM our group has 
shown that ten-weeks of AThigh can alleviate diabetes-related impairments in insulin-
stimulated vasa nervorum dilation, which also coincides with improved motor nerve 
conduction velocity (32). Further, others have shown an increase in cutaneous blood flow 
in response to local microinjections of insulin in exercise trained STZ-T1DM rats (15). 
To our knowledge, this is the first study to demonstrate that AThigh can increase vascular 
insulin sensitivity in conduit arteries of T1DM rats, which could have large implications 
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for a patient population at a heightened risk for vascular disease (4, 18, 38). In contrast to 
AThigh, RT failed to demonstrate an improvement in insulin-induced vasorelaxation. This 
work does not support previous evidence that used healthy rats to demonstrate an increase 
in insulin-induced vasodilation immediately following a single bout of RT (11). These 
discrepancies may be explained by the fact that arteries in the present investigation were 
not harvested until three days following the last exercise bout, which may have mitigated 
any acute benefits of RT. Nonetheless, it has been hypothesized that increases in vascular 
insulin sensitivity following exercise training occurs as a result of shear stress caused by 
exercise-induced hyperemia (33). It is plausible that an increase in the sensitivity to 
insulin following AThigh only may be a result of a lack of exercise-induced hyperemia 
associated with this RT protocol.  
 Endothelial dysfunction often precedes vascular complications, while deficiencies 
in vascular insulin signalling often occurs early in the progression of endothelial 
dysfunction (10, 22, 29). Here, the results demonstrate that AThigh, when paired with more 
modest glycemic control (CIT), can drastically increase insulin-induced vasorelaxation. 
Interestingly, more intensive glycemic control did not significantly improve vasomotor 
function. Increased vascular actions of insulin resulting from regular physical activity can 
have positive implications on both conduit and resistance arteries (33). It has been shown 
that insulin resistance in the vasculature is selective, in that only the vasodilatory 
PI3K/Akt pathway is disturbed, leaving the Ras/MAPK intact and possibly enhanced (26, 
29). In the present study, the enhanced vasorelaxation response to insulin in the femoral 
artery was likely Akt-dependent, as the expression of the active phosphorylated form of 
Akt was only elevated in D-AThigh. Further, D-AThigh exhibited a higher expression of 
phosphorylated MAPK. Contrary to the elevation in phosphorylated MAPK evident in D-
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IIT, the increased expression of phosphorylated MAPK in D-AThigh is likely indicative of 
an overall increase in insulin signalling in the femoral artery. Indeed, despite D-AThigh 
and D-RT having the same insulin dose, D-AThigh demonstrated increased expression of 
both phosphorylated Akt and MAPK compared to D-RT.  
 In conclusion, long-term AThigh results in enhanced insulin-induced vasorelaxation 
in the femoral artery, likely as a result of increased Akt expression. Findings presented 
here suggest that the inclusion of AThigh into the treatment of T1DM, despite being 
accompanied by less reliance on glycemic control, can provide greater improvements in 
vascular insulin sensitivity than IIT alone. Long term clinical studies are warranted to 
investigate the importance of AThigh in mitigating T1DM-related vascular insulin 
resistance and whether this benefit exceeds the well-established cardiovascular 
improvements reported with lifelong IIT. 
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CHAPTER 6 
 
6 «General Discussion» 
 
6.1 Summary 
The principal objective of this dissertation was to determine which exercise 
regime provides the greatest cardiovascular protection for populations with Type 1 
diabetes mellitus (T1DM), while assessing the risk of exercise-induced hypoglycemia. 
Sufficient evidence exists for health practitioners to encourage regular exercise for the 
prevention of chronic disease (4). A recent review of the literature has recognized 
numerous benefits of exercise for patients with T1DM, most namely reduced insulin 
requirement, improved lipid levels, increased insulin sensitivity, and reduced 
cardiovascular disease and mortality (7). However, for the patient with T1DM, the ideal 
intensity, duration, or modality (aerobic/resistance) has yet to be fully established (7).  
Further, the largest barrier that patients must overcome when initiating an exercise 
program is exercise-induced hypoglycemia and the manifestation of hypoglycemia 
following exercise training is largely unknown (2, 5).  
The main findings of these collective studies were as follows; (1) the magnitude 
of the abrupt decline in blood glucose in response to a single bout of exercise in T1DM 
rats remains consistent after exercise training and infrequently reaches hypoglycemic 
concentrations if blood glucose concentrations are elevated prior to exercise (Chapters 2, 
3), (2) both exercise-induced fluctuations in blood glucose and the amount of 
cardiovascular protection obtained from regular exercise training appears to be modality-
specific (Chapter 3), and (3) maintaining a more modest glycemic control (conventional 
insulin therapy) that is combined with regular exercise may provide similar (Chapter 4), 
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or even greater (Chapter 5),  cardiovascular benefits than tight glycemic control through 
intensive insulin therapy. 
In order to fulfil the objectives of this dissertation it was important that the acute 
blood glucose response to each exercise protocol in T1DM rats were comparable to data 
reported in exercising patients with T1DM. In T1DM rats, D-ATmod and D-AThigh caused 
a significant reduction in blood glucose during exercise, while the D-RT protocol resulted 
in a more gradual decline in blood glucose concentrations during the recovery phase of 
exercise. Indeed, these acute exercise-induced changes in blood glucose mirror those 
responses reported in human populations with T1DM (25). Despite training-related 
changes in several glucoregulatory hormones (insulin, glucagon, and epinephrine) in 
T1DM rats (10, 14), the acute exercise-induced reduction in blood glucose was consistent 
throughout the training period, provided the exercise was of at least moderate intensity 
(Chapters 2, 3). Following short-term D-ATlow training the initial reduction in blood 
glucose in response to exercise was abolished, although this form of exercise training 
provided little cardioprotection. When blood glucose concentrations were elevated prior 
to the initiation of exercise, the risk of experiencing hypoglycemia appeared to be reduced 
during D-AThigh and D-RT, as exercising T1DM rats did not reach hypoglycemic blood 
glucose concentrations (<3mmol/l). In the clinical setting, through increased carbohydrate 
ingestion and insulin adjustment, the intentional elevation of blood glucose 
concentrations prior to exercise is one of the most practiced approaches for preventing 
hypoglycemia during exercise in patients with T1DM (21, 28). It has been reported that 
exercise should be initiated when blood glucose concentrations are between 
approximately 8-14 mmol/l, provided significant amounts of ketones are not present (28). 
As a consequence of frequent exercise, this blood glucose range is experienced 
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chronically by exercising patients with T1DM, and in turn, these patients are often 
characterized as using a more conventional insulin therapy strategy. Thus, the moderately 
glycemic T1DM rodent model used in these studies is reflective of the exercising patient 
with T1DM who utilizes a conventional insulin therapy strategy to offset the risk of 
hypoglycemia (23).  
A high relative risk of mortality from ischemic injury to the heart exists in 
populations with T1DM (12). In fact, cardiovascular disease is the leading cause of death 
for both T1DM and T2DM (15). The second objective of this dissertation set out to 
determine which exercise modality would provide the largest degree of cardiovascular 
protection. By elevating blood glucose concentrations prior to exercise the use of both D-
AThigh and D-RT appears to be manageable for the patient with T1DM; however, based 
on the current findings the degree of cardiovascular protection they provide is duration 
and exercise-specific. Results demonstrated that following different modalities of short-
term exercise training (D-ATlow, D-AThigh, or D-RT) the greatest protection following an 
ischemia-reperfusion (I-R) injury occurred following D-AThigh (Chapter 3). These 
findings are supported by data in patients with T2DM from the ADVANCE (Action in 
Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled 
Evaluation) trial which showed that moderate to vigorous intensities of exercise are 
associated with a larger reduction in the incidence of cardiovascular events, 
microvascular complications, and all-cause mortality compared to a milder intensity (3). 
While D-AThigh may provide the greatest cardiovascular protection, the minimal 
decline in blood glucose with D-RT suggests that this form of exercise may be most 
manageable form of exercise in patients with T1DM. This finding is similar to clinical 
data, whereby the use of resistance exercise alone, or prior to a bout of aerobic exercise, 
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reduces the exercise-induced declines in blood glucose (25–27). Although the risk of 
exercise-induced hypoglycemia was minimal in D-RT, results presented here would 
suggest that in order for D-RT to provide cardioprotection the exercise must be continued 
long-term. Following just six weeks of resistance exercise it was found that the recovery 
from an I-R injury was similar to T1DM rats that remained sedentary (Chapter 3). 
However, after twelve weeks of training, the level of cardioprotection that resistance 
exercise provided during an I-R injury was comparable to D-AThigh (Chapter 4). Further, 
the combination of aerobic and resistance exercises (D-ART) led to greater increases in 
the maximal rate of developed pressure and relaxation during the I-R injury compared to 
AThigh alone (Chapter 4). While these results suggest that D-ART may be the superior 
exercise modality, it is of importance to note that D-AThigh resulted in the largest increase 
in constitutive amounts of Hsp70 in the heart. Further, D-AThigh was the only exercise 
modality to increase vascular insulin sensitivity (Chapter 5), which may indicate that this 
modality of exercise was the most advantageous in regards to the entire cardiovascular 
system. Although D-RT failed to increase vascular insulin sensitivity in the femoral 
artery, it is unknown if increases in insulin sensitivity were seen in other arteries. 
Increases in vascular insulin sensitivity following exercise training is recognized to occur 
specifically in the arteries supplying the active skeletal muscle (19). Secondly, it is not 
clear whether vascular insulin sensitivity improvements are evident following combined 
aerobic and resistance exercise training (D-ART). Studies examining vascular insulin 
responsiveness in multiple levels of the vasculature are warranted; particularly given that 
the greatest improvement in whole body insulin sensitivity was evident following this 
form of exercise training (Chapter 4). To this point, the results presented here would 
suggest each exercise training modality appears to provide unique benefits, underlining 
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the need to tailor an exercise treatment program to the individual patient with T1DM to 
best reduce their risk of cardiovascular disease development.   
Many practitioners suggest that patients with diabetes should avoid intense forms 
of exercise due to the possible increased risk of a cardiovascular event (24). However, 
more recent evidence in a rehabilitation setting indicates that the risk of a cardiovascular 
event during exercise is relatively low, even in patients with coronary heart disease (22). 
Previously our laboratory has demonstrated numerous benefits of D-AThigh, such as 
reduction in cardiovascular autonomic neuropathy (9), improved micro- and 
macrovascular function (17, 18), and improved insulin sensitivity (8, 10). The current 
findings further add to this extensive list of potential benefits of this form of exercise 
training in patients with T1DM. Concurrent with increased recovery from I-R injury, D-
AThigh also led to increased left ventricular Hsp70 and SOD protein content, as well as 
improved glycemic control (lowered fructosamine levels) (Chapter 3, 4). Further, D-
AThigh resulted in the increased sensitivity to insulin in the femoral artery following 
twelve-weeks of exercise training (Chapter 5). This exercise-related increase in vascular 
insulin sensitivity may have several implications on the prevention of cardiovascular 
disease development in patients with T1DM. For example, increases in vascular insulin 
sensitivity can reduce the risk of atherosclerosis (20), improve insulin and glucose 
delivery to skeletal muscle (6), and improve glycemic control (1, 19). Due to the 
relationship between vascular insulin resistance and endothelial dysfunction, the initiation 
of D-AThigh shortly after the diagnosis of T1DM is a promising avenue for preventing the 
development of vascular disease (11, 13, 16). Secondly, the finding that D-AThigh paired 
with a more conventional insulin therapy (CIT), actually improved glycemia (glycated 
fructosamine) to a comparable level as intensive insulin therapy (IIT) is extremely 
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promising. Taken together, the present work would strongly support the use of high 
intensity aerobic exercise and conventional insulin therapy in the prevention of 
cardiovascular complications associated with T1DM.  
Initially (Chapter 2, 3), studies were designed to determine the optimal form of 
exercise training for the patient with T1DM. As the experiments of this thesis progressed 
and the cardiovascular benefits associated with D-AThigh became extensive, it was 
important to then determine how these benefits of CIT and D-AThigh (or D-RT) compared 
to IIT alone, the current ‘gold standard’ treatment of T1DM (Chapters 4, 5). These 
studies demonstrated that when CIT was paired with D-AThigh the amount of 
cardioprotection from I-R injury was similar to IIT (without exercise training). In fact, 
results presented here would suggest that the amount of cardiovascular protection this 
treatment regime (CIT with D-AThigh) provides for a population with T1DM may be 
superior to IIT, due to increases in left ventricular Hsp70 protein content and heightened 
vascular insulin sensitivity (Chapters 4, 5). The results herein demonstrate that while 
hyperglycemia is a contributing factor in the development of cardiovascular 
complications other factors (i.e. insulin resistance) must be considered. Nonetheless, 
reduced reliance on strict glycemic control may allow for exercise to be performed safely 
(and providing cardiovascular benefits), while preventing complications associated with 
IIT (weight gain, insulin resistance, hypoglycemia). 
6.2 Conclusions 
 The findings of this dissertation would strongly suggest that high intensity aerobic 
exercise may provide the largest amount of cardiovascular protection for individuals with 
T1DM. While high intensity aerobic exercise when accompanied with conventional 
insulin therapy appears to mitigate hypoglycemia onset, it does not eliminate the risk, and 
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such a regime requires careful monitoring of blood glucose concentrations during and 
following each exercise bout. Nonetheless, the minimal risk of hypoglycemia associated 
with high intensity aerobic exercise might be outweighed by the cardiovascular benefits 
associated with this form of exercise. Results from this body of work suggests that the 
cardiovascular benefits of high intensity aerobic exercise appear to be equal to or better 
than intensive insulin therapy alone.  
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Appendices 
 
Appendix A. Multiple Low-dose Streptozotocin Protocol (rat) 
       
PURPOSE: 
To induce Type I diabetes in rats 
 
MATERIALS: 
Gloves 
Lab Coat 
Streptozotocin (STZ) 
5X Stock Citric Acid/Citrate Buffer  
!" Anhydrous Citric Acid 
!" Sodium Citrate Dihydrate 
!" MilliQ Deionized Water 
13M HCl 
3 Falcon Tube 
Sterile Filter 
 
EQUIPMENT: 
Biological Safety Cabinet 
Weigh Scale 
pH Meter 
 
PROCEDURE: 
Preparing 5X Citric Acid/Citrate Buffer 
1." For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add 
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate 
ii. 23.8g Sodium Citrate Dihydrate (Sigma) 
Mix into    iii.   175mL of MilliQ water 
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH) 
2." Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml 
mark (pH will move slightly).  If satisfied with the pH, adjust volume in a 250 ml 
graduated cylinder and filter in a 0.2µm filter. 
 
3." Store at room temperature.  This is your 5X stock solution. 
 
Making up Streptozotocin (STZ) for Injection 
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate 
amounts of STZ to be prepared. 
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1." Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of 
distilled water filtered through a 0.2µm syringe filter.  Check the pH.  This gives you 
a working concentration of 153 mM 
 
2." The desired pH is between 4.5-4.7.  Under the fume hood, add 1 drop at a time of 
concentrated HCl to the buffer, checking pH in between until desired pH is reached.     
 
3." Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe 
filter as before).  If pH is below 4.5, restart. 
 
4." Weigh out an appropriate amount of STZ for the number of animals (see calculations 
below) that will be injected in a 15 minute time frame. 
 
 
Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g 
(avg. weight of rats to be injected), you will require a minimum of 40mg.  
  20mg/kg X 0.2kg = 4mg per animal 
The amount of STZ weighed out should be more than the minimum as some solution 
will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g) 
5." Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).  
Shake to dissolve powder (approx. 1min).  Sterile filter using a 0.2µm syringe filter.   
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 
 4mg ÷ 16mg/mL solution = 0.25mL 
6." STZ is time dependent and must be used within 15 minutes 
 
Injecting and Follow-Up of the Animals 
1." Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of 
20mg/mL (in this example, 0.25mL).  Do not use anymore STZ solution more than 15 
minutes after it has been dissolved in the sodium citrate buffer. 
 
2." Dispose of any container having come into contact with the STZ (in either powder or 
dissolved form) into a biohazardous waste receptacle.  Dispose of needles into a 
sharps container. 
 
3." Return injected rats to their cage.  Record the date of STZ injection and add a 
biohazard label to the cage (leave biohazard label on cage for at least 3 days 
following the last injection). 
 
4." Repeat this procedure the following day. 
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5." Check blood glucose daily.  Diabetes is achieved with two non-fasting blood glucose 
readings of >18 mmol  Diabetes should be achieved after 5-8 injections (i.p. 
20mg/kg). 
 
REFERENCES: 
Low dose STZ induction protocol. Animal Models of Diabetic Complications 
Consortium AMDCC Protocols. 2003 
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for 
the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 
176–181, 1996. 
1. Kim E, Sohn S, Lee M, Jung J, Kineman RD, Park S. Differential responses of the 
growth hormone axis in two rat models of streptozotocin-induced insulinopenic diabetes. 
J Endocrinol 188: 263–70, 2006. 
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model 
of poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise 
training. Diabetes Metab 39: 226–235, 2013. 
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Appendix B. Insulin Pellet Implantation (rat) 
MATERIALS: 
LinShin LinPlant Insulin Pellet 
Rat anesthetic - Isoflurane 
Ampicillin 
Sterile water 
1ml syringe with 25 g needle 
10% providone-iodine solution 
gauze (or swab) 
Tissue forceps 
Scalpel handle and blades (or scissors) 
Silk suture 
Needle drivers 
IsofluoraneAnaesthetic Machine 
Hair clippers 
Heat lamp 
 
PROCEDURE: 
Pellet implantation: 
 
1." Anesthetize the animal using the isofluorane machine by placing it in the 
induction chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. 
Open the stopcock valve so gas reaches the chamber.  Keep in chamber until 
the animal is unconscious. 
 
2." Remove the animal and place its nose in the nose cone, reduce the isofluorane 
to 3% to maintain the plane of anesthesia.   
 
3." Shave the area where the pellet is to be implanted.  
 
4." Using gauze (or a swab), apply 10% providone-iodine solution to the skin, 
followed by 70% ethanol, to disinfect the site of insertion. 
 
5." Hold the skin with forceps and make a subcutaneous incision. 
 
6." Cleanse a 12g trocar with 10% providone-iodine solution and insert it through 
the puncture site to a depth of at least 2 cm. 
 
7." Using forceps, briefly immerse the pellet in 10% providone-iodine solution, 
rinse with saline and insert into the subcutaneous region.  
 
8." Use 1 pellet for the first 350g of body weight.  
 
9." Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % 
providone-iodine solution over the opening.  
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10." Close the incision by suturing. 
 
11." Place the animal under a heat lamp and monitor until it recovers from 
anesthesia. 
 
12." Record on the cage card that insulin pellets have been implanted.  
 
 
Pellet removal: 
1." Anesthetize the animal as described above for implantation.  
 
2." Shave and palpate the area of implantation to locate pellets. Sterilize this area 
by applying 10% providone-iodine solution followed by 70% ethanol. 
 
3." Using a scalpel (or scissors), make an incision through the skin superficial to 
the location of the pellets.  
 
4." Using forceps, remove the pellet. Some connective tissue may need to be cut 
away using scissors. Discard the pellet. 
 
5." Close the incision by suturing.  
 
6." Place the animal under a heat lamp and monitor until it recovers from 
anesthesia. 
 
7." Record on the cage card that the pellets have been removed. 
 
 
REFERENCES: 
Wang, Paul Y. "Sustained-Release Implants for Insulin Delivery", in Biotechnology of 
Insulin Therapy, Pickup, John C., ed., Chapter 3, pp 42-74, Blackwell Scientific, London 
UK (1991). 
 
http://www.linshincanada.com  
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Appendix C. Intravenous Glucose Tolerance Test (rat) 
 
MATERIALS: 
15 ml Falcon tube  
D-glucose 
Distilled water 
0.2 um syringe filter 
5 ml vacutainer 
Lidocaine Cream 
3 ml syringe  
Restraining towel 
Microcentrifuge tubes 
Vaseline 
27 G needles 
30 G needles 
Gauze squares 
Mettler balance 
Biological safety cabinet 
Heat lamp with 175 watt bulb 
Glucometer (Freestyle mini) 
Timer 
 
PROCEDURE: 
Fasting Rats: 
 
1." Fast animals for 8-12 hours prior to the tolerance test 
 
 
Glucose preparation: 
1." On the morning of the test, dispense 5ml distilled water into a clean 15 ml 
Falcon tube. 
 
2." Weigh out 5 grams of D-glucose, and add it to the tube containing the sterile 
water. Dissolve by vortexing to result in a 50% glucose solution. 
 
3." In a biological safety cabinet, sterilize the glucose solution using a 0.2 um 
syringe filter. 
 
4." Transfer the sterile glucose solution to a new sterile 15mL Falcon tube. 
 
Intravenous Glucose Tolerance Test (IVGTT): 
1." Place the cage containing the rat under a heat lamp. Remove the tube from the 
cage, and provide water for the rat. Warm the rat in this manner for 10 
minutes. 
 
2." Remove the rat from the cage and scrub the tail using soap and water. 
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3." Measure and record the rat’s weight. 
 
4." Obtain a baseline blood glucose reading from saphenous vein and collect a 
baseline serum sample (keep blood sample on ice). 
 
5." Return the rat to the cage and warm for an additional 20 minutes. 
 
6." Place the rat’s tail in a container of warm tap water for 30-60 seconds. 
 
7." One person should dry the tail and restrain the rat by wrapping it in a green 
drape so the tail is exposed. Occlude the lateral tail vein by applying pressure.  
 
8." Using a 3 ml syringe and a 27 G needle, a second person will draw up the 
50% glucose solution at a dose of 1g/kg (2 ml/kg). Locate the lateral tail vein 
and draw back on the plunger to ensure that the needle is within the vein.  
 
9." Release the occlusion while the glucose solution is injected. Draw back the 
plunger a couple of times during the injection to ensure that the needle 
remains located within the vein. 
 
10." Start the timer and return the rat to its cage. Continue warming it for the 
duration of the IVGTT. 
 
11." Check and record the blood glucose values for the rat at 5, 10, 20, 30, 40, 50 
and 60 minutes post glucose challenge. If by 60 minutes, the blood glucose 
value hasn’t returned to baseline, continue to check every 30 minutes until it 
does so (up to a maximum of 180 minutes). 
 
12." Obtain a blood serum sample 10 minutes following D-glucose injection (store 
at -70°C until insulin analyses). 
 
13." Upon completion of the IVGTT, remove the rat from under the heat lamp and 
return the tube to the cage. Place food on the wire lid of the cage, and ensure 
that the rat has access to water. 
 
14." Note on the cage card that an IVGTT has been performed. 
 
REFERENCE: 
Straczkowski M et al, The effect of exercise training on glucose tolerance and skeletal 
muscle triacylglycerol in rats fed with a high-fat diet. Diabetes and Metabolism (2001) 21 
p19 
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Appendix D. Fine-wire Vascular Myography 
Protocol has been adapted from: Campos Oscar. Insulin sensitivity and the insulin-
mediated vasorelaxation response in physically active and sedentary rats. 
University of Western Ontario: 2011. 
Pharmacological agents tested:  
Phenylephrine (PE), Acetylcholine (ACh), Sodium Nitroprusside (SNP), Insulin  
 
Tissues tested:  
Aorta, Carotid, Illiac, Femoral  
 
Before you begin  
Make sure you have the following materials:  
1.5L of ddH2O maintained at 37° C in one beaker  
0.5L of ddH2O maintained at 37° C in one Erlenmeyer flask  
Pre-weighed portions of: 
1) calcium chloride dihydrate (CaCl2·2H2O) – 0.441 ± 0.001 g  
2) sodium bicarbonate (NaHCO3) – 4.201 ± 0.001 g  
Pre-made 0.1 M ACh solution in 1.5 mL Eppendorf tube (stored in -20°C freezer)  
Small printed 2 mm x 2 mm grid (or graphing paper)  
 
Buffer preparation  
1. Turn on heated water pump at the myography system.  
2. Prepare the Krebs-Henseleit buffer  
a. Sequentially add the different components:  
1.  2 portions of pre-made modified 1L Krebs-Henseleit buffer powder    
    (Sigma K3753)  
2. 1 portion (0.441 ± 0.001 g) of CaCl2·2H2O  
3. 1 portion (4.201 ± 0.001 g) of NaHCO3  
b. Pour warm ddH2O from the Erlenmeyer flask into the 2L beaker until the total 
volume while stirring is just about 2L.  
Check pH with an electronic pH meter if desired. pH should automatically 
be at around 7.4 after dissolution of NaHCO3.  
3.Place the completed Krebs-Henseleit buffer bottle back into the 37°C water bath. 
 
Washing  
4. Prepare approximately 4L of ddH2O.  
5. Add water to myography system and check to make sure the temperature of the bath is 
within the appropriate range (36.5 – 37.5° C). If not, then make a slight adjustment to the 
heated water pump setting.  
6. Make sure to turn on the gas so that you push out any residual solution from the lines 
of the myography system.  
7. Flush each organ bath with multiple washes. 
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To remove the last bit of fluid from the reservoir, you have to tip it as much as 
possible in the direction of flow.  
8. Perform two 2L flushes of the reservoir, tubing, and organ baths using ddH2O. 
9. Add the 2L of Krebs-Henseleit buffer to the reservoir and fill each organ bath. 
- Make sure to turn on the gas again and set to the appropriate flow rates.  
- The working pressure should be approximately 15 PSI.  
- Adjusting the individual organ bath, and reservoir gas flow rates is rather 
subjective. The guideline is that you want a steady flow of bubbles, but not 
enough that it will eventually disturb the vessel  
10. Leave the gas on for about 20 minutes (aerating the buffer may ultimately change the 
pH. Thus, pH may need to be adjusted to 7.4) 
 
Calibration  
11. As this is going on, calibrate the transducers  
1. If not already done, turn on the computer and PowerLab acquisition hardware, 
and log in.  
2. Hang each “upper leg” of the tissue holders on each of the transducers.  
3. Open the LabChart 7 program.  
4. Adjust the settings if not already saved  
5. Click on the “channel settings” button and a window with settings opens  
6. Change the number of active channels to “4” in the box near the bottom of the 
window and close the window.  
 
Optional: Change the “sampling frequency” in the top right area of the window to 
100 Hz (default is 1 kHz). There is no noticeable difference in using frequencies 
above 100 Hz. Secondly, sampling at a lower rate reduces computer resource 
usage (RAM) and makes files smaller when saved.  
 
Optional: Drag each channel “value display” from the right hand side onto the 
main chart area, and resize to make the values clearly visible from a distance.  
 
7. Press the “Start” button in the lower right side of the window to start recording, 
and set the “display scale” (just below the chart area) to 5:1 or 10:1 (50:1 or 100:1 
if using a 1 kHz sampling frequency).  
If voltages are not close to 0 V, adjust the “zeroing screw” on the BRAM-
4 amplifier with a screwdriver. Turning the screw clockwise makes the 
voltage more negative, and counter clockwise makes it more positive.  
8. If voltages are close to 0 V, then sequentially hang the 10 g weight on each of 
the tissue holder “upper leg” for a few seconds. Be very careful to ensure the 
weight is very steady and not swinging like a pendulum.  
9. Once this is done, press the “Stop” button in the lower right side of the window 
to stop recording.  
10. In each of the channel chart areas, highlight a portion of the recording in 
which the 10 g weight had been hung from the tissue holder upper leg. Make sure 
the highlight includes areas with and without the added 10 g weight.  
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11. In each of the channel “side bars” (on the right), the press on the lower drop-
down menu and select “unit conversion”.  
12. A window pops up with several settings and a representation of your 
highlighted area.  
13. In the top right of this window select “g” as the unit you want to convert to 
from the drop-down box, and set the number of decimal places to 3.  
14. Just to the left of “unit drop-down box”, set each of the points to 0 and 10 g.  
15. In the recording shown at the bottom, select a region that corresponds to 0 g 
tension, and press on the “arrow” button to the left of the empty box 
corresponding to the 0 g row. Do the same for 10 g.  
16. Do this for each of the channels.  
12. Once the transducers are calibrated, wipe down all of the tissue holders (upper and 
lower legs) with 70% ethanol.  
13. After about 20 minutes of aerating the buffer, collect about 200mL of Krebs-
Henseleit buffer directly from the reservoir.  
14. Turn off the gas flow, and quickly release the gas pressure from the oxy-manifold.  
15. Place the collected amount of Krebs-Henseleit buffer on ice.  
 
Dissection  
17. Prepare the dissection area and tools needed. Both the previously collected Krebs-
Henseleit buffer as well as some Petri dishes will be placed on ice.  
- Find the dissection tools: “rat-tooth” tissue forceps, large sharp/blunt end 
scissors, medium blunt end scissors, small surgical scissors, 2 fine-tip curved 
dissection forceps, and a large haemostat.  
- Set up about 6 – 8 small Petri dishes (without lids). On one Petri dish, tape a 
small pre-made 2 mm x 2 mm grid so that the grid can be seen through the bottom 
of the Petri dish.  
- If collecting a piece of artery or other tissue for molecular analysis, find a Dewar 
vacuum flask and fill it with liquid nitrogen.  
18. Anesthetize the rat with isoflurane gas. When the rat is fully unconscious and displays 
no reflexes the dissection can begin. Prior to heart exsanguination, remove at least 10mL 
of blood from the rat via the inferior vena cava.  
 
Ring preparation  
19. Prior to removing the vessel from the animal attempt to clear as much connective 
tissue as possible.  
20. Once the artery is removed clean the vessel of remaining connective and adipose 
tissue.  
21. When cleaning the vessel take great care not to directly handle the artery, or when 
pulling the connective tissue apart, to not stretch (in any direction). 
22. During dissection, place the aorta in fresh Krebs-Henseleit buffer every 5 minutes.  
23. When finished cleaning, place the artery into the dish with attached 2mm x 2mm grid.  
24. Using a new razor blade, cut several (up to 4) 2 mm-long tubes/rings.  
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Mounting  
25. Take the rings (for myography) to the myograph system along with a pair of fine-tip 
forceps.  
26. Turn on the gas once again, and make sure any residual Krebs-Henseleit buffer is 
pushed out of the gas lines.  
27. Empty each organ bath and refill with fresh Krebs-Henseleit buffer. Make sure the 
fresh buffer is warm (i.e. not at room temperature).  
28. Start recording on LabChart (press “Start” in the lower right corner of the window). 
Very carefully, but quickly, mount each aortic ring onto the myograph system.  
 
1)" Place the upper leg of the myograph unit onto the force transducer.  
2)" Align the upper and lower legs (using the micrometers) so that the two tissue 
holder needles are touching. The upper leg needle may rest on the lower leg 
needle.  
3)" Once aligned, remove the upper leg, and manually push the lower leg back a 
few mm.  
4)" Pick up a ring with the upper leg. Place the upper leg, with ring, back onto the 
force transducer.  
5)" Align the upper and lower leg needles, and “slide” the lower leg needle into 
the lumen of the ring. An illustration of this process can be seen below.  
6)" Once mounted, quickly adjust the tension using the vertical micrometer to 
about 0.7 – 1 g.  
7)" Quickly and very carefully lower the myograph unit into the organ bath. 
Lower the unit until the ring is at about the center of the organ bath. Once in 
the buffer, readjust the tension to approximately 1 g.  
8)" Mount subsequent vessels. 
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Equilibration  
29. Although the tension was set at initially at 1 g, this tension gradually decreases as the 
rings relax. Tensions may drop down as low as 0.4 g by 5 minutes.  
30. Gradually increase tension over ~30 minutes (Aorta: 2 grams, Carotid: 1.5 grams, 
Iliac: 1.5 grams Femoral: 1 grams). During this process continually wash vessels every 5-
10 minutes. 
31. Allow the rings to remain stable at their desired tensions for ~30 minutes.  
32. During this equilibration period, prepare PE, ACh, SNP and insulin dilution series in 
1.5 mL Eppendorf tubes.  
 
 Phenylephrine (PE): 
!" PE needs to be made fresh. Measure out 0.041 ± 0.001g of PE and place into a 
15 mL Falcon tube.  
!" Dissolve the PE in Krebs-Henseleit buffer (e.g. buffer left over from 
dissection) and top up to approximately 2mL. This creates a 0.1M (i.e. -1 log 
M) PE solution (0.1mol/l x 203.67g/mol = 20.367g/mol).  
Acetylcholine (ACh): 
!" ACh stock (-1 log M) can be prepared ahead of time and frozen at -70°C. 
Measure out 0.018g of ACh and dissolve in 1mL buffer. This creates a 0.1M 
(i.e. -1 log M) ACh solution (0.1mol/l x 181.66g/mol = 18.166g/mol). 
Sodium Nitroprusside (SNP): 
!" SNP needs to be made fresh. Measure out 0.0298g of SNP and dissolve in 
1mL buffer. This creates a 0.1M (i.e. -1 log M) SNP solution (0.1mol/l x 
298g/mol = 29.8g/mol). 
L-NMMA: 
!" L-NMMA stock (-1 log M) can be prepared ahead of time and frozen at -
70°C. Measure out 0.0248g of L-NMMA and dissolve in 1mL buffer. This 
creates a 0.1M (i.e. -1 log M) L-NMMA solution (0.1mol/l x 248.28g/mol = 
24.829g/mol). 
Insulin: 
!" Insulin used: Sigma 10516-5ml bovine insulin 10mg/ml 
 
 Create PE, ACh, SNP, Insulin series dilutions in Eppendorf tubes:  
!" For ten-fold dilutions (e.g. -1 to -2 log M), pipet 100 µL of solution (e.g. -1 
log M) into 900 µL of Krebs-Henseleit buffer.  
!" For approximately three-fold dilutions (e.g. -3 to -3.5 log M), pipet 300 µL of 
solution (e.g. -3 log M) into 700 µL of Krebs-Henseleit buffer. (This dilution 
makes concentrations approximately -3.5 log M. The actual concentration is: -
3.5229 log M).  
 
Viability test  
33. Once equilibration is complete, pipet 5 µL of -3.5 log M PE into each organ bath.  
- After the last wash, make sure each organ bath has approximately 5 mL of  
buffer in it. 
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- The final concentration of PE in the organ bath is -6.5 log M.  
- Make sure to add comments in the upper section of the chart view each time a 
new pharmacological agent is added or a wash is performed.  
34. Wait for the tension to reach a new plateau.  
- Tension should begin to increase within 10 seconds after the addition of PE.  
- Tension increases in an exponential fashion and should plateau in approximately 
10 – 20 minutes.  
35. Once plateau is reached, pipet 5 µL of -3.5 log M ACh into each organ bath.  
- The final concentration of ACh in the organ bath is -6.5 log M.  
36. Again, wait for tension to reach a new plateau.  
- Tension should begin to decrease within 10 seconds after the addition of ACh.  
- Tension decreases exponentially and should plateau in approximately 5 – 10 
minutes.  
37. Once plateau is reached, begin a series of 4 washes/buffer changes at 5 minute 
intervals.  
- By the end of these washes (i.e. 15 minutes), tension should return to a baseline 
level. 
- If vessels failed to relax after ACh dose repeat steps 33-37. Occasionally, 
vessels will need this procedure to “awaken”. 
 
Concentration response curves 
38. At the end of this equilibration period, and after the wash, pipet 5µL of -3.5 M PE 
into each organ bath as before, and follow the same guidelines as before.  
- Using a dose of -2M PE (-5M PE in bath) is best for pre-constricting the femoral 
artery. 
- PE sometimes causes a greater contraction the second time.  
39. Once plateau is reached, begin concentration-response experiments with ACh, SNP or 
insulin.  
 
ACh 
Concentration(-logM) -5.5 -5 -4.5 -4 -3.5 -3 -2.5 -2 
 
SNP 
Concentration(-logM) -8 -7 -6 -5 -4 -3 
 
Insulin 
Concentration(mg/ml) 1 10 100 1000 10 000 100 000 
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40. For PE concentration curves after the vessel achieves a basal tone pipette the 
following doses of PE. 
PE 
Concentration(-logM) -5 -4.5 -4 -3.5 -3 -2.5 -2 
 
41. To evaluate NO contribution concentration curves (or a single dose from the middle 
of the concentration curve) by adding L-NMMA (0.1 –logM; 0.4 –logM in bath) to bath 
prior at least 10 minutes prior to PE contraction. 
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Appendix E. Glycogen Quantification Protocol 
MATERIALS: 
Tissue samples 
Fume hood 
3 x 100mm glass test tubes 
Potassium hydroxide (KOH) pellets 
Sodium sulfate (Na2SO4) 
95% ethanol 
Glycogen powder 
Phenol crystals 
96-98 % Sulfuric Acid (H2S04) 
490nm spectrophotometer 
 
STANDARD CURVE: 
Prepare standard curve with stock glycogen solution (1mg/mL). 
Standard [Glycogen] (mg/ml)  Volume (µl)  Water (µl) 
 1  0.000    0   1000 
 2  0.005    5   995 
 3  0.010    10   990 
 4  0.050    50   950 
 5  0.100    100   900 
 6  0.200    200   800 
 7  0.300    300   700  
8   0.500    500   500 
9   1.000    1000   0 
 
 
Colour Reaction: 
1." Add 1 ml of 5 % phenol. 
 
2." Rapidly add 5 ml of 96-98 % H2S04. 
 
3." Let samples stand for 10 min.   
 
4." Vortex and place in water bath (25 to 30°C) for 10 to 20 minutes. 
 
5." Read tubes at 490 nm. 
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PROCEDURE: 
1." Cut and weigh approximately 20mg of tissue samples and place in glass test tube. 
2." Saturate 30% KOH stock solution with sodium sulfate (Na2SO4) 
3." Add 0.5 ml of 30 % KOH saturated with Na2S04. Make sure that tissue is 
completely submerged. 
4." Put caps on tubes and immerse in boiling water bath until homogenous solution is 
obtained (30 minutes). 
5." Place tubes on ice. 
6." Precipitate glycogen with 1mL of 95 % ethanol for 30 minutes (on ice). 
7." Spin tubes at 840 x g (3 000 rpm on Sorval) for 20 to 30 minutes. 
8." Remove supernatants and immediately dissolve precipitates in 3mL ddH2O. Do 
not allow precipitated to dry. 
9." Pipette 1 ml glycogen solution into 3 separate glass test tubes (3 x 100mm). -3 
separate tubes of glycogen solution are necessary for analysis in triplicates. 
10." Add 1 ml of 5 % phenol. 
11." Rapidly add 5 ml of 96-98 % H2S04. 
12." Let samples stand for 10 min.   
13." Vortex and place in water bath (25 to 30°C) for 10 to 20 minutes. 
14." Read tubes at 490 nm. 
15." Calculate glycogen content by: 
g of glycogen / 100g tissue = A490 x V x 10-4 
  k        v     W 
where, V = total volume of glycogen solution; v = volume of aliquot used in 
colour reaction; A490 = absorbance at 490 mn; W = weight of tissue samples in 
grams; k = slope of standard curve; units = 1 per microgram glycogen. 
 
SOLUTIONS: 
Glycogen Stock Solution 
(1mg/mL) 
100mL ddH2O 
100mg Glycogen powder 
 
30% Potassium Hydroxide Stock Solution 
300g Potassium Hydroxide Pellets 
(KOH) 
1L ddH2O 
Reaction is exothermic; therefore, it might 
be necessary to put on ice. 
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SPEC PROCEDURE: 
1." Turn on ~20minutes before needed (TRANS) 
 
2." Set desired λ& insert appropriate filter 
 
3." Insert a blank tube (dH2O) 
 
4." With spec. on “TRANS”, set to 0.000 using “zero” button & while pressing “zero 
set” 
 
5." Release “zero set”, but adjust value to 100.00 with spec set to “TRANS” using 
“100% T/OA” adjustments 
 
6." Set spec from “TRANS” to “ABS” using LHS button 
 
7." Check that “ABS” reading is 0.00; if not adjust with “100%T/OA” 
 
8." Check that a true a zero reading has been reached by reading the abs values of 2 
other blank tubes 
 
9." Read 3 reagent tubes (blank) and record zero on the middle value using 
“100%T/OA” 
 
10."Read all standard samples 
 
Reference:  
Lo, S.L., Russell, J.C., and Taylor, A.W. (1970) J Appl. Physiol, 28(2), 234-6. 
 
 
 
 
 
 
 
 
 
 
 
5% Phenol Stock Solution 
50g Phenol crystals 
1L ddH2O 
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APPENDIX F. Immunohistological Staining of Pancreatic Islets (glucagon 
or insulin) 
 
Tissue Preparation 
After tissue extraction pancreata were placed in formalin for 72hrs.  Formalin was 
replaced every 24hrs with fresh formalin.  After 72hrs, tissues were placed in 70% 
ethanol until the time of tissue processing.  Tissue is processed and embedded in paraffin 
at Robarts Molecular Pathology Laboratory using the Leica ASP 300.  
 
Tissue Sectioning 
Initially blocks were trimmed at 10-15µm in order to expose tissue.  Pancreata were 
sectioned at 5µm and placed on positively charged slides.  Tissues on slides were 
incubated overnight at 37°C to reduce background staining. 
 
Protocol for Deparaffinization 
1." Deparaffinization is completed using the “auto-staining machine” at the 
Molecular Pathology Laboratory at Robarts (Program 11) 
a. The slide carriage was placed in 2 separate solutions of Xylene for 5 minutes 
each.  
b. The slide carriage was placed in 2 separate solutions of 100% ethanol for 2 
minutes each.  
c. The slide carriage was placed in 1 solution of 95% ethanol for 1 minutes.  
d. The slide carriage was placed in 1 solution of 70% ethanol for 1 minutes.  
e. The slide carriage was placed in 1 ddH2O bath for 2 minutes.  
 
2." Antigen retrieval is completed after deparaffinization (also at Molecular 
Pathology Laboratory at Robarts).  Duration 2 hours. 
 
 
 
 
 
 
 
 
 
 
3." Slides were 
brought back to lab in PBS solution1 
 
Immunostaining Protocol 
Quenching: 
1." Place slides in a 3% Hydrogen Peroxide solution for 20 minutes (blocking of 
endogenous peroxidase) – must be prepared fresh 
 
 
10mM Sodium Citrate Buffer Solution with 0.05% 
Tween-20 
1000mL ddH2O 
2.4g Trisodium Citrate (Labelled Sodium 
Citrate Dihydrate) 
Adjust pH to 6.0 
0.5mL Tween-20 
Store at room temperature for 3 months  
or 4°C for long term storage 
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2." Wash slides in 1x in TPBS 2min. 
3." Wash 2x PBS for 1min. 
4." Add grease circles around tissue 
 
Blocking: 
1." Prepare enough blocking solution to cover all tissue (approx. 100µL per tissue) 
2." Add 4 drops of avidin (approx. 180µL) to 1000µL 10% blocking solution2 
3." Cover tissue with blocking solution and incubate for overnight in the fridge at 
4°Cc 
 
Primary: 
1." In 2 separate tubes, Add 4 drops of biotin (approx. 180µL) into tube containing 
1000µL of 1% blocking solution 
2." Add primary antibody (abcam Monoclonal Anti-glucagon antibody: 1:4000, 
Dako Polyclonal Guinea Pig Anti-Insulin: Dako: 1:100) to the first of the tubes 
(biotin/blocking solution)  
3." Apply solution containing the primary antibody to frosted side of the 
microscope slide 
4." Apply only the biotin/blocking solution to the tissue furthest from the frosted 
side of the microscope slide 
5." Incubate slides for 1hr in the dark on the bench 
6." Wash slides 1x in TPBS for 2min. 
7." Wash slides 2x in PBS for 2min. 
 
Secondary: 
1." Add secondary antibody (biotinylated anti-Mouse Goat) in a ratio of 1:400 
(2.5µL) for glucagon or (biotinylated anti-Rabbit Goat) 1:200 (5 µL) for insulin to 
1000µL 1% blocking solution  
2." Apply solution containing the secondary antibody to all tissues 
3." Incubate tissues for 30min. at room temperature in the dark  
 
Vectastain 
2.5mL PBS 
1 drop Bottle A (Avidin) 
1 drop Bottle B (Biotin) 
Must be prepared at least 30min. 
prior to use 
 
4." Wash slides 1x in PBS for 5min. 
5." Wash slides 2x in PBS for 2min. 
 
3% Hydrogen Peroxide (per slide carriage) 
7.5mL 15mL H2O2 
67.4mL 134.8mL ddH2O 
ie. 1 part 30%  H2O2 and 9 parts ddH2O 
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Detection: 
1." Apply 80µL of Vectastain to all tissues and incubate in the dark at room 
temperature for 30hr. 
2." Wash slides 1x in PBS for 5min. 
3." Wash slides 2x in PBS for 2min. 
4." Prepare DAB solution: 
 
Diaminobenzine (DAB) Solution 
Add in sequential order 
2.5mL ddH2O 
1 drop Buffer Solution 
2 drop Diaminobenzidine 
(DAB) 
1 drop Hydrogen Peroxide 
(H2O2) 
1 drop Nickel (Ni) 
 
5." Apply the DAB solution to all tissues for 6min. 
6." Wash DAB off tissues by lightly squirting ddH2O onto the slide and into a waste 
beaker 
7." Place slides in ddH2O and wash for at least 5min. 
8." Dispose of the DAB contents into waste bottle in fume hood 
 
Dehydration and Haematoxylin Counterstain: 
1." Dehydration and counterstaining is best completed using the “auto-staining 
machine” at the Molecular Pathology Laboratory at Robarts (Program 4) 
 
OR 
 
1." Submerge slides in a Haematoxylin solution for 1min (nondiluted) 
2." Wash slides with ddH2O for 5min (2min in bath 1, 3min in bath 2 (fresh 
water)). 
3." Place slides in 70% ethanol for 1min 
4." Place slides in 95% ethanol for 1min 
5." Place slides in 100% ethanol 2x for 3min 
6." Place slides in Xylene 2x for 5min 
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SOLUTIONS: 
 
 
 
 
 
 
 
 
 
 
Phosphate Buffer Saline (PBS): 10x Stock 
Solution 
1300mL ddH2O 
112g Sodium Chloride (NaCl)  
2.8g  Potassium Chloride (KCl)  
20.18g Disodium Monophosphate (Na2HPO4) – 
labeled as: Sodium Phosphate Dibasic 
Anhydrous  
2.8g Potassium Diphosphate (KH2PO4) – 
labeled as: Di-Potassium Hydrogen 
Orthophosphate 
Adjust pH to 7.4 
Bring volume to 1400mL 
Store at room temperature 
 
 
Tween-20 PBS (TPBS) 
1L PBS 
100µL Tween-20 
 
 
 
Vectastain)
2.5mL" PBS"
1"drop" Bottle"A"(Avidin)"
1"drop" Bottle"B"(Biotin)"
Prepare"at"least"30min."prior"
 
 
 
 
 
 
 
 
10mM Sodium Citrate Buffer Solution with 0.05% 
Tween-20 
1000mL ddH2O 
2.4g Trisodium Citrate (Labelled Sodium 
Citrate Dihydrate) 
Adjust pH to 6.0 
0.5mL Tween 
Store at 4°C 
10% Goat Serum Blocking 
Solution 
1mL Goat Serum 
9mL TPBS 
Diaminobenzine (DAB) Solution 
Add in sequential order 
2.5mL ddH2O 
1 drop Buffer Solution 
2 drop Diaminobenzidine 
(DAB) 
1 drop Hydrogen Peroxide 
(H2O2) 
1 drop Nickel (Ni) 
Working solution lasts up to 6hrs 
in the dark at 4°C 
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Appendix G. Homogenizing Protocol 
 
MATERIALS: 
," Glass plate to cut tissue 
," Razor blade 
," 1000 µl pipette 
," Homogenizing tubes 
," Bucket of ice to keep samples cold 
," Homogenizing buffer – make sure it’s fresh 
," Eppendorf tubes 
," Beaker ddH2O to clean homogenizer between samples 
," Make sure to label tubes: both homogenizing and eppendorf tubes 
 
1." Measure 0.1g sample (cut in freezer by surgery room). 
 
2." Put in eppendorf tubes. 
 
3." Add homogenizing buffer:  0.1g equals 0.1 ml @ 1x 
Therefore 1ml @ 10x 
1ml = 1000µl 
  Example: 
 
 
 
 
4." Complete steps 1-3 for each sample. 
 
5." Homogenize each sample (never run homogenizer dry and always clean between 
samples). 
 
6." Centrifuge homogenates 
 
7." Pipette homogenized sample to eppendorf tubes and freeze at -70°C. 
 
 
 
 
 
 
 
 
 
 
 
sample g of tissue µl homogenizing 
buffer 
D - 1 0.0957 957 
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Appendix H. Bradford Protein Assay 
!
1." Dilute 1 part of dye reagent with 4 parts water (Bio-Rad 500-0006, found in 
fridge). 
," 1 microplate requires 25ml dye reagent. 
 
2." Filter the diluted solution through Whatman 1 filter paper. 
 
3." Get a microplate and label. 
 
4." Get a second set (different colour) of eppendorf tubes and label. 
 
5." Add 5µl of sample with 95µL ddH2O in separate eppendorf tubes. 
," An alternate to pipetting 0.5µl of sample and 9.5µl ddH2O 
 
 BSA : Water 
+ 
200µl reagent 
 
Add 10µl of mixed sample + 200µl reagent 
(everything done in 3’s) 
1 2 3 4 5 6 7 8 9 10 11 12 
0 0 + 10          
1 1 + 9          
2 2 + 8          
3 3 + 7          
4 4 + 6          
5 5 + 5          
             
             
 
6." Shake microplate and Incubate at room temperature 5 to 60 minutes. 
!
!
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Appendix I. Western Blotting Protocol 
 
Tissue: skeletal muscle, heart, liver 
 
Preparation of Samples 
1." Place the homogenized samples on ice. 
2." Determine the amount of protein necessary to load in each well (initially a protein 
loading curve may be necessary).  
3." The volume of homogenate needed is determined from the Bradford protein 
quantification assay (see Bradford protocol). 
4." Label a new set of eppendorf tubes with the appropriate sample names. 
5." Dilute the smallest possible volume of sample (determined from Bradford Assay) 
in sample buffer. (1:1 ratio, make sure to Vortex) 
6." Prior to loading the sample into gel make sure to place the diluted sample in 
boiling water for up to 5 minutes (it may be necessary to poke holes in the tops of 
tubes). 
7." Bring samples back to room temperature before loading in gel. 
 
Preparation of Gels 
1." Clean mini glass plates with 70% ethanol before use and then prepare gel cassette.  
2." Prepare separating gel according to chart in relation to the number of gels and 
percent acrylamide to be used (10% Separating Gel works best for most proteins 
of interest; may be a different concentration when using very small or large 
proteins). 
 
10% Separating Gel 
 
ddH2O 
1 Gel 2 Gel 4 Gel 6 Gel 8 Gels 
4 ml 8 ml 16 ml 24 ml 32 ml 
30% Acrylamide 
(in fridge) 
3.33 ml 6.67 ml 13.3 ml 20 ml 26.7 ml 
Separating Buffer 2.5 ml 5 ml 10 ml 15 ml 20 ml 
10% SDS 100 µl 200 µl 400 µl 600 µl 800 µl 
10% APS  
(in fridge: 0.1g in 
1ml DDH2O) 
62.5 µl 125 µl 250 µl 375 µl 500 µl 
TEMED  
(in fumehood) 
6.25 µl 12.5 µl 25 µl 37.5 µl 50 µl 
 
3." Pour separating gel using Pasteur pipette while trying to eliminate any bubbles 
(keep left over separating gel in beaker to make sure it polymerizes). 
4." Immediately overlay the gel with water saturated isobutanol. This is done to 
remove bubbles and ensure a continuous charge from separating to stacking gel. 
5." Wait for approximately 30-60 minutes until gel polymerizes and then rinse off 
overlay solution with ddH20 and dry clean with filter paper. 
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6." Prepare and pour stacking gel (4%) according to the chart below: 
 
 
ddH20 
1 Gel 2 Gel 4 Gel 6 Gel 8 Gels 
3.05 ml 6.1 ml 12.2 ml 18.3 ml 24.4 ml 
30% Acrylamide 
(in fridge) 
0.65 ml 1.3 ml 2.6 ml 3.9 ml 5.2 ml 
Stacking Buffer 1.25 ml 2.5 ml 5 ml 7.5 ml 10 ml 
10% SDS 50 µl 100 µl 200 µl 300 µl 400 µl 
10% APS  
(in fridge) 
31.3 µl 62.6 µl 125 µl 188 µl 250 µl 
TEMED  
(in fumehood) 
6.25 µl 12.5 µl 25 µl 37.5 µl 50 µl 
 
7." Place the correct sized comb between the glass plates, making sure no air bubbles 
are trapped in the wells.   
8." Prepare 1L of 1x running buffer per every 2 gels and store in refrigerator.  
9." Once the stacking gel has polymerized (30-60 minutes), gently remove comb. 
10."Fill wells with 1x running buffer. To allow for easier identification of wells when 
loading use a permanent marker to identify the bottom of wells.  
11."Load correct amount of sample (determined from Bradford Assay) using 
micropipette with loading tip.  
12."Once loading is complete place gels in running unit. 
13."Fill running unit with cold 1x running buffer (make sure to fill the inside of the 
unit as well).  
14."Run gels at 70V until through stacking portion of gel (~30 minutes) and then 
120V until samples are fully through the gel. 
15."Stop once dye (ie. Blue line) has moved completely through the gel. 
16."During the running period prepare transfer buffer and keep in refrigerator. 
 
 
 
 
 
Transfer of Gels to Nitrocellulose 
1." Cut filter paper and nitrocellulose to appropriate size. 
2." Soak filter paper, nitrocellulose and Brillo pads in cold transfer buffer.  
3." Carefully separate gel from gel electrophoresis cassette and place in transfer 
buffer. 
4." Assemble the transfer apparatus (“sandwich”) as shown below, making sure to 
remove all air bubbles between gel and nitrocellulose paper (bubbles will cause 
protein not to transfer). 
 
 
 
 
Transfer 
Buffer 
(4 BLOTS) 
10x Running 
Buffer 
100ml 
Bring to 800ml with ddH20 
Methanol 200ml 
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5." Place “sandwich” in transfer holding tank.  Fill tank with cold transfer buffer. 
6." Connect to power supply and run at 70V for 1 ½ hours on ice. 
Blocking 
1." Prepare 1L 1x TBS per every 2 blots. 
2." After transfer, remove gel and place in small container with 5% blocking solution.  
Incubate for 1 hour on shaker at room temperature. 
3." After blocking prepare primary antibody (at least 15mL of solution). 
4." Incubate blots (back-to-back) in primary antibody solution overnight at 4°C. 
5." Once finished the 1ᵒ antibody solution can be stored at 4ᵒC to be used within a 
week. 
6." Wash blots 3x in TTBS for 5 minutes each. 
7." Prepare secondary antibody (HRP – don’t use AP) solution (1:5000 a good 
starting point). 
8." Incubate blots for 1 hour on shaker at room temperature. 
9." Wash blots 2x in TTBS and 1x in TBS for 5 minutes each wash. 
!
!
!
!
!
!
!
!
!
!
Gel!
Nitrocellulose!
(+ve)!,!RED!
Filter!Paper!
Brillo!Pad!
(,ve)!,!BLACK!
Filter!Paper!
Brillo!Pad!
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WESTERN BLOTTING SOLUTIONS: 
!
!
 
 
 
 
 
 
 
 
 
 
 
 
 
! 168!
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SEPARATING GEL: 
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STACKING GEL: 
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2014. 
“This is an Accepted Manuscript of an article published by Taylor & Francis in 
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or “post my accepted manuscript on my departmental or personal website after 
publication” you must “include a link to the version of record”.  
Excerpt from: http://authorservices.taylorandfrancis.com/wp-
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